

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Association between administration or recommendation of the human papillomavirus vaccine and primary care physicians' knowledge about vaccination during proactive recommendation suspension: a nationwide cross-sectional study in Japan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-074305
Article Type:	Original research
Date Submitted by the Author:	04-Apr-2023
Complete List of Authors:	<p>Sakanishi, Yuta; Sakanishi Internal Medicine and Pediatrics Clinic; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Takeuchi, Jiro; Hyogo College of Medicine, Clinical Epidemiology; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Suganaga, Rei; Tessyoukai Kameda Family Clinic Tateyama; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Nakayama, Kuniko; My family Clinic Gamagori; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Nishioka, Yosuke; Nishioka Memorial Central Clinic; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Chiba, Hiroshi; Family Medical Practice Hanoi; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Kishi, Tomomi; Japan Baptist Hospital; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Machino, Aco; Gondo Dermatological Clinic</p> <p>Mastumura, Mami; School of Public Health, Graduate School of Medicine, Kyoto University, Department of Preventive Services; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Okada, Tadao; Tessyoukai Kameda Family Clinic Tateyama; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p> <p>Suzuki, Tomio; Osaka Medical and Pharmaceutical University, Department of General Medicine; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association</p>
Keywords:	Primary Care < Primary Health Care, PREVENTIVE MEDICINE, Community child health < PAEDIATRICS

SCHOLARONE™
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

ABSTRACT

Objective In 2013, the Japanese government suspended its proactive recommendation of the human papillomavirus (HPV) vaccine (HPVv). The vaccination rate of the HPVv declined to <1% in 2014–2015. Previous studies have shown that the recommendation by a physician affects a recipient's decision to receive a vaccine, and physicians' accurate knowledge about vaccination is important to increase vaccine administration. This study aimed to evaluate the association between physicians' vaccination knowledge and the administration or recommendation of the HPVv among primary care physicians (PCPs) without proactive recommendation from the government in Japan.

Design Cross-sectional study.

Setting In 2019, a web-based, self-administered questionnaire was distributed among physicians of the Japan Primary Care Association (JPCA) on the official mailing list.

Participants Physicians who were not part of the mailing list, junior residents, those living outside Japan, those employed in a non-clinical setting, and those with missing/insufficient data were excluded.

Primary and secondary outcome measures The outcome of this study was the association between PCPs' vaccination knowledge and the administration or recommendation of the HPV vaccine. We obtained information on physicians' background and vaccination quiz scores and performed logistic regression analysis to estimate the adjusted odds ratios (AORs).

1
2
3
4 1 **Results** We received responses from 1,084 PCPs (20.1%) and enrolled 981 participants in the
5
6
7 2 analysis. PCPs with a higher score on the vaccination quiz were significantly more likely to
8
9
10 3 administer the HPVv for routine and voluntary vaccination (AOR 2.28, 95% confidence interval [CI]
11
12
13 4 1.58–3.28; AOR 2.71, 95% CI 1.81–4.04, respectively) and recommend the HPVv for routine and
14
15
16 5 voluntary vaccination than PCPs with a lower score (AOR 2.17, 95% CI 1.62–2.92; AOR 1.88, 95%
17
18
19 6 CI 1.32–2.67, respectively).

20
21
22 7 **Conclusions** We identified a positive association between the administration or recommendation of
23
24
25 8 the HPVv and PCPs with accurate vaccination knowledge.
26
27
28
29

30 10 **Strengths and limitations of this study**

- 31
32
33 11 • This is the first study to focus on the association between primary care physicians' (PCPs)
34
35
36 12 vaccination knowledge and the administration or recommendation of the HPV vaccine without
37
38
39 13 proactive recommendation from the government in Japan.
- 40
41
42 14 • To explore this association, multivariable logistic regression analysis was performed with 10
43
44
45 15 possible confounding factors including the physicians' postgraduate year, the percentage of
46
47
48 16 paediatric patients, and information resources about vaccination.
- 49
50
51 17 • One limitation of this study was its potential selection bias, which was due to the PCPs' voluntary
52
53
54 18 participation in the survey.
- 55
56
57 19 • Furthermore, the effects of vaccine hesitancy from parents or the media on the PCPs were not
58
59
60

1
2
3
4 1 evaluated.
5
6
7 2
8
9

10 3 **Data availability statement**
11
12

13 4 Data are available upon reasonable request.
14
15
16 5
17
18
19 6
20

21 7 **Keywords:** HPV vaccine; primary care physicians; administration; recommendation; vaccination
22
23
24 8
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTRODUCTION

2 The World Health Organization (WHO) recognises the importance of cervical cancer and other
3 human papillomavirus (HPV)-related diseases as global public health problems and recommends that
4 HPV vaccines (HPVv) should be included in national immunization programmes.(1) In Japan, the
5 HPVv was introduced in 2009 as a voluntary vaccination without a recommendation or funding from
6 the Government of Japan.(2, 3) Since 2010, an urgent promotional campaign for vaccination has
7 been conducted by the Ministry of Health, Labour and Welfare (MHLW), and the Government of
8 Japan implemented subsidies to local governments for HPVv fees.(2, 3) This campaign was
9 successful, and the vaccination rate of HPVv reached 70–80% of the targeted group, young girls, in
10 2012.(3, 4, 5, 6) In April 2013, HPV vaccination for 12- to 16-year-old girls was initiated as part of
11 the routine vaccination program.(3, 7) However, the media widely reported an “adverse event” of
12 HPV vaccination in young girls, that gave rise to social distrust, and vaccine hesitancy of the HPVv
13 arose.(3, 7, 8) Consequently, the MHLW suspended proactive recommendation of HPV vaccination
14 in June 2013,(7, 9) and the HPV vaccination rate declined to less than 1% in 2014–2015.(5, 6)

15 The Global Advisory Committee on Vaccine Safety (GACVS) reviewed the safety data of HPVv
16 from 2008 to 2015, and the committee considered HPVv to be extremely safe(10). In 2017, GACVS
17 expressed concerns regarding the situation in Japan, stating that the mortality rate from cervical
18 cancer was expected to increase because HPVv was not proactively recommended.(10) In 2018,
19 Suzuki et al. reported that there was no association between HPVv and adverse post-vaccination

1
2
3
4 1 symptoms in Nagoya, Japan.(11) However, the MHLW still continued the suspension of proactive
5
6
7 2 recommendation of HPV vaccination as of 2019. Vaccine hesitancy has occurred in other countries
8
9
10 3 as well, and the WHO has identified vaccine hesitancy one of 10 threats to global health in 2019.(12)
11
12

13 4 Previous studies have shown that vaccine recommendation by a physician affects the recipient's
14
15
16 5 decision in receiving a vaccine.(13, 14, 15, 16, 17, 18) Physicians' accurate knowledge about
17
18
19 6 vaccination is important to increase vaccine administration or recommendation rates.(19, 20, 21) In
20
21
22 7 Japan, the HPVv is administered not only by paediatricians, obstetricians, and gynaecologists
23
24
25 8 (OBGYNs), but also by primary care physicians (PCPs).(22, 23) A nationwide survey on practices
26
27
28 9 and attitudes towards vaccination among PCPs was conducted in Japan in 2012,(22, 23) when the
29
30
31 10 proportion of PCPs who were administering and actively recommending HPV vaccination was
32
33
34 11 58.3% and 46.5%, respectively.(22) A significant association between PCPs' awareness of public
35
36
37 12 subsidies for the HPVv and recommendations for HPV vaccination was reported.(23)
38
39

40 13 As previously indicated, the government vaccination policy for the HPVv changed after that
41
42
43 14 survey(22, 23) and it was expected that these proportions would also change, but the current fraction
44
45
46 15 of the PCPs that either administer or recommend the HPVv and the association between PCPs'
47
48
49 16 knowledge about vaccination and their attitude towards HPVv in Japan is unknown. Therefore, this
50
51
52 17 study aimed to evaluate the association between PCPs' knowledge about vaccination and the
53
54
55 18 administration or recommendation of the HPVv without proactive recommendation from the
56
57
58 19 government.
59
60

2 METHODS

3 Study design, setting, and population

4 This study used a cross-sectional design with data collected using a web-based, self-administered
5 questionnaire conducted by the Preventive Medicine and Health Promotion Committee Vaccine
6 Team of the Japan Primary Care Association (JPCA), which is the largest academic association for
7 PCPs in Japan. The majority of the JPCA physicians were internists working as PCPs at clinics or
8 hospitals. The survey was conducted from March to June 2019 and included only JPCA physician
9 members. The inclusion criteria were physicians who were JPCA members using the official mailing
10 list for only JPCA members. PCPs who were junior residents within 2 years after graduation from
11 medical school were excluded, as this group cannot administer outpatient vaccinations without the
12 supervision of attending physicians. Further exclusion criteria included PCPs who were living
13 outside Japan, retired, employed in a non-clinical setting, and those with missing data.

15 Patient and public statement

16 Patient and/or the public were not involved in this study.

18 Questionnaire

1
2
3
4 1 Questionnaire items were revised from previous questionnaires administered by the Preventive
5
6
7 2 Medicine and Health Promotion Committee Vaccine Team of JPCA,(22, 23) and were distributed
8
9
10 3 through the online mailing list of JPCA members. The questionnaire was self-conducted and
11
12
13 4 anonymous, collecting data on the participating physicians' baseline characteristics, such as sex,
14
15
16 5 career after graduation, experience raising children, provision of daily paediatric medical service,
17
18
19 6 provision of medical services at their main working facility, and vaccination quiz scores.
20
21
22 7

25 8 Main outcome

26
27
28 9 The primary outcome of this study was the association between PCPs' knowledge about vaccines
29
30
31 10 and administration of the HPVv for routine and voluntary vaccination, respectively. As of 2019, the
32
33
34 11 target group for HPV vaccination is as follows: routine vaccination, bivalent and quadrivalent HPVv
35
36
37 12 for 12–16-year-old females; voluntary vaccination, bivalent HPVv for ≥ 10 -year-old females and
38
39
40 13 quadrivalent HPVv for ≥ 9 -year-old females.(24) The PCPs were asked the following yes/no
41
42
43 14 question: “Do you administer routine vaccination of the human papillomavirus vaccine for
44
45
46 15 children?” The secondary outcome of this study was the association between PCPs' knowledge about
47
48
49 16 the vaccine and PCPs' recommendation of routine vaccination for HPV for children. The
50
51
52 17 respondents were asked, “How do you recommend routine vaccination for HPV for children?” The
53
54
55 18 response options, on a Likert-type scale, were “Actively recommend,” “Recommend occasionally,”
56
57
58 19 “No opinion,” “Not actively recommend,” and “Not recommend.” An answer of “Actively
59
60

1
2
3
4 1 recommend” was defined as “recommending behaviour,” which is a more positive behaviour.(14)

5
6
7 2 Furthermore, “Recommend occasionally,” “No opinion,” “Not actively recommend,” and “Not

8
9
10 3 recommend” were defined as “no recommending behaviour.”

11
12
13 4

14
15
16 5 Main factor

17
18
19 6 The main factor was PCPs’ knowledge of vaccination, measured by the score on a vaccination quiz.

20
21
22 7 The quiz was created by the Preventive Medicine and Health Promotion Committee Vaccine Team

23
24
25 8 of the JPCA using the Delphi method.(25) The quiz comprised six general vaccine questions

26
27
28 9 covering Japanese vaccination affairs, including a question on the HPVv. The quiz score was the

29
30
31 10 number of correct answers to each of the six questions: 0–6 points. To obtain a binary variable, we

32
33
34 11 designated scores above the average as high, and those below the average as low. High or low

35
36
37 12 vaccination quiz score was considered as the independent variable.

38
39
40 13

41
42
43 14 Possible confounding factors

44
45
46 15 Possible confounding factors included the physician’s sex, postgraduate year (3–5, 6–10, 11–20, 21–

47
48
49 16 30, 31–40, and ≥ 41 years), possession of any specialist qualifications including primary care, main

50
51
52 17 practice category (primary care or not), practice setting (university hospital or general hospital, other

53
54
55 18 hospital, clinic, others; university, research institution, government, health organization, etc.), the

56
57
58 19 proportion of paediatric patients (number of paediatric patients with respect to the total patient

1
2
3
4 1 population) that was high ($\geq 10\%$) or low ($< 10\%$), main working area as an administrative unit of the
5
6
7 2 local government in an urban area ($\geq 50,000$ people) or not, experience as a kindergarten or school
8
9
10 3 physician, experience raising children as a parent, and information resources about vaccinations
11
12
13 4 (government, academic, commercial,(26) online professional community such as website / Facebook
14
15
16 5 group / Twitter / JPCA mailing list,(27) and none).
17
18

19 6 20 21 22 7 Statistical analysis

23
24
25 8 We performed univariate and multivariate logistic regression analysis to estimate the odds ratios, the
26
27
28 9 adjusted odds ratios (AORs), and 95% confidence intervals (CIs), using binary variables for the main
29
30
31 10 outcome. We investigated the association between knowledge of vaccination among PCPs and their
32
33
34 11 administration or recommendations for the HPVv.
35
36

37 12 Multiple logistic regression analysis was performed, adjusting for confounding factors as listed
38
39
40 13 above: physician's sex, postgraduate year, possession of any specialist qualifications, including
41
42
43 14 primary care, main practice category, practice setting, a high or low proportion of paediatric patients,
44
45
46 15 experience raising children as a parent, and information resources about vaccinations.
47
48

49 16 We conducted sensitivity analysis to inspect each variation only for HPVv knowledge (correct or
50
51
52 17 incorrect) rather than for the total quiz score. We used penalized maximum likelihood logistic
53
54
55 18 regression for the analyses when any confounding factors were completely separated.(28)
56
57
58
59
60

1
2
3
4 1 The analysis participants were selected after excluding participants with missing data for the main
5
6
7 2 outcome, main factor, and possible confounders (mentioned above).
8
9

10 3 All statistical analyses used two-tailed tests of significance, with significance set at $p < 0.05$.
11
12

13 4 Analyses were performed using Stata/SE 14.2 (StataCorp LLC, College Station, TX, USA).
14
15

16 5

17
18
19 6

22 7 **RESULTS**

25 8 Study flow and demographics

26
27
28 9 Among the 10,470 physician members of the JPCA, 5,075 who did not subscribe to the mailing list
29
30
31 10 were excluded. We received responses from 1,084 of 5,395 PCPs, for a response rate of 20.1%. The
32
33
34 11 respondents were from all 47 prefectures of Japan. An additional 103 participants were excluded
35
36
37 12 because they lived outside Japan, performed nonclinical work, or had missing data. The analysis
38
39
40 13 included 981 participants (Figure 1). The median (interquartile range) score for the vaccination quiz
41
42
43 14 was 4 (range, 2–5) points. The minimum and maximum scores were 0 and 6 points, respectively, and
44
45
46 15 the mean (standard deviation) score was 3.47 (1.68) points. To obtain a binary variable, scores of ≥ 4
47
48
49 16 were designated as high and scores of ≤ 3 as low. Baseline characteristics showed that 739 (75.3%)
50
51
52 17 participants were men, 358 (36.5%) had been working for 11–20 years after graduation, 420 (42.8%)
53
54
55 18 were working in clinics, 719 (73.3%) were working in the urban areas, and 283 (28.9%) were
56
57
58 19 working in a clinical setting where the proportion of paediatric patients was $\geq 10\%$ (Table 1).
59
60

2 Factors associated with the administration of the HPVv for routine vaccination

3 We found that 229 PCPs (23.3%) administered the HPVv for routine vaccination. PCPs with
4 higher vaccination quiz scores were significantly more likely to administer the HPVv for routine
5 vaccination than those with lower scores (AOR 2.28, 95% CI 1.58–3.28, $p < 0.001$) (Table 2). There
6 was also a positive association between administration of routine HPV vaccination and PCPs who
7 worked at clinics (AOR 2.64, 95% CI 1.60–4.36, $p < 0.001$), those who had a higher proportion of
8 paediatric patients (AOR 1.78, 95% CI 1.24–2.55, $p = 0.002$), and those who had experience as a
9 kindergarten or school physician (AOR 2.12, 95% CI 1.45–3.10, $p < 0.001$).

11 Factors associated with the administration of the HPVv for voluntary vaccination

12 We found that 175 PCPs (17.8%) administered the HPVv for voluntary vaccination. PCPs with
13 higher scores on the vaccination quiz were significantly more likely to administer the HPVv for
14 voluntary vaccination than those with lower scores (AOR 2.71, 95% CI 1.81–4.04, $p < 0.001$) (Table
15 3). There was also a positive association between administration of voluntary HPV vaccination and
16 PCPs who acquired information from governments (AOR 1.90, 95% CI 1.17–3.08, $p = 0.009$) and
17 those who had social network service or mailing list from an individual or group of medical service
18 providers (AOR 1.82, 95% CI 1.25–2.64, $p = 0.002$).

1
2
3
4 1 Factors associated with the recommendation of the HPVv for routine vaccination

5
6
7 2 The classification of PCPs recommendation of the HPVv for routine vaccination showed that 408
8
9
10 3 PCPs (41.6%) “Actively recommend,” 319 (32.5%) “Recommend occasionally,” 181 (18.5%) “No
11
12
13 4 opinion,” 49 (5.0%) “Not actively recommend,” and 24 (2.5%) “Not recommend.” PCPs with higher
14
15
16 5 scores on the vaccination quiz were significantly more likely to recommend the HPVv for routine
17
18
19 6 vaccination than those with lower scores (AOR 2.17, 95% CI 1.62–2.92; $p < 0.001$) (Table 4).
20
21
22 7 However, there was a negative association between recommending routine HPV vaccination and
23
24
25 8 PCPs who worked at other hospitals (AOR 0.69, 95% CI 0.48–1.00, $p = 0.048$) and clinics (AOR
26
27
28 9 0.67, 95% CI 0.46–0.98, $p = 0.041$), those who had a higher proportion of paediatric patients (AOR
29
30
31 10 0.50, 95% CI 0.36–0.70, $p < 0.001$), and those who acquired information from government sources
32
33
34 11 (AOR 0.69, 95% CI 0.50–0.96, $p = 0.026$).
35
36
37 12

38
39
40 13 Factors associated with recommendation of the HPVv for voluntary vaccination

41
42
43 14 The classification of PCPs recommendation of the HPVv for voluntary vaccination showed: 216
44
45
46 15 PCPs “Actively recommend” (22.0%), 358 “Recommend occasionally” (36.5%), 288 “No opinion”
47
48
49 16 (29.4%), 75 “Not actively recommend” (7.7%), and 44 “Not recommend” (4.5%).
50
51

52 17 PCPs with higher vaccination quiz scores were significantly more likely to recommend the HPVv
53
54
55 18 for voluntary vaccination than those with low scores (AOR 1.88, 95% CI 1.32–2.67, $p < 0.001$)
56
57
58 19 (Table 5). There was also a positive association between recommendation of voluntary HPV
59
60

1
2
3
4 1 vaccination and PCPs who were male (AOR 1.67, 95% CI 1.12–2.49, $p = 0.012$) and those who had
5
6
7 2 social network service or mailing list for medical service from an individual or group of providers
8
9
10 3 (AOR 1.56, 95% CI 1.09–2.24, $p = 0.016$). However, there was a negative association between
11
12
13 4 recommendation of voluntary HPV vaccination and PCPs who had a higher proportion of paediatric
14
15
16 5 patients (AOR 0.52, 95% CI, 0.34–0.78, $p = 0.002$) and those who had experience raising children
17
18
19 6 (AOR 0.67, 95% CI 0.45–1.00, $p = 0.049$).
20
21
22 7
23
24

25 8 Sensitivity analysis

26
27
28 9 PCPs with correct answers to the HPV vaccination quiz were significantly more likely to administer
29
30
31 10 the HPVv than those with incorrect answers for routine vaccination (AOR 2.06, 95% CI 1.38–3.09, p
32
33
34 11 < 0.001) and for voluntary vaccination (AOR 2.16, 95% CI 1.39–3.34, $p = 0.001$).
35
36

37 12 PCPs with correct answers on the HPV vaccination quiz were significantly more likely to
38
39
40 13 recommend HPV vaccination than those with incorrect answers for routine vaccination (AOR 1.51,
41
42
43 14 95% CI 1.12–2.04, $p = 0.006$) and for voluntary vaccination (AOR 1.53, 95% CI 1.07–2.19, $p =$
44
45
46 15 0.02).
47
48
49 16
50
51

52 17 **DISCUSSION**

53
54
55 18 This is the first study to focus on the association between PCPs' knowledge of vaccination and their
56
57
58 19 practice or attitude toward the HPVv without proactive recommendation from the government in
59
60

1
2
3
4 1 Japan. We found positive associations between PCPs' vaccination knowledge and the administration
5
6
7 2 or recommendation of the HPVv for routine and voluntary vaccination. We also found positive
8
9
10 3 associations between different information resources and administration or recommendations of
11
12
13 4 voluntary HPV vaccination.

16 5 As of 2019, the proportion of PCPs who administered or actively recommended the HPVv for
17
18
19 6 routine vaccination (23.3% and 41.6%, respectively) was the lowest compared with other routine
20
21
22 7 vaccines (39.5–95.5% and 74.5–92.0%, respectively) in Japan.(29) Compared to a previous study in
23
24
25 8 2012,(22) the proportion of HPVv administration among PCPs decreased from 58.3% for voluntary
26
27
28 9 vaccination only(22) to 23.3% for routine vaccination and 17.8% for voluntary vaccination, and the
29
30
31 10 proportion of HPVv recommendation among PCPs decreased from 46.5% for voluntary vaccination
32
33
34 11 only(22) to 41.6% for routine vaccination and 22.0% for voluntary vaccination. A study conducted
35
36
37 12 among paediatricians in Osaka, Japan, in 2020 and 2021 reported that the proportion of
38
39
40 13 paediatricians who administered or actively recommended the HPVv for routine vaccination was
41
42
43 14 44.5% and 32.5% in 2020 and 67.9% and 40% in 2021, respectively.(30) In addition, a study
44
45
46 15 conducted among OBGYNs in Osaka, Japan, reported that the proportion of OBGYNs who
47
48
49 16 recommended the HPVv for teenagers was 70.1% in 2017(3) and 84.6% in 2019.(31) As of 2018, the
50
51
52 17 proportion of family physicians and paediatricians in the United States who administered the HPVv
53
54
55 18 was 84.1% and 95.3%, respectively,(32) and the proportion who strongly recommended the HPVv
56
57
58 19 was 72–90% and 85–99% (11- to 12-year-old, 13- to 14-year-old, and ≥ 15 years female patients),
59
60

1
2
3
4 1 respectively.(32) Our study revealed that in Japan, PCPs may administer routine HPV vaccination
5
6
7 2 less than paediatricians,(30) and PCPs might actively recommend routine HPV vaccination more
8
9
10 3 than paediatricians,(30) but less than OBGYNs.(3) In addition, our study shows that Japanese PCPs
11
12
13 4 might administer or recommend the HPVv less than family physicians in the United States.(32)
14
15

16 5 Our study revealed the association between PCPs' accurate knowledge of vaccination and their
17
18
19 6 recommendation for HPV vaccination. In addition, as a sensitivity analysis, our study showed that
20
21
22 7 physicians with accurate knowledge of HPV vaccination were likely to recommend the HPVv. A
23
24
25 8 systematic review published in 2021 that examined healthcare providers' vaccine perceptions,
26
27
28 9 knowledge, and recommendations to patients, including 96 papers from 34 countries, showed that
29
30
31 10 recommendations were positively associated with healthcare provider knowledge and experience,
32
33
34 11 beliefs about disease risk, and perceptions of vaccine safety, necessity, and efficacy.(33) The results
35
36
37 12 of our study are consistent with this systematic review.(33) In Lebanon, where HPVv is not included
38
39
40 13 in their national routine vaccination schedule as of 2017, physicians practicing in OB-GYN,
41
42
43 14 paediatrics, family medicine, and infectious diseases with higher scores of knowledge about HPV
44
45
46 15 and HPVv recommend the HPVv more often (AOR 3.4).(34) Further, in the United States, higher
47
48
49 16 rates of HPV vaccination completion of three doses (IRR 1.28) were observed among primary care
50
51
52 17 clinicians including family medicine physicians, general paediatricians, and family and paediatric
53
54
55 18 nurse-practitioners with greater knowledge of HPV and the HPVv (35). Our results also support
56
57
58 19 these findings. Another study investigating the association between PCPs' knowledge of vaccination
59
60

1
2
3
4 1 and the administration or recommendation of voluntary mumps vaccination for adults showed the
5
6
7 2 same positive associations.(36)
8
9

10 3 Information resources from social network services or mailing lists from medical service providers
11
12
13 4 seem to be positively associated with the administration or recommendation of voluntary HPV
14
15
16 5 vaccination. This might be because PCPs use virtual communities as valuable knowledge portals for
17
18
19 6 sourcing clinically relevant information(37) and could be interested in understanding how and why
20
21
22 7 other physicians recommend and administer vaccination.(21, 36) Government information resources
23
24
25 8 were positively associated with the administration of voluntary HPVv; however, it was negatively
26
27
28 9 associated with the recommendation of routine HPV vaccination. As of 2019, the suspension of
29
30
31 10 proactive recommendation for routine HPV vaccination by the MHLW was still implemented. This
32
33
34 11 suspension was not meant to suspend routine vaccination, although some PCPs might have
35
36
37 12 misinterpreted it as suspension of routine vaccination. Therefore, PCPs who know this policy from
38
39
40 13 government information might administer voluntary instead of routine HPV vaccination, and might
41
42
43 14 not recommend routine HPV vaccination. Alternatively, PCPs who know of the suspension might
44
45
46 15 lose their confidence to recommend the HPVv. A previous study reported that the lack of
47
48
49 16 government recommendations was one of the barriers for PCPs to recommend vaccination.(22) In
50
51
52 17 November 2021, the MHLW ended this suspension and restarted “proactive recommendation,”
53
54
55 18 targeting girls born in or after the fiscal year (FY) 2006, beginning in April 2022(38), and started
56
57
58 19 “catch-up vaccinations” for 3 years, from April 2022 to March 2025, for females born in FY1997 to
59
60

1
2
3
4 1 FY2005 who became eligible for routine HPV vaccination, while they might have missed the
5
6
7 2 opportunity to receive the vaccination because of the suspension.(39, 40) The results of our study
8
9
10 3 suggest that providing accurate knowledge and information about HPV vaccination to PCPs might
11
12
13 4 make more PCPs administer and recommend the HPVv, which might increase the vaccination rate.
14
15
16 5 The JPCA vaccine team provides information about vaccination through websites(41) and regular
17
18
19 6 onsite and online vaccine seminars for physicians.(42)
20
21

22 7 Our study also shows that PCPs who are working at clinics, providing daily paediatric medical
23
24
25 8 services (more than 10% of total patients), and have experience as kindergarten or school physicians
26
27
28 9 tend to administer routine HPV vaccination (Table 2). The target population for routine HPV
29
30
31 10 vaccination is 12- to 16-year-old girls, and PCPs with this experience might understand the need for
32
33
34 11 routine vaccination; therefore, they might be more likely to administer the vaccination. In contrast,
35
36
37 12 PCPs working at clinics or other hospitals providing daily paediatric medical services (more than
38
39
40 13 10% of total patients) were less likely to recommend routine HPV vaccination (Table 4). In addition,
41
42
43 14 PCPs who provide daily paediatric medical services (more than 10% of total patients) and had
44
45
46 15 experience raising children tended to be less likely to recommend voluntary HPV vaccination (Table
47
48
49 16 5). These results suggest that PCPs who had more opportunity to provide medical service to 12- to
50
51
52 17 16-year-old girls might have less confidence to recommend the HPVv during the suspension of
53
54
55 18 proactive recommendation by the MHLW or might be more affected by anxiousness or hesitancy of
56
57
58 19 the parents.(18, 22, 43)
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 This study has some limitations. First, there was a potential selection bias due to the low response
2 rate. PCPs who more actively promoted vaccination may have been more likely to respond, and the
3 actual proportion of PCPs' administration or recommendation for the HPVv may be lower. Second,
4 our study did not include voluntary vaccination for HPVv in men. In Japan, as of 2019, the target
5 group for both routine and voluntary HPV vaccination was only women, although, in 2020, men
6 were approved for voluntary vaccination with the quadrivalent HPVv. Third, our study did not
7 evaluate 9-valent HPVv for voluntary vaccination, although, in 2021, the 9-valent HPVv was
8 approved for voluntary vaccination(24) and will be approved for routine vaccination from April
9 2023.(44) In future studies, men should also be targeted in addition to women while performing such
10 surveys, and 9-valent HPVv should be included as a study subject. Fourth, we did not evaluate the
11 effects of vaccine hesitancy from the parents or mainstream media and social media on the PCPs.(43)
12 Including the effect of vaccine hesitancy as one of exposures in the future studies would be useful.
13 Fifth, we did not evaluate the effects of unknown confounding factors, which is a general limitation
14 of observational studies. Finally, although the study participants were physician members of the
15 JPCA, the largest society for PCPs in Japan, generalisability of the results to PCPs outside of Japan
16 was unclear. The vaccination policy for the HPVv in Japan(39) changed after this study was
17 conducted, and further surveys are needed to assess the current situation of HPV vaccination and
18 attitude among PCPs.

1 2 3 4 **1 CONCLUSIONS**

5
6
7 **2** We revealed a positive association between PCPs' vaccine knowledge and the administration or
8
9
10 **3** recommendation of routine and voluntary HPV vaccination without proactive recommendation from
11
12
13 **4** the government. Several factors influence PCP's perception of HPV vaccinations, ultimately
14
15
16 **5** affecting public healthcare. Our results suggest that providing more knowledge about vaccination to
17
18
19 **6** PCPs may increase their likelihood to administer or recommend the HPVv, thereby improving
20
21
22 **7** vaccination rates. Moreover, the results of our study can be applied to other countries with similar
23
24
25 **8** vaccination situations, such as those with vaccine hesitancy and disagreements between the scientific
26
27
28 **9** community and governments on vaccine policy.(8, 45)
29
30

31 **10**

32 33 34 **11 Data availability statement**

35
36
37 **12** Data are available upon reasonable request.
38
39

40 **13**

41 42 43 **14 Ethics statements**

44
45
46 **15** Patient consent for publication
47
48

49 **16** We obtained written informed consent from all participants before conducting the survey.
50
51

52 **17** Ethics approval
53
54

55 **18** The study protocol was approved by the Institutional Review Board of XXX.
56
57

58 **19**

1 **Acknowledgments**

2 We would like to thank Tesshu Kusaba, President of the Japan Primary Care Association, and head
3 office staff for their corporation in delivering the questionnaire; all physicians who took part in this
4 survey. We would like to thank Editage (www.editage.com) for English language editing.

5
6 **Contributors:** All authors declare they have contributed to this article. YS conducted the
7 questionnaire, designed and implemented the survey, and performed analysis, interpretation of the
8 data, wrote the draft manuscript, and performed critical revisions. JT conducted the questionnaire,
9 designed and implemented the survey, interpretation of the data, and performed critical revisions.
10 RS, KN, YN, HC, TK and AM conducted the questionnaire, interpretation of the data, and critical
11 revisions. MM interpretation of the data, and critical revisions. TO and TS arranged for delivering
12 the questionnaire, and critical revisions. All authors read and approved this manuscript version for
13 submission.

14
15 **Funding:** This work was supported by JSPS KAKENHI (Grant Numbers JP19K19445).

16
17 **Competing interests:** None declared.

1
2
3
4 1 **Provenance and peer review:** Not commissioned; externally peer reviewed.
5
6
7 2
8
9
10 3
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4 **TABLES**
5

6 **TABLE 1** Characteristics of the participants
7

	Participants, n=981	Responders, n=1084
	n (%)	n (%)
Sex: male	739 (75.3), Missing 0	749 (69.1), Missing 88 (8.1)
Postgraduate year (y)	Missing 0	Missing 88 (8.1)
3–5	92 (9.4)	92 (8.5)
6–10	178 (18.1)	181 (16.7)
11–20	358 (36.5)	364 (33.6)
21–30	193 (19.7)	197 (18.2)
31–40	134 (13.7)	135 (12.5)
≥41	26 (2.7)	27 (2.5)
Main practice category: primary care	697 (71.1), Missing 0	705 (65.0), Missing 90 (8.3)
Practice setting	Missing 6 (0.6)	Missing 95 (8.8)
University hospital or general hospital	281 (28.6)	283 (26.1)
Other hospital	254 (25.9)	255 (23.5)
Clinic	420 (42.8)	426 (39.3)
Others (University, research institution, government, health organization, etc.)	20 (2.0)	25 (2.3)
Providing daily paediatric medical service (≥ 10% of total patients)	283 (28.9), Missing 0	291 (26.9), Missing 88 (8.1)
Mainly working in an urban area (≥50,000 people as an administrative unit of the local government)	719 (73.3), Missing 2 (0.2)	733 (67.6), Missing 90 (8.3)
Experience of kindergarten or school physician	474 (48.3), Missing 0	478 (44.1), Missing 88 (8.1)
Experience raising children	721 (73.5), Missing 0	734 (67.7), Missing 88 (8.1)
Main practice category: primary care: Answered main practice category as family physician or general practitioner or hospitalist/general physician		

TABLE 2 Factors associated with administration of HPV vaccine for routine vaccination

	PCPs who administer HPV vaccine, n=229 (23.3%)	PCPs who do not administer HPV vaccine, n=752 (76.7%)	Crude odds ratio (95% CI), n=981	<i>p</i> -value	Adjusted odds ratio* (95% CI), n=977	<i>p</i> -value
Factors	n (%)	n (%)	n (%)		n (%)	
High scores in vaccination quiz (4–6 points)	172 (75.1)	339 (45.1)	3.68 (2.64–5.12)	<0.001	2.28 (1.58–3.28)	<0.001
Sex: male	178 (77.7)	561 (74.6)	1.19 (0.84–1.69)	0.380	1.11 (0.75–1.65)	0.600
Postgraduate year (y)						
3–5	14 (6.1)	78 (10.4)	Reference		Reference	
6–10	28 (12.2)	150 (20.0)	1.04 (0.52–2.09)	0.910	0.48 (0.20–1.18)	0.110
11–20	95 (41.5)	263 (35.0)	2.01 (1.09–3.72)	0.026	0.83 (0.34–2.02)	0.680
21–30	51 (22.3)	142 (18.9)	2.00 (1.04–3.84)	0.037	0.91 (0.37–2.27)	0.850
31–40	34 (14.9)	100 (13.3)	1.89 (0.95–3.77)	0.069	0.80 (0.32–1.99)	0.630
≥41	7 (3.1)	19 (2.5)	2.05 (0.73–5.79)	0.170	0.79 (0.23–2.67)	0.700
Position of any specialist qualification	201 (87.8)	643 (85.6)	1.21 (0.77–1.88)	0.410	1.04 (0.57–1.89)	0.890
Main practice category: primary care	183 (79.9)	514 (68.4)	1.84 (1.29–2.63)	0.001	1.18 (0.74–1.88)	0.500
Practice setting						
University hospital or general hospital	28 (12.2)	253 (33.8)	Reference		Reference	
Other hospital	35 (15.3)	219 (29.2)	1.44 (0.85–2.45)	0.170	1.18 (0.68–2.06)	0.550
Clinic	164 (71.6)	256 (34.2)	5.79 (3.74–8.96)	<0.001	2.64 (1.60–4.36)	<0.001

1							
2	Others	2 (0.87)	21 (2.8)	0.86 (0.19–3.86)	0.850	0.90 (0.22–3.73)	0.880
3	(University, research institution,						
4	government, health organization, etc.)						
5	Providing daily paediatric medical	113 (49.3)	170 (22.6)	3.33 (2.45–4.55)	<0.001	1.78 (1.24–2.55)	0.002
6	service (≥ 10% of total patients)						
7	Mainly working in an urban area	164 (71.6)	555 (74.0)	0.89 (0.64–1.23)	0.480	1.07 (0.73–1.55)	0.740
8	(≥50,000 people as an administrative						
9	unit of the local government)						
10	Experience of kindergarten or school	165 (72.1)	309 (41.1)	3.70 (2.68–5.11)	<0.001	2.12 (1.45–3.10)	<0.001
11	physician						
12	Experience raising children	176 (76.9)	545 (72.5)	1.26 (0.89–1.78)	0.190	0.86 (0.56–1.32)	0.480
13	Information resource						
14	Government	189 (82.5)	558 (74.2)	1.64 (1.13–2.40)	0.010	1.25 (0.82–1.90)	0.290
15	Academia	226 (98.7)	687 (91.4)	7.13 (2.22–22.90)	0.001	1.76 (0.55–5.64)	0.340
16	Commerce	71 (31.0)	212 (28.2)	1.14 (0.83–1.58)	0.410	0.85 (0.58–1.23)	0.380
17	Social network service or mailing list	94 (41.1)	205 (27.3)	1.86 (1.36–2.53)	<0.001	1.26 (0.88–1.80)	0.210
18	by individuals or group of medical						
19	service providers						
20	None	0	19 (2.5)	0.08 (0.05–1.36)*	0.081	0.35 (0.02–8.24)	0.520

*Penalized maximum likelihood logistic regression. PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

1
2

TABLE 3 Factors associated with administration of HPV vaccine for voluntary vaccination

	PCPs who administer HPV vaccine, n=175 (17.8%)	PCPs who do not administer HPV vaccine, n=806 (82.2%)	Crude odds ratio (95% CI), n=981	<i>p</i> -value	Adjusted odds ratio* (95% CI), n=977	<i>p</i> -value
Factors	n (%)	n (%)	n (%)		n (%)	
High scores in vaccination quiz (4–6 points)	132 (75.4)	379 (47.0)	3.46 (2.39–5.01)	<0.001	2.71 (1.81–4.04)	<0.001
Sex: male	131 (74.8)	608 (75.4)	0.97 (0.66–1.41)	0.870	0.89 (0.59–1.35)	0.580
Postgraduate year (y)						
3–5	12 (6.9)	80 (9.9)	Reference		Reference	
6–10	21 (12.0)	157 (19.5)	0.89 (0.42–1.90)	0.770	0.48 (0.19–1.23)	0.130
11–20	66 (37.7)	292 (36.2)	1.51 (0.78–2.92)	0.230	0.69 (0.27–1.75)	0.430
21–30	41 (23.4)	152 (18.9)	1.80 (0.89–3.61)	0.099	0.97 (0.38–2.50)	0.960
31–40	28 (16.0)	106 (13.2)	1.76 (0.84–3.67)	0.130	0.98 (0.38–2.53)	0.970
≥41	7 (4.0)	19 (2.4)	2.46 (0.85–7.07)	0.096	1.35 (0.40–4.57)	0.630
Position of any specialist qualification	154 (88.0)	690 (85.7)	1.22 (0.74–2.01)	0.430	1.12 (0.59–2.12)	0.730
Main practice category: primary care	141 (80.6)	556 (69.0)	1.86 (1.25–2.79)	0.002	1.52 (0.93–2.49)	0.098
Practice setting						
University hospital or general hospital	36 (20.6)	245 (30.5)	Reference		Reference	
Other hospital	29 (16.6)	225 (28.0)	0.89 (0.52–1.48)	0.620	0.68 (0.39–1.19)	0.180
Clinic	109 (62.3)	311 (38.7)	2.39 (1.58–3.60)	<0.001	1.27 (0.77–2.08)	0.350

1							
2	Others	1 (0.57)	22 (2.7)	0.31 (0.04–2.37)	0.260	0.37 (0.06–2.10)	0.260
3	(University, research institution,						
4	government, health organization, etc.)						
5							
6	Providing daily paediatric medical	66 (37.7)	217 (26.9)	1.64 (1.17–2.32)	0.005	1.04 (0.70–1.55)	0.840
7	service ($\geq 10\%$ of total patients)						
8							
9							
10							
11	Mainly working in an urban area	135 (77.1)	584 (72.6)	1.27 (0.86–1.87)	0.220	1.26 (0.83–1.91)	0.270
12	($\geq 50,000$ people as an administrative						
13	unit of the local government)						
14							
15							
16							
17							
18	Experience of kindergarten or school	106 (60.6)	368 (45.7)	1.83 (1.31–2.55)	<0.001	1.23 (0.82–1.84)	0.310
19	physician						
20							
21	Experience raising children	129 (73.7)	592 (73.5)	1.01 (0.70–1.47)	0.070	0.70 (0.45–1.08)	0.110
22							
23	Information resource						
24	Government	152 (86.9)	595 (73.8)	2.34 (1.47–3.73)	<0.001	1.90 (1.17–3.08)	0.009
25	Academia	170 (97.1)	743 (92.2)	2.88 (1.14–7.28)	0.025	0.93 (0.35–2.43)	0.880
26	Commerce	55 (31.4)	228 (28.3)	1.16 (0.82–1.66)	0.410	0.84 (0.57–1.25)	0.390
27	Social network service or mailing list	80 (45.7)	219 (27.2)	2.26 (1.61–3.16)	<0.001	1.82 (1.25–2.64)	0.002
28	by individuals or group of medical						
29	service providers						
30							
31	None	0	19 (2.4)	0.12 (0.01–1.91)*	0.130	0.39 (0.02–8.00)	0.540
32							
33							
34							
35							

*Penalized maximum likelihood logistic regression. PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

1

TABLE 4 Factors associated with recommendation of HPV vaccine for routine vaccination

	PCPs who recommend HPV vaccine, n=408 (41.6%)	PCPs who do not recommend HPV vaccine, n=573 (58.4%)	Crude odds ratio (95% CI), n=981	p-value	Adjusted odds ratio (95% CI), n=977	p-value
Factors	n (%)	n (%)	n (%)		n (%)	
High scores in vaccination quiz (4–6 points)	248 (60.8)	263 (45.9)	1.83 (1.41–2.36)	<0.001	2.17 (1.62–2.92)	<0.001
Sex: male	319 (78.2)	420 (73.3)	1.31 (0.97–1.76)	0.080	1.37 (0.99–1.90)	0.056
Postgraduate year (y)						
3–5	44 (10.8)	48 (8.4)	Reference		Reference	
6–10	69 (16.9)	109 (19.0)	0.69 (0.42–1.15)	0.150	0.89 (0.47–1.68)	0.720
11–20	153 (37.5)	205 (35.8)	0.81 (0.51–1.29)	0.380	1.03 (0.53–1.99)	0.940
21–30	90 (22.1)	103 (18.0)	0.95 (0.58–1.57)	0.850	1.28 (0.64–2.53)	0.480
31–40	45 (11.0)	89 (15.5)	0.55 (0.32–0.95)	0.032	0.73 (0.36–1.48)	0.380
≥41	7 (1.7)	19 (3.3)	0.40 (0.15–1.05)	0.062	0.56 (0.19–1.62)	0.280
Position of any specialist qualification						0.350
347 (85.1)	497 (86.9)	0.86 (0.60–1.24)	0.410	0.79 (0.49–1.29)		
Main practice category: primary care	281 (68.9)	416 (72.6)	0.84 (0.63–1.10)	0.210	0.79 (0.55–1.11)	0.180
Practice setting						
University hospital or general hospital	143 (33.8)	143 (25.1)	Reference		Reference	
Other hospital	101 (24.8)	219 (29.2)	0.68 (0.49–0.96)	0.030	0.69 (0.48–1.00)	0.048
Clinic	161 (39.5)	259 (45.4)	0.64 (0.47–0.87)	0.005	0.67 (0.46–0.98)	0.041

1							
2	Others	8 (2.0)	15 (2.6)	0.55 (0.23–1.34)	0.190	0.51 (0.20–1.31)	0.160
3	(University, research institution,						
4	government, health organization, etc.)						
5	Providing daily paediatric medical	95 (23.3)	188 (32.8)	0.62 (0.47–0.83)	0.001	0.50 (0.36–0.70)	<0.001
6	service (≥10% of total patients)						
7	Mainly working in an urban area	305 (74.9)	414 (72.4)	1.14 (0.85–1.52)	0.370	1.08 (0.78–1.47)	0.650
8	(≥50,000 people as an administrative						
9	unit of the local government)						
10	Experience of kindergarten or school	190 (46.6)	284 (49.6)	0.89 (0.69–1.14)	0.360	1.09 (0.80–1.49)	0.570
11	physician						
12	Experience raising children	296 (72.6)	425 (74.2)	0.92 (0.69–1.23)	0.570	0.79 (0.56–1.10)	0.160
13	Information resource						
14	Government	294 (72.1)	453 (79.1)	0.68 (0.51–0.92)	0.011	0.69 (0.50–0.96)	0.026
15	Academia	385 (94.4)	528 (92.2)	1.43 (0.85–2.40)	0.180	1.21 (0.63–2.35)	0.560
16	Commerce	113 (27.7)	170 (29.7)	0.91 (0.69–1.20)	0.500	0.91 (0.67–1.25)	0.560
17	Social network service or mailing	136 (33.3)	163 (28.5)	1.26 (0.96–1.65)	0.100	1.33 (0.98–1.82)	0.071
18	list by individuals or group of						
19	medical service providers						
20	None	7 (1.7)	12 (2.1)	0.82 (0.32–2.09)	0.670	0.82 (0.25–2.68)	0.740

1 PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

TABLE 5 Factors associated with recommendation of HPV vaccine for voluntary vaccination

	PCPs who recommend HPV vaccine, n=216 (22.0%)	PCPs who do not recommend HPV vaccine, n=765 (78.0%)	Crude odds ratio (95% CI), n=981	<i>p</i> -value	Adjusted odds ratio (95% CI), n=977	<i>p</i> -value
Factors	n (%)	n (%)	n (%)		n (%)	
High scores in vaccination quiz (4–6 points)	131 (60.6)	380 (49.7)	1.56 (1.15–2.12)	0.005	1.88 (1.32–2.67)	<0.001
Sex: male	174 (80.6)	565 (73.9)	1.47 (1.01–2.13)	0.045	1.67 (1.12–2.49)	0.012
Postgraduate year (y)						
3–5	24 (11.1)	68 (8.9)	Reference		Reference	
6–10	30 (13.9)	148 (19.4)	0.57 (0.31–1.06)	0.074	0.81 (0.37–1.75)	0.590
11–20	87 (40.3)	271 (35.4)	0.91 (0.54–1.54)	0.720	1.40 (0.63–3.08)	0.410
21–30	52 (24.1)	141 (18.4)	1.04 (0.59–1.84)	0.880	1.73 (0.77–3.88)	0.190
31–40	21 (9.7)	113 (14.8)	0.53 (0.27–1.02)	0.056	0.84 (0.36–1.98)	0.690
≥41	2 (0.9)	24 (3.1)	0.24 (0.05–1.02)	0.062	0.38 (0.07–1.89)	0.240
Position of any specialist qualification	184 (85.2)	660 (86.4)	0.91 (0.59–1.39)	0.65	0.74 (0.40–1.35)	0.320
Main practice category: primary care	148 (68.5)	549 (71.7)	0.86 (0.62–1.19)	0.35	0.84 (0.55–1.27)	0.400
Practice setting						
University hospital or general hospital	81 (37.5)	200 (26.3)	Reference		Reference	
Other hospital	53 (24.5)	201 (26.4)	0.65 (0.44–0.97)	0.030	0.69 (0.45–1.06)	0.091

1							
2	Clinic	77 (35.7)	343 (45.0)	0.55 (0.39–0.79)	0.001	0.67 (0.43–1.04)	0.075
3	Others	5 (2.3)	18 (2.4)	0.69 (0.25–1.91)	0.470	0.63 (0.21–1.84)	0.400
4							
5	(University, research institution,						
6	government, health organization,						
7	etc.)						
8							
9	Providing daily paediatric medical	43 (19.9)	240 (31.4)	0.54 (0.38–0.78)	0.001	0.52 (0.34–0.78)	0.002
10	service ($\geq 10\%$ of total patients)						
11							
12	Mainly working in an urban area	171 (80.0)	547 (71.6)	1.59 (1.10–2.30)	0.014	1.42 (0.95–2.11)	0.084
13	($\geq 50,000$ people as an						
14	administrative unit of the local						
15	government)						
16							
17	Experience of kindergarten or	87 (40.3)	387 (50.6)	0.66 (0.48–0.90)	0.008	0.79 (0.55–1.14)	0.210
18	school physician						
19							
20	Experience raising children	153 (70.8)	568 (74.3)	0.84 (0.60–1.18)	0.32	0.67 (0.45–1.00)	0.049
21							
22	Information resource						
23							
24	Government	155 (71.8)	592 (77.4)	0.74 (0.53–1.04)	0.087	0.80 (0.55–1.16)	0.240
25							
26	Academia	202 (93.5)	711 (92.9)	1.10 (0.60–2.01)	0.770	0.94 (0.44–2.04)	0.880
27							
28	Commerce	60 (27.8)	223 (29.2)	0.93 (0.67–1.31)	0.690	0.91 (0.63–1.32)	0.620
29							
30	Social network service or mailing	79 (36.6)	220 (28.8)	1.43 (1.04–1.96)	0.028	1.56 (1.09–2.24)	0.016
31	list by individuals or group of						
32	medical service providers						
33							
34	None	4 (1.9)	15 (2.0)	0.94 (0.31–2.87)	0.920	0.84 (0.21–3.40)	0.810

1 PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

1
2
3
4 **1 Figure Legends**

5
6
7 **2 Figure 1.** Study flowchart

8
9
10 **3 REFERENCES**

- 11
12
13 • 1. World Health Organization. Electronic address swi. Human papillomavirus vaccines: WHO
14
15
16 position paper, May 2017-Recommendations. *Vaccine*. 2017;35(43):5753-5.
17
18
19 • 2. Hanley SJ, Yoshioka E, Ito Y, Konno R, Hayashi Y, Kishi R, et al. Acceptance of and
20
21
22 attitudes towards human papillomavirus vaccination in Japanese mothers of adolescent girls.
23
24
25 *Vaccine*. 2012;30(39):5740-7.
26
27
28 • 3. Sawada M, Ueda Y, Yagi A, Morimoto A, Nakae R, Kakubari R, et al. HPV vaccination in
29
30
31 Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their
32
33
34 opinions toward the vaccine. *Int J Clin Oncol*. 2018;23(1):121-5.
35
36
37 • 4. Ueda Y, Enomoto T, Sekine M, Egawa-Takata T, Morimoto A, Kimura T. Japan's failure to
38
39
40 vaccinate girls against human papillomavirus. *Am J Obstet Gynecol*. 2015;212(3):405-6.
41
42
43 • 5. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. *Lancet*.
44
45
46 2015;385(9987):2571.
47
48
49 • 6. Masayuki Sekine RK, Sosuke Adachi, Manako Yamaguchi, Yutaka Ueda, Tomomi Takata,
50
51
52 Akiko Morimoto, Yusuke Tanaka, Asami Yagi, Etsuko Miyagi, Takayuki Enomoto. Japanese crisis
53
54
55 of HPV vaccination. *International Journal of Pathology and Clinical Research*. 2016;IJPCR-2-039,
56
57
58 (Volume 2, Issue 2):1-3.
59
60

- 1
2
3
4 1 • 7. Yagi A, Ueda Y, Egawa-Takata T, Tanaka Y, Nakae R, Morimoto A, et al. Realistic fear of
5
6
7 2 cervical cancer risk in Japan depending on birth year. *Hum Vaccin Immunother.* 2017;13(7):1700-4.
8
9
10 3 • 8. Inokuma Y, Kneller R. Imprecision in adverse event reports following immunization against
11
12
13 4 HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and
14
15
16 5 government policy. *Eur J Clin Pharmacol.* 2023;79(2):269-78.
17
18
19 6 • 9. Ministry of Health, Labour and Welfare of Japan . Correspondence about the routine
20
21
22 7 vaccination of human papilloma virus infection (recommendation). 2013. (in Japanese) Available:
23
24
25 8 https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/pdf/kankoku_h25_6_01.pdf
26
27
28 9 [Accessed 25 Mar 2023]
29
30
31 10 • 10. World Health Organization. Meeting of the Global Advisory Committee on Vaccine Safety,
32
33
34 11 7–8 June 2017. *Wkly Epidemiol Rec.* 2017;92(28):393-402.
35
36
37 12 • 11. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination
38
39
40 13 symptoms in Japanese young women: Results of the Nagoya study. *Papillomavirus Res.*
41
42
43 14 2018;5(17):96-103.
44
45
46 15 • 12. World Health Organization. Ten threats to global health in 2019. 2019. Available:
47
48
49 16 <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>. [Accessed 25 Mar
50
51
52 17 2023]
53
54
55 18 • 13. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed,
56
57
58 19 systematic review. *Preventive medicine.* 2007;45(2-3):107-14.
59
60

- 1
2
3
4 1 • 14. Oster NV, McPhillips-Tangum CA, Averhoff F, Howell K. Barriers to adolescent
5
6
7 2 immunization: a survey of family physicians and pediatricians. *The Journal of the American Board*
8
9
10 3 of Family Practice / American Board of Family Practice. 2005;18(1):13-9.
11
12
13 4 • 15. Taylor JA, Darden PM, Slora E, Hasemeier CM, Asmussen L, Wasserman R. The influence
14
15
16 5 of provider behavior, parental characteristics, and a public policy initiative on the immunization
17
18
19 6 status of children followed by private pediatricians: a study from Pediatric Research in Office
20
21
22 7 Settings. *Pediatrics*. 1997;99(2):209-15.
23
24
25 8 • 16. Tsuchiya Y, Shida N, Izumi S, Ogasawara M, Kakinuma W, Tsujiuchi T, et al. Factors
26
27
28 9 associated with mothers not vaccinating their children against mumps in Japan. *Public Health*.
29
30
31 10 2016;137:95-105.
32
33
34 11 • 17. Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider
35
36
37 12 communication and HPV vaccination: The impact of recommendation quality. *Vaccine*.
38
39
40 13 2016;34(9):1187-92.
41
42
43 14 • 18. Gilkey MB, McRee AL. Provider communication about HPV vaccination: A systematic
44
45
46 15 review. *Hum Vaccin Immunother*. 2016;12(6):1454-68.
47
48
49 16 • 19. Collange F, Fressard L, Pulcini C, Sebbah R, Peretti-Watel P, Verger P. General
50
51
52 17 practitioners' attitudes and behaviors toward HPV vaccination: A French national survey. *Vaccine*.
53
54
55 18 2016;34(6):762-8.
56
57
58 19 • 20. Wong MCS, Lee A, Ngai KKL, Chor JCY, Chan PKS. Knowledge, Attitude, Practice and
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Barriers on Vaccination against Human Papillomavirus Infection: A Cross-Sectional Study among
2 Primary Care Physicians in Hong Kong. PLoS ONE. 2013;8(8):e71827.

3 • 21. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine
4 hesitancy and healthcare providers. Vaccine. 2016;34(52):6700-6.

5 • 22. Sakanishi Y, Hara M, Fukumori N, Kusaba T, Tanaka K, Sugioka T, et al. Primary care
6 physician practices, recommendations, and barriers to the provision of routine and voluntary
7 vaccinations in Japan. An Official Journal of the Japan Primary Care Association. 2014;37(3):254-9.

8 • 23. Sakanishi Y, Yamamoto Y, Hara M, Fukumori N, Goto Y, Kusaba T, et al. Public subsidies
9 and the recommendation of child vaccines among primary care physicians: a nationwide cross-
10 sectional study in Japan. BMJ Open. 2018;8(7):e020923.

11 • 24. Ministry of Health, Labour and Welfare of Japan. Q & A regarding HPV vaccine. 2022. (in
12 Japanese) Available: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou/hpv_qa.html#Q2-2.
13 [Accessed 25 Mar 2023]

14 • 25. Jones J, Hunter D. Consensus methods for medical and health services research. Bmj.
15 1995;311(7001):376-80.

16 • 26. Watkins C, Moore L, Harvey I, Carthy P, Robinson E, Brawn R. Characteristics of general
17 practitioners who frequently see drug industry representatives: national cross sectional study. BMJ.
18 2003;326(7400):1178-9.

19 • 27. Klee D, Covey C, Zhong L. Social media beliefs and usage among family medicine

1
2
3
4 1 residents and practicing family physicians. *Fam Med*. 2015;47(3):222-6.

5
6
7 2 • 28. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. *Stat*
8
9
10 3 *Med*. 2002;21(16):2409-19.

11
12
13 4 • 29. Sakanishi Y, Takeuchi J, Chiba H, Nishioka Y, Kishi T, Machino A, et al. Practices,
14
15
16 5 Recommendations, Knowledge, and Sources of Information for Primary Care Physicians regarding
17
18
19 6 Vaccinations: A Nationwide Survey in Japan, 2019. *An Official Journal of the Japan Primary Care*
20
21
22 7 *Association*. 2022;45(2):49-58.

23
24
25 8 • 30. Kubota M, Kondo K, Tomiyoshi Y, Fukushima W. Survey of pediatricians concerning the
26
27
28 9 human papillomavirus vaccine in Japan: Positive attitudes toward vaccination during the period of
29
30
31 10 proactive recommendation being withheld. *Hum Vaccin Immunother*. 2022;18(6):2131337.

32
33
34 11 • 31. Nagase YA-O, Ueda Y, Abe H, Yagi A, Sawada M, Nakagawa S, et al. Changing attitudes
35
36
37 12 in Japan toward HPV vaccination: a 5-year follow-up survey of obstetricians and gynecologists
38
39
40 13 regarding their current opinions about the HPV vaccine. 2020(2164-554X (Electronic)).

41
42
43 14 • 32. Kempe A, O'Leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, et al. HPV
44
45
46 15 Vaccine Delivery Practices by Primary Care Physicians. *Pediatrics*. 2019;144(4).

47
48
49 16 • 33. Lin C, Mullen J, Smith D, Kotarba M, Kaplan SJ, Tu P. Healthcare Providers' Vaccine
50
51
52 17 Perceptions, Hesitancy, and Recommendation to Patients: A Systematic Review. *Vaccines (Basel)*.
53
54
55 18 2021;9(7).

56
57
58 19 • 34. Abi Jaoude J, Khair D, Dagher H, Saad H, Cherfan P, Kaafarani MA, et al. Factors
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 associated with Human Papilloma Virus (HPV) vaccine recommendation by physicians in Lebanon,
2 a cross-sectional study. *Vaccine*. 2018;36(49):7562-7.

3 • 35. Rutten LJ, St Sauver JL, Beebe TJ, Wilson PM, Jacobson DJ, Fan C, et al. Clinician

4 knowledge, clinician barriers, and perceived parental barriers regarding human papillomavirus
5 vaccination: Association with initiation and completion rates. *Vaccine*. 2017;35(1):164-9.

6 • 36. Takeuchi J, Sakanishi Y, Okada T, Nakayama K, Chiba H, Suganaga R, et al. Factors

7 associated between behavior of administrating or recommending mumps vaccine and primary care
8 physicians' knowledge about vaccination: A nationwide cross-sectional study in Japan. *J Gen Fam
9 Med*. 2022;23(1):9-18.

10 • 37. Rolls K, Hansen M, Jackson D, Elliott D. How Health Care Professionals Use Social Media
11 to Create Virtual Communities: An Integrative Review. *J Med Internet Res*. 2016;18(6):e166.

12 • 38. Ministry of Health, Labour and Welfare of Japan. Notices and Administrative
13 Communication Regarding HPV Vaccine. 2021. (in Japanese) Available:

14 <https://www.mhlw.go.jp/content/000875155.pdf> [Accessed 25 Mar 2023]

15 • 39. Yagi A, Ueda Y, Nakagawa S, Ikeda S, Kakuda M, Hiramatsu K, et al. Can Catch-Up

16 Vaccinations Fill the Void Left by Suspension of the Governmental Recommendation of HPV
17 Vaccine in Japan? *Vaccines (Basel)*. 2022;10(9).

18 • 40. Ministry of Health, Labour and Welfare of Japan. Notices and Administrative
19 Communication Regarding HPV Vaccine. 2022. (in Japanese) Available:

1
2
3
4 1 <https://www.mhlw.go.jp/content/000915791.pdf> [Accessed 25 Mar 2023]

5
6
7 2 • 41. Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association.

8
9
10 3 Vaccination Website “Vaccination for all”. (in Japanese) Available: <https://www.vaccine4all.jp>.

11
12
13 4 [Accessed 25 Mar 2023]

14
15
16 5 • 42. Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association. The 5th

17
18
19 6 vaccine seminar “Tiger’s Den” 2022 was held!. 2023. (in Japanese) Available:

20
21
22 7 <https://www.vaccine4all.jp/topics-detail.php?tid=63>. [Accessed 25 Mar 2023]

23
24
25 8 • 43. Tsui J, Vincent A, Anuforo B, Btoush R, Crabtree BF. Understanding primary care

26
27
28 9 physician perspectives on recommending HPV vaccination and addressing vaccine hesitancy. Hum

29
30
31 10 Vaccin Immunother. 2021;17(7):1961-7.

32
33
34 11 • 44. Ministry of Health, Labour and Welfare of Japan. Information provisions and


35
36
37 12 Administrative Communication Regarding HPV Vaccine. 2022. (in Japanese) Available:

38
39
40 13 <https://www.mhlw.go.jp/content/001021317.pdf> [Accessed 25 Mar 2023]

41
42
43 14 • 45. Okubo R, Yoshioka T, Ohfuji S, Matsuo T, Tabuchi T. COVID-19 Vaccine Hesitancy and

44
45
46 15 Its Associated Factors in Japan. Vaccines (Basel). 2021;9(6).

47
48
49 16



STROBE 2007 (v4) Statement—Checklist of items that should be included in reports of *cross-sectional studies*

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	1-2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4-5
Objectives	3	State specific objectives, including any prespecified hypotheses	5
Methods			
Study design	4	Present key elements of study design early in the paper	6
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	6
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants	6
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	7-9
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	6-8
Bias	9	Describe any efforts to address potential sources of bias	6
Study size	10	Explain how the study size was arrived at	-
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	-
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	9
		(b) Describe any methods used to examine subgroups and interactions	-
		(c) Explain how missing data were addressed	6
		(d) If applicable, describe analytical methods taking account of sampling strategy	-
		(e) Describe any sensitivity analyses	9
Results			

Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	10,29
		(b) Give reasons for non-participation at each stage	10, 29
		(c) Consider use of a flow diagram	29
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	10
		(b) Indicate number of participants with missing data for each variable of interest	20
Outcome data	15*	Report numbers of outcome events or summary measures	11-12, 22-28
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	11-12, 22-28
		(b) Report category boundaries when continuous variables were categorized	10
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	-
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	13
Discussion			
Key results	18	Summarise key results with reference to study objectives	13-14
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	18
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14-17
Generalisability	21	Discuss the generalisability (external validity) of the study results	18
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	20

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Association between administration or recommendation of the human papillomavirus vaccine and primary care physicians' knowledge about vaccination during proactive recommendation suspension: a nationwide cross-sectional study in Japan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-074305.R1
Article Type:	Original research
Date Submitted by the Author:	29-Aug-2023
Complete List of Authors:	Sakanishi, Yuta; Sakanishi Internal Medicine and Pediatrics Clinic; Japan Primary Care Association, Committee for Infectious Diseases, Vaccine Team Takeuchi, Jiro; Hyogo College of Medicine, Clinical Epidemiology; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Suganaga, Rei; Tessyoukai Kameda Family Clinic Tateyama; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Nakayama, Kuniko; My family Clinic Gamagori; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Nishioka, Yosuke; Nishioka Memorial Central Clinic; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Chiba, Hiroshi; Family Medical Practice Hanoi; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Kishi, Tomomi; Japan Baptist Hospital; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Machino, Ako; Gondo Dermatological Clinic Mastumura, Mami; School of Public Health, Graduate School of Medicine, Kyoto University, Department of Preventive Services; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Okada, Tadao; Tessyoukai Kameda Family Clinic Tateyama; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Suzuki, Tomio; Osaka Medical and Pharmaceutical University, Department of General Medicine; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Public health, Epidemiology, Paediatrics
Keywords:	Primary Care < Primary Health Care, PREVENTIVE MEDICINE, Community child health < PAEDIATRICS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 TITLE PAGE

5
6
7 2 **Association between administration or recommendation of the human papillomavirus vaccine**
8
9
10 3 **and primary care physicians' knowledge about vaccination during proactive recommendation**
11
12
13 4 **suspension: a nationwide cross-sectional study in Japan**
14

15 5
16
17
18 6 Yuta Sakanishi*, MD, PhD, MPH¹⁾, Jiro Takeuchi*, MD, PhD²⁾, Rei Suganaga*, MD³⁾, Kuniko
19
20
21 7 Nakayama*, MD, PhD, DTM&H⁴⁾, Yosuke Nishioka*, MD⁵⁾, Hiroshi Chiba*, MD, PhD, MPH⁶⁾,
22
23
24 8 Tomomi Kishi*, MD⁷⁾, Ako Machino, MD⁸⁾, Mami Matsumura*, MD⁹⁾, Tadao Okada*, MD, MPH³⁾,
25
26
27 9 Tomio Suzuki*, MD, PhD.¹⁰⁾
28
29

30 10
31
32
33 11 ¹⁾ Sakanishi Internal Medicine and Pediatrics Clinic, Omuta, Japan
34

35
36 12 ²⁾ Clinical Epidemiology, Hyogo Medical University, Nishinomiya, Japan
37

38
39 13 ³⁾ Tessyoukai Kameda Family Clinic Tateyama, Tateyama, Japan
40

41
42 14 ⁴⁾ My family Clinic Gamagori, Gamagori, Japan
43

44
45 15 ⁵⁾ Nishioka Memorial Central Clinic, Shima, Japan
46

47
48 16 ⁶⁾ Family Medical Practice Hanoi, Hanoi, Vietnam
49

50
51 17 ⁷⁾ Japan Baptist Hospital, Kyoto, Japan
52

53 18 ⁸⁾ Gondo Dermatological Clinic, Tosu, Japan
54

55 19 ⁹⁾ Department of Preventive Services, School of Public Health, Graduate School of Medicine, Kyoto
56
57
58 20 University, Kyoto, Japan
59
60

1
2
3
4 1 ¹⁰⁾ Osaka Medical and Pharmaceutical University, Department of General Medicine, Takatsuki,
5
6
7 2 Japan

8
9
10 3 * Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan

11
12
13 4
14
15
16 5 Corresponding author:

17
18
19 6 Yuta Sakanishi, MD, PhD, MPH, Sakanishi Internal Medicine and Pediatrics Clinic, 2-8 Harayama-
20
21
22 7 machi, Omuta-shi, Fukuoka 836-0862, Japan (email:1976yuta@gmail.com)

23
24
25 8 Telephone: +81-944-52-2025, Fax: +81-944-52-2036

26
27
28 9
29
30 10 Short running title: HPV vaccination and primary care physicians

31
32
33 11
34
35
36 12 Keywords: cross-sectional study, HPV vaccine, physicians, primary care, vaccination

37
38
39 13
40
41
42 14 ORCID

43
44
45 15 Yuta Sakanishi <https://orcid.org/0000-0002-4059-6932>

46
47
48 16
49
50
51 17 Word count 4125 words

52
53 18
54
55
56 19
57
58
59
60

1
2
3
4 1
5
6
7 2 ABSTRACT
8
9

10 3 **Objective** The Japanese government suspended the proactive recommendation of the human
11
12
13 4 papillomavirus vaccine (HPVv) in 2013, and the vaccination rate of HPVv declined to <1% during
14
15
16 5 2014–2015. Previous studies have shown that the recommendation by a physician affects a
17
18
19 6 recipient's decision to receive a vaccine, and physicians' accurate knowledge about vaccination is
20
21
22 7 important to increase vaccine administration. This study aimed to evaluate the association between
23
24
25 8 physicians' knowledge of vaccination and the administration or recommendation of HPVv by
26
27
28 9 primary care physicians (PCPs) in the absence of proactive recommendations from the Japanese
29
30
31 10 government.
32

33 11 **Design** Cross-sectional study analysed data obtained through a web-based, self-administered
34
35
36 12 questionnaire survey.
37
38

39 13 **Setting** The questionnaire was distributed to Japan Primary Care Association (JPCA) members.
40
41

42 14 **Participants** JPCA members who were physicians and on the official JPCA mailing list (n=5,395)
43
44
45 15 were included.
46
47

48 16 **Primary and secondary outcome measures** The primary and secondary outcomes were the
49
50
51 17 administration and recommendation of HPVv, respectively, by PCPs. The association between PCPs'
52
53
54 18 knowledge regarding vaccination and each outcome was determined based on their background and
55
56
57
58
59
60

1
2
3
4 1 vaccination quiz scores and a logistic regression analysis to estimate the adjusted odds ratios
5
6
7 2 (AORs).
8
9

10 3 **Results** We received responses from 1,084 PCPs and included 981 of them in the analysis. PCPs
11
12
13 4 with a higher score on the vaccination quiz were significantly more likely to administer the HPVv for
14
15
16 5 routine and voluntary vaccination (AOR 2.28, 95% confidence interval [CI] 1.58–3.28; AOR 2.71,
17
18
19 6 95% CI 1.81–4.04, respectively) and recommend the HPVv for routine and voluntary vaccination
20
21
22 7 than PCPs with a lower score (AOR 2.17, 95% CI 1.62–2.92; AOR 1.88, 95% CI 1.32–2.67,
23
24
25 8 respectively).
26

27 9 **Conclusions** These results suggest that providing accurate knowledge regarding vaccination to PCPs
28
29
30 10 may improve their administration and recommendation of HPVv, even in the absence of active
31
32
33 11 government recommendations.
34
35

36 12

37 13 **Strengths and limitations of this study**

38

- 39 14 • This is the first study to evaluate the association between primary care physicians' (PCPs)
40
41
42 15 vaccination knowledge and HPV vaccine administration and recommendation without proactive
43
44
45 16 recommendation from the Japanese government.
46
47
- 48 17 • This nationwide study targeted the physician members of the Japan Primary Care Association,
49
50
51 18 which is the largest academic society for PCPs in Japan.
52
53
- 54 19 • A limitation of this study was its potential selection bias due to the voluntary participation of the
55
56
57
58
59
60

1
2
3
4 1 PCPs in the survey.
5
6

7 2 • Furthermore, the effects of vaccine hesitancy among parents and media on the PCPs were not
8
9
10 3 evaluated.
11
12

13 4
14
15

16 5 **Data availability statement**
17

18
19 6 Data are available from the corresponding author upon reasonable request.
20
21

22 7
23
24

25 8
26

27 9 **Keywords:** HPV vaccine; primary care physicians; administration; recommendation; vaccination
28
29

30 10
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTRODUCTION

2 The World Health Organization (WHO) recognises cervical cancer and other human
3 papillomavirus (HPV)-related diseases as important global public health concerns and recommends
4 the inclusion of HPV vaccines (HPVv) in national immunisation programmes.(1) In Japan, HPVv
5 was introduced in 2009 as a voluntary vaccine without recommendation or funding from the
6 government.(2, 3) In 2010, the Ministry of Health, Labour and Welfare (MHLW) initiated an urgent
7 promotional campaign for vaccination, and the Government of Japan provided subsidies to local
8 governments for HPVv.(2, 3) This campaign was successful, and the vaccination rate of HPVv
9 increased to 70–80% in the targeted group of young girls in 2012.(3-6) In April 2013, free-of-charge
10 HPV vaccination of 12- to 16-year-old girls was initiated as part of the routine vaccination
11 programme.(3, 7, 8) On the other hand, three doses of voluntary bivalent HPVv for ≥ 10 -year-old
12 females and quadrivalent HPVv for ≥ 9 -year-old females cost approximately ¥45,000 (US \$450, as of
13 April 2013). However, the media widely reported concerns regarding potential adverse effects of
14 HPV vaccination among young girls, including complex regional pain syndrome, giving rise to
15 social distrust and vaccine hesitancy related to HPVv.(3, 4, 7, 9) Consequently, the MHLW
16 suspended proactive recommendation of HPV vaccination in June 2013;(7, 10) the local
17 governments stopped sending individual notifications to the homes of girls eligible for HPVv
18 although it continued being a part of the routine vaccine programme.(10) The HPV vaccination rate
19 declined to less than 1% during 2014–2015.(5, 6)

1
2
3
4 1 The Global Advisory Committee on Vaccine Safety (GACVS) reviewed the safety data of HPVv
5
6
7 2 from 2008 to 2015 and found it to be extremely safe(11). In 2017, the GACVS expressed concerns
8
9
10 3 regarding the situation in Japan, stating that the mortality rate from cervical cancer was expected to
11
12
13 4 increase because HPVv was not proactively recommended.(11) In 2018, Suzuki et al. reported that
14
15
16 5 there was no association between HPVv and adverse post-vaccination symptoms in Nagoya,
17
18
19 6 Japan.(12) However, the MHLW did not resume the proactive recommendation of HPV vaccination
20
21
22 7 as of 2019. Vaccine hesitancy has also been reported in other countries, and the WHO identified it as
23
24
25 8 one of 10 threats to global health in 2019.(13)

26
27
28 9 Previous studies have shown that vaccine recommendation by a physician affects the recipient's
29
30
31 10 decision in receiving a vaccine.(14-19) Physicians' accurate knowledge regarding vaccination is
32
33
34 11 important to increase vaccine administration or recommendation rates.(20-22) In Japan, the HPVv is
35
36
37 12 administered not only by paediatricians, obstetricians, and gynaecologists (OBGYNs), but also by
38
39
40 13 primary care physicians (PCPs).(23, 24) A 2012 nationwide survey on practices and attitudes
41
42
43 14 towards vaccination among PCPs in Japan(23, 24) showed that the proportion of PCPs administering
44
45
46 15 and actively recommending HPVv was 58.3% and 46.5%, respectively.(23) A significant association
47
48
49 16 between PCPs' awareness of public subsidies for HPVv and recommendation of HPVv vaccination
50
51
52 17 was reported.(24) As previously indicated, the government vaccination policy for the HPVv changed
53
54
55 18 following the survey(23, 24), and it was expected that these proportions would also change.
56
57
58 19 However, the current fraction of PCPs administering or recommending the HPVv and the association
59
60

1
2
3
4 1 between PCPs' knowledge about vaccination and their attitude towards HPVv in Japan remain
5
6
7 2 unknown. Therefore, this study aimed to evaluate the association between PCPs' knowledge about
8
9
10 3 vaccination and the administration or recommendation of HPVv without proactive recommendation
11
12
13 4 by the government.
14
15

16 5

19 6 **METHODS**

22 7 Study design, setting, and population

25 8 This cross-sectional study analysed data obtained from a web-based, self-administered questionnaire
26
27
28 9 conducted by the Preventive Medicine and Health Promotion Committee Vaccine Team of the Japan
29
30
31 10 Primary Care Association (JPCA), which is the largest academic association for PCPs in Japan. Most
32
33
34 11 JPCA physicians were internists working as PCPs at clinics or hospitals. The survey was conducted
35
36
37 12 from March to June 2019, and the inclusion criteria were JPCA members who were physicians and
38
39
40 13 on the official mailing list for JPCA members. PCPs who were junior residents within 2 years after
41
42
43 14 graduation from medical school were excluded, as this group cannot administer outpatient
44
45
46 15 vaccinations without the supervision of attending physicians. We excluded PCPs who lived outside
47
48
49 16 Japan, were retired, employed in a non-clinical setting, or had missing data.
50

52 17

55 18 Patient and public involvement

58 19 There was no patient or public involvement in this study.
59
60

1
2
3
4 15
6
7 2 Questionnaire

8
9
10 3 The questionnaire items were obtained from previous questionnaires administered by the Preventive
11
12
13 4 Medicine and Health Promotion Committee Vaccine Team of JPCA(23, 24) and were distributed
14
15
16 5 using the online mailing list for JPCA members. The questionnaire was conducted using an online
17
18
19 6 tool, SurveyMonkey. The questionnaire was self-conducted and anonymous. It collected data on the
20
21
22 7 participating physicians' attitudes regarding vaccines, including HPVv (administration or
23
24
25 8 recommendation), through a vaccination quiz; information resources on vaccinations; and baseline
26
27
28 9 characteristics, such as sex, career after graduation, main practice category, practice setting,
29
30
31 10 provision of daily paediatric medical service, population size of the main working area as an
32
33
34 11 administrative unit of the local government, experience as a kindergarten or school physician, and
35
36
37 12 experience raising children (details below).

38
39
40 1341
42
43 14 Main outcome

44
45
46 15 The primary outcome of this study was the administration of HPVv for routine and voluntary
47
48
49 16 vaccination. The PCPs were asked to respond with 'yes' or 'no' to the following question: 'Do you
50
51
52 17 administer routine/voluntary human papillomavirus vaccine?' Then, we investigated the association
53
54
55 18 between PCPs' knowledge of vaccination and vaccine administration after adjusting for potential
56
57
58 19 confounders (described below).

1
2
3
4 1 The secondary outcome of this study was the recommendation of routine and voluntary HPV
5
6
7 2 vaccination by PCPs. The respondents were asked, 'How do you recommend routine/voluntary
8
9
10 3 vaccination for HPV?' The following response options were provided using a Likert-type scale:
11
12
13 4 'actively recommend', 'recommend occasionally', 'no opinion', 'do not actively recommend', and
14
15
16 5 'do not recommend'. The response 'actively recommend' was considered 'recommending
17
18
19 6 behaviour', which is a more positive behaviour.(15) Furthermore, the responses 'recommend
20
21
22 7 occasionally', 'no opinion', 'do not actively recommend', and 'do not recommend' were considered
23
24
25 8 'non-recommending behaviour'. Then, we investigated the association between PCPs' knowledge of
26
27
28 9 vaccination and vaccine recommendation after adjusting for possible confounders (described below).
29
30

10

11 Main factor

12 The main factor was PCPs' knowledge of vaccination, which was assessed based on a vaccination
13 quiz. The quiz was created by the Preventive Medicine and Health Promotion Committee Vaccine
14 Team of the JPCA using the Delphi method.(25) The quiz comprised six general vaccine questions
15 encompassing Japanese vaccination affairs, including a question on HPVv. Scores of 0–6 were
16 assigned based on the number of correct answers to each of the six questions. To obtain a binary
17 variable, we designated scores above the average as high and those below the average as low. The
18 vaccination quiz score (high or low) was considered an independent variable.

19 Vaccination quiz

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Q1. A 12-year-old boy has no history of mumps vaccination according to the Maternal and Child
2 Health Handbook. His mother states that he had developed mumps in his childhood. She mentions
3 that he had visited a clinic with bilateral parotid gland swelling, and the doctor had suspected mumps
4 based on clinical examination without blood tests. Is it then correct to recommend a mumps vaccine
5 to the boy? (Correct answer: correct)

6 Q2. A 3-month pregnant woman requests an influenza vaccine, and the only available influenza
7 vaccine in the hospital contains thimerosal. Is this vaccine acceptable or contraindicated for this
8 patient? (Correct answer: acceptable)

9 Q3. Is the 23-valent pneumococcal vaccine, an inactivated vaccine, less likely to cause swelling
10 when injected intramuscularly than when injected subcutaneously? (Correct answer: Correct)

11 Q4. Is there a limit to the number of vaccines (including live vaccines) that can be concurrently
12 administered? (Correct answer: there is no limit)

13 Q5. Is it correct that ‘suspending proactive recommendation of HPV vaccination’ means
14 ‘withholding local governments from sending individual pre-vaccination screening questionnaires
15 for HPV vaccine and notices to each household and actively calling for HPV vaccination through
16 various media rather than the suspension of routine vaccination’? (Correct answer: correct)

17 Q6. Is it correct that under the ‘Adverse Event Following Immunization reporting system’,
18 physicians are obligated to report to the Pharmaceuticals and Medical Devices Agency (PMDA)
19 when a vaccinated individual begins exhibiting certain symptoms? (Correct answer: correct)

1
2
3
4 1
5
6
7 2 Other factors

8
9
10 3 Other factors included the physician's sex, postgraduate years (3–5, 6–10, 11–20, 21–30, 31–40, and
11
12
13 4 ≥ 41 years), any specialist qualifications, including those related to primary care, main practice
14
15
16 5 category (primary care; family physician, general practitioner, hospitalist/general physician or others;
17
18
19 6 paediatricians, OBGYNs, industrial physician, researcher, administrative staff, and others), practice
20
21
22 7 setting (e.g., university hospital or general hospital, other hospital, clinic, others; university, research
23
24
25 8 institution, government, and health organisation), proportion of paediatric patients (number of
26
27
28 9 paediatric patients with respect to the total patient population) that was high ($\geq 10\%$) or low ($< 10\%$),
29
30
31 10 main working area as an administrative unit of the local government in an urban area ($\geq 50,000$
32
33
34 11 people), experience as a kindergarten or school physician, experience raising children as a parent,
35
36
37 12 and information resources about vaccinations (government, academic, commercial,(26) online
38
39
40 13 professional community such as website/Facebook group/Twitter/JPCA mailing list,(27) and none).
41
42
43 14

44
45
46 15 Statistical analysis

47
48
49 16 We performed univariate and multivariate logistic regression analysis to estimate the odds ratios,
50
51
52 17 adjusted odds ratios (AORs), and 95% confidence intervals (CIs), using binary variables for the main
53
54
55 18 outcome. We investigated the association between PCPs' knowledge of vaccination and HPVv
56
57
58 19 administration or recommendation.
59
60

1
2
3
4 1 Multiple logistic regression analysis was performed by adjusting for the following possible
5
6
7 2 confounding factors: physician's sex, postgraduate year, possession of any specialist qualifications,
8
9
10 3 including primary care, main practice category, practice setting, a high or low proportion of
11
12
13 4 paediatric patients, experience raising children as a parent, and information resources about
14
15
16 5 vaccinations.

17
18
19 6 We conducted a sensitivity analysis to inspect each variation only for HPVv knowledge (correct or
20
21
22 7 incorrect) rather than for the total quiz score. We used penalized maximum likelihood logistic
23
24
25 8 regression for the analyses when any confounding factors were completely separated.(28)

26
27
28 9 The analysis participants were selected after excluding participants with missing data for the main
29
30
31 10 outcome, main factor, and the above-mentioned possible confounders.

32
33
34 11 All statistical analyses used two-tailed tests of significance, with significance set at $p < 0.05$.

35
36
37 12 Analyses were performed using Stata/SE 14.2 (StataCorp LLC, College Station, TX, USA).

38 39 40 13 41 42 43 14 **RESULTS**

44 45 46 15 Study flow and demographics

47
48
49 16 Of the 10,470 physician members of the JPCA, 5,075 who did not subscribe to JPCA mails and
50
51
52 17 were, therefore, not on the mailing list were excluded. We received responses from 1,084 of 5,395
53
54
55 18 PCPs, with a response rate of 20.1%. The respondents were from all 47 prefectures of Japan. An
56
57
58 19 additional 103 participants were excluded because they lived outside Japan, performed nonclinical
59
60

1
2
3
4 1 work, or had missing data. The analysis included 981 participants (Figure 1). The median
5
6
7 2 (interquartile range) score for the vaccination quiz was 4 (range, 2–5) points. The minimum and
8
9
10 3 maximum scores were 0 and 6 points, respectively, and the mean (standard deviation) score was 3.47
11
12
13 4 (1.68) points. To obtain a binary variable, scores of ≥ 4 were designated as high, and scores of ≤ 3 as
14
15
16 5 low. Evaluation of the participant baseline characteristics revealed that 739 (75.3%) participants
17
18
19 6 were men, 358 (36.5%) had worked for 11–20 years after graduation, 420 (42.8%) worked in clinics,
20
21
22 7 719 (73.3%) worked in the urban areas, and 283 (28.9%) worked in a clinical setting where the
23
24
25 8 proportion of paediatric patients was $\geq 10\%$ (Table 1).
26
27
28 9

10 Factors associated with HPVv administration under routine vaccination

11 We found that 229 PCPs (23.3%) administered HPVv under routine vaccination (Table 2). PCPs
12 with higher vaccination quiz scores were significantly more likely to administer HPVv as routine
13 vaccination than those with lower scores (AOR 2.28, 95% CI 1.58–3.28, $p < 0.001$) (Supplementary
14 Table 1). There was also a positive association between the administration of routine HPV
15 vaccination and PCPs who worked at clinics (AOR 2.64, 95% CI 1.60–4.36, $p < 0.001$), those who
16 had a higher proportion of paediatric patients (AOR 1.78, 95% CI 1.24–2.55, $p = 0.002$), and those
17 who had experience as a kindergarten or school physician (AOR 2.12, 95% CI 1.45–3.10, $p < 0.001$)
18 (Supplementary Table 1).
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Factors associated with HPVv administration under voluntary vaccination

2 We found that 175 PCPs (17.8%) administered HPVv under voluntary vaccination. PCPs with
3 higher scores on the vaccination quiz were significantly more likely to administer HPVv as voluntary
4 vaccination than those with lower scores (AOR 2.71, 95% CI 1.81–4.04, $p < 0.001$) (Supplementary
5 Table 1). There was also a positive association between administration of voluntary HPVv and PCPs
6 who acquired information from governments (AOR 1.90, 95% CI 1.17–3.08, $p = 0.009$) and those
7 who participated in a social network service or mailing list from an individual or group of medical
8 service providers (AOR 1.82, 95% CI 1.25–2.64, $p = 0.002$) (Supplementary Table 1).

9 Factors associated with HPVv recommendation under routine vaccination

10 The PCPs selected the following options regarding the recommendation of HPVv under routine
11 vaccination: ‘actively recommend’, 408 PCPs (41.6%); ‘recommend occasionally’, 319 PCPs
12 (32.5%); ‘no opinion’, 181 PCPs (18.5%); ‘do not actively recommend’, 49 (5.0%); and ‘do not
13 recommend’, 24 (2.5%) (Table 2). PCPs with higher scores on the vaccination quiz were
14 significantly more likely to recommend HPVv under routine vaccination than those with lower
15 scores (AOR 2.17, 95% CI 1.62–2.92; $p < 0.001$) (Supplementary Table 2). However, there was a
16 negative association between recommending routine HPV vaccination and PCPs who worked at
17 other hospitals (AOR 0.69, 95% CI 0.48–1.00, $p = 0.048$) and clinics (AOR 0.67, 95% CI 0.46–0.98,
18 $p = 0.041$), those who had a higher proportion of paediatric patients (AOR 0.50, 95% CI 0.36–0.70, p

1
2
3
4 1 < 0.001), and those who acquired information from government sources (AOR 0.69, 95% CI 0.50–
5
6
7 2 0.96, $p = 0.026$) (Supplementary Table 2).
8
9

10 3

13 4 Factors associated with HPVv recommendation under voluntary vaccination

16 5 The PCPs selected the following options regarding the recommendation of HPVv under voluntary
17
18
19 6 vaccination: ‘actively recommend’, 216 PCPs (22.0%); ‘recommend occasionally’, 358 (36.5%); ‘no
20
21
22 7 opinion’, 288 (29.4%); ‘do not actively recommend’, 75 (7.7%); and ‘do not recommend’, 44 (4.5%)
23
24
25 8 (Table 2).
26
27

28 9 PCPs with higher vaccination quiz scores were significantly more likely to recommend HPVv
29
30
31 10 under voluntary vaccination than those with low scores (AOR 1.88, 95% CI 1.32–2.67, $p < 0.001$)
32
33
34 11 (Supplementary Table 2). There was also a positive association between the recommendation of
35
36
37 12 voluntary HPV vaccination and PCPs who were male (AOR 1.67, 95% CI 1.12–2.49, $p = 0.012$) and
38
39
40 13 those who participated in a social network service or mailing list for medical service from an
41
42
43 14 individual or group of providers (AOR 1.56, 95% CI 1.09–2.24, $p = 0.016$). However, there was a
44
45
46 15 negative association between the recommendation of voluntary HPV vaccination and PCPs who had
47
48
49 16 a higher proportion of paediatric patients (AOR 0.52, 95% CI, 0.34–0.78, $p = 0.002$) and those who
50
51
52 17 had experience raising children (AOR 0.67, 95% CI 0.45–1.00, $p = 0.049$) (Supplementary Table 2).
53
54
55 18

1
2
3
4 1 The correlation coefficient between vaccine administration and recommendation for routine and
5
6
7 2 voluntary HPV vaccination was 0.17 and 0.23, respectively.
8
9

10 3 11 12 13 4 Sensitivity analysis

14
15
16 5 PCPs with correct responses to the HPV vaccination quiz were significantly more likely to
17
18
19 6 administer HPVv than those with incorrect responses regarding routine vaccination (AOR 2.06, 95%
20
21
22 7 CI 1.38–3.09, $p < 0.001$) and voluntary vaccination (AOR 2.16, 95% CI 1.39–3.34, $p = 0.001$).
23
24
25

26 8 PCPs with correct responses to the HPV vaccination quiz were also significantly more likely to
27
28
29 9 recommend HPV vaccination than those with incorrect responses regarding routine (AOR 1.51, 95%
30
31
32 10 CI 1.12–2.04, $p = 0.006$) and voluntary vaccination (AOR 1.53, 95% CI 1.07–2.19, $p = 0.02$).
33
34
35 11

36 37 38 12 **DISCUSSION**

39
40
41 13 Vaccine hesitancy is a global health concern(13), and hesitancy for HPV vaccination has been
42
43
44 14 reported in many countries, including Japan.(4-6) This is the first study to focus on the association
45
46
47 15 between PCPs' knowledge of vaccination and their practice or attitude towards HPVv in the absence
48
49
50 16 of proactive recommendations from the government of Japan. We found positive associations
51
52
53 17 between accurate vaccination knowledge among PCPs and the administration or recommendation of
54
55
56 18 HPVv under routine and voluntary vaccination. In addition, the sensitivity analysis showed that
57
58
59 19 physicians with accurate knowledge of HPV vaccination were likely to recommend HPVv.
60

1
2
3
4 1 A 2021 systematic review of 96 papers from 34 countries examined the perceptions, knowledge, and
5
6
7 2 recommendations of healthcare providers regarding vaccines. It showed that the healthcare
8
9
10 3 providers' recommendations were positively associated with their knowledge and experience, beliefs
11
12
13 4 about disease risk, and perceptions of vaccine safety, necessity, and efficacy.(29) The present results
14
15
16 5 are consistent with these findings.(29) In Lebanon, where HPVv is not included in the national
17
18
19 6 routine vaccination schedule as of 2017, physicians practicing in obstetrics and gynaecology,
20
21
22 7 paediatrics, family medicine, and infectious diseases with greater knowledge regarding HPV and
23
24
25 8 HPVv recommend HPVv more often than physicians with less knowledge (AOR 3.4).(30) Further, in
26
27
28 9 the United States, higher rates of completion of three HPVv doses (IRR 1.28) were observed among
29
30
31 10 the patients of primary care clinicians, including family medicine physicians, paediatricians, and
32
33
34 11 family and paediatric nurse-practitioners, with greater knowledge regarding HPV and HPVv (31).
35
36
37 12 Our results also support these findings. Another study investigating the association between PCPs'
38
39
40 13 knowledge of vaccination and the administration or recommendation of voluntary mumps
41
42
43 14 vaccination for adults showed the same positive associations.(32)

44
45
46 15 Compared to that in our previous study from 2012,(23) the proportion of PCPs recommending or
47
48
49 16 administering HPVv was lower in the present study: the proportion of HPVv administration
50
51
52 17 decreased from 58.3%(23) to 23.3% for routine vaccination (Table 2). The proportion of PCPs
53
54
55 18 recommending HPVv decreased from 46.5%(23) to 41.6% for routine vaccination (Table 2).
56
57
58
59
60

1
2
3
4 1 A study conducted among paediatricians in Osaka, Japan, in 2020 and 2021 revealed that the
5
6
7 2 proportion of paediatricians who administered or actively recommended the HPVv for routine
8
9
10 3 vaccination was 44.5% and 32.5% in 2020 and 67.9% and 40% in 2021, respectively.(33) In
11
12
13 4 addition, a study conducted among OBGYNs in Osaka, Japan, showed that the proportion of
14
15
16 5 OBGYNs recommending the HPVv for teenagers was 70.1% in 2017(3) and 84.6% in 2019.(34) As
17
18
19 6 of 2018, the proportion of family physicians and paediatricians in the United States administering the
20
21
22 7 HPVv was 84.1% and 95.3%, respectively,(35) and the proportion of those who strongly
23
24
25 8 recommended the HPVv was 72–90% and 85–99% (11- to 12-year-old, 13- to 14-year-old, and ≥15-
26
27
28 9 year-old female patients), respectively.(35) Our study revealed that in Japan, PCPs may administer
29
30
31 10 routine HPVv less than paediatricians(33) and actively recommend routine HPVv more than
32
33
34 11 paediatricians(33) but less than OBGYNs.(3) In addition, our study shows that Japanese PCPs may
35
36
37 12 administer or recommend the HPVv less than family physicians in the United States.(35)
38
39

40 13 We also found positive associations between different information resources and administration or
41
42
43 14 recommendation of voluntary HPV vaccination. Information resources from social network services
44
45
46 15 or mailing lists from medical service providers seem to be positively associated with the
47
48
49 16 administration or recommendation of voluntary HPV vaccination. This might be because PCPs use
50
51
52 17 virtual communities as valuable knowledge portals for clinically relevant information(36) and could
53
54
55 18 be interested in how and why other physicians recommend and administer vaccination.(22, 32)
56
57
58 19 Government information resources were positively associated with the administration of voluntary
59
60

1
2
3
4 1 HPVv but were negatively associated with the recommendation of routine HPVv. As of 2019, the
5
6
7 2 MHLW had not resumed the proactive recommendation of routine HPV vaccination. Although the
8
9
10 3 suspension of proactive recommendation was not intended to discontinue routine vaccination, it may
11
12
13 4 have been misinterpreted as discontinuation of routine vaccination by some PCPs. Therefore, PCPs
14
15
16 5 referring to government sources for information regarding this policy may administer HPVv as part
17
18
19 6 of voluntary instead of routine vaccination and may not recommend routine HPV vaccination.
20
21
22 7 Alternatively, PCPs aware of the suspension may lose confidence to recommend the HPVv. A
23
24
25 8 previous study reported that the lack of government recommendations was a barrier for PCPs to
26
27
28 9 recommend vaccination.(23) In November 2021, the MHLW ended this suspension and resumed
29
30
31 10 proactively recommending HPV vaccination for girls born in or after the fiscal year (FY) 2006,
32
33
34 11 beginning in April 2022(37), and provided 'catch-up vaccinations' for 3 years, from April 2022 to
35
36
37 12 March 2025, for females born from FY1997 to FY2005, who became eligible for routine HPV
38
39
40 13 vaccination and may have missed the opportunity to receive the vaccination because of the
41
42
43 14 suspension.(38, 39) The results of our study suggest that providing accurate knowledge and
44
45
46 15 information about HPV vaccination to PCPs may help promote HPVv administration and
47
48
49 16 recommendation by PCPs and thereby increase the vaccination rate. The JPCA vaccine team
50
51
52 17 provides information about vaccination through websites(40) and regular onsite and online vaccine
53
54
55 18 seminars for physicians.(41) Further research can help determine the optimal methods to provide
56
57
58 19 accurate knowledge regarding vaccination to health care providers with vaccine hesitancy.(42)
59
60

1
2
3
4 1 Our study also shows that PCPs working at clinics, providing daily paediatric medical services
5
6
7 2 (more than 10% of total patients), and with experience as kindergarten or school physicians tend to
8
9
10 3 administer routine HPV vaccination (Supplementary Table 1). The target population for routine HPV
11
12
13 4 vaccination is 12- to 16-year-old girls, and PCPs experienced in treating this group may better
14
15
16 5 understand the need for routine vaccination; therefore, they may be more likely to administer the
17
18
19 6 vaccine. In contrast, PCPs working at clinics or other hospitals providing daily paediatric medical
20
21
22 7 services (more than 10% of total patients) were less likely to recommend routine HPV vaccination
23
24
25 8 (Supplementary Table 2). In addition, PCPs providing daily paediatric medical services (more than
26
27
28 9 10% of total patients) and with experience in raising children tended to be less likely to recommend
29
30
31 10 voluntary HPV vaccination (Supplementary Table 2). These results suggest that PCPs with more
32
33
34 11 opportunity to provide medical service to 12- to 16-year-old girls may have less confidence to
35
36
37 12 recommend the HPVv during the suspension of proactive recommendation by the MHLW or may be
38
39
40 13 more affected by the anxiousness or hesitancy of the parents.(19, 23, 43)
41
42

43 14 This study has some limitations. First, there was a potential selection bias due to the low response
44
45
46 15 rate. PCPs who more actively promoted vaccination may have been more likely to respond, and the
47
48
49 16 actual proportion of PCPs administering or recommending HPVv may be lower. Second, our study
50
51
52 17 did not consider voluntary HPV vaccination for men. In Japan, as of 2019, the target group for both
53
54
55 18 routine and voluntary HPV vaccination included only women. However, in 2020, administration of
56
57
58 19 voluntary quadrivalent HPVv was approved for men. Third, our study did not evaluate 9-valent
59
60

1
2
3
4 1 HPVv for voluntary vaccination, although in 2021, the 9-valent HPVv was approved for voluntary
5
6
7 2 vaccination(44) and will be approved for routine vaccination from April 2023 onwards.(45) Future
8
9
10 3 studies should include both men and women and consider the 9-valent HPVv. Fourth, we did not
11
12
13 4 evaluate the effects of vaccine hesitancy among parents or mainstream media and social media on
14
15
16 5 the PCPs.(43) The effect of vaccine hesitancy should be considered as one of the exposures in future
17
18
19 6 studies. Fifth, we did not evaluate the effects of unknown confounding factors, which is a general
20
21
22 7 limitation of observational studies. Finally, although the study participants were physician members
23
24
25 8 of the JPCA, the largest society for PCPs in Japan, the generalisability of the results to PCPs outside
26
27
28 9 of Japan is unclear. The policy for HPVv administration in Japan(38) changed after this study was
29
30
31 10 conducted, and further surveys are needed to assess the current situation of HPVv administration and
32
33
34 11 attitudes among PCPs.

35
36
37 12 Our results suggest that providing accurate knowledge regarding vaccination to PCPs may improve
38
39
40 13 their administration and recommendation of the HPVv, even in the absence of active government
41
42
43 14 recommendations.
44
45
46 15

47 48 49 16 **CONCLUSIONS**

50
51
52 17 We revealed a positive association between PCPs' knowledge of vaccines and the administration or
53
54
55 18 recommendation of routine and voluntary HPV vaccination without a proactive recommendation
56
57
58 19 from the government. Several factors influence PCPs' perception of HPV vaccinations, ultimately
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 affecting public healthcare. The results of our study can be applied to other countries with similar
2 vaccination-related concerns, such as vaccine hesitancy and disagreements on vaccine policy
3 between the scientific community and governments.(9, 46)

4 Our results suggest that providing more knowledge about vaccination to PCPs may increase their
5 likelihood to administer or recommend the HPVv, thereby improving vaccination rates.

6 7 **Data availability statement**

8 Data are available upon reasonable request.

9 10 **Ethics statements**

11 Patient consent for publication

12 We obtained written informed consent from all participants before conducting the survey.

13 Ethics approval

14 The study protocol was approved by the Institutional Review Board of Osaka Medical College (Rin-
15 763).

16 17 **Acknowledgments**

1
2
3
4 1 We thank Tesshu Kusaba, President of the Japan Primary Care Association, and head office staff for
5
6
7 2 helping us disseminate the questionnaire. We also thank all physicians who participated in this
8
9
10 3 survey. We thank Editage (www.editage.com) for English language editing.
11
12
13 4

16 5 **Contributors:** All authors declare they have contributed to this article. YS designed and
17
18
19 6 implemented the questionnaire survey, contributed to data analysis and interpretation, drafted the
20
21
22 7 manuscript, and critically revised it. JT designed and implemented the questionnaire survey,
23
24
25 8 contributed to data interpretation, and critically revised the manuscript. RS, KN, YN, HC, TK, and
26
27
28 9 AM designed and implemented the questionnaire survey, contributed to data interpretation, and
29
30
31 10 critically revised the manuscript. MM contributed to data interpretation and critically revised the
32
33
34 11 manuscript. TO and TS disseminated the questionnaire and critically revised the manuscript. All
35
36
37 12 authors have read and approved this manuscript version for submission.
38
39
40 13

43 14 **Funding:** This work was supported by JSPS KAKENHI (Grant Numbers JP19K19445).
44
45
46 15
47
48

49 16 **Competing interests:** None declared.
50
51
52 17
53
54

55 18 **Provenance and peer review:** Not commissioned; externally peer reviewed.
56
57
58 19
59
60

1
2
3
4 **TABLES**
5

6 **TABLE 1** Characteristics of the participants
7

	Participants, n=981
	n (%)
Sex: male	739 (75.3), Missing 0
Postgraduate year (y)	Missing 0
3–5	92 (9.4)
6–10	178 (18.1)
11–20	358 (36.5)
21–30	193 (19.7)
31–40	134 (13.7)
≥41	26 (2.7)
Main practice category: primary care	697 (71.1), Missing 0
Practice setting	Missing 3 (0.3)
University hospital or general hospital	281 (28.6)
Other hospital	254 (25.9)
Clinic	420 (42.8)
Others (e.g., University, research institution, government, and health organisation)	23 (2.3)
Providing daily paediatric medical service (≥ 10% of total patients)	283 (28.9), Missing 0
Mainly working in an urban area (≥50,000 people as an administrative unit of the local government)	719 (73.3), Missing 2 (0.2)
Experience as kindergarten or school physician	474 (48.3), Missing 0
Experience raising children	721 (73.5), Missing 0
Main practice category: primary care: Answered main practice category as family physician or general practitioner or hospitalist/general physician	

TABLE 2 Vaccination quiz scores and HPV vaccine administration or recommendation levels among primary care physicians

Vaccination quiz	Total, n (%)	Administration of HPV vaccine	Recommendation level for HPV vaccine, n (%)				
			Actively recommend	Recommend occasionally	No opinion	Do not actively recommend	Do not recommend
			Routine HPV vaccination, n=981				
			Voluntary HPV vaccination, n=981				
High scores (4–6 points)	511 (52.1)	172 (33.7)	248 (48.5)	179 (35.0)	59 (11.6)	19 (3.7)	6 (1.2)
		132 (25.8)	131 (25.6)	211 (41.3)	120 (23.5)	31 (6.1)	18 (3.5)
Low scores (0–3 points)	470 (47.9)	57 (12.1)	160 (34.0)	140 (29.8)	122 (26.0)	30 (6.4)	18 (3.8)
		43 (9.2)	85 (18.1)	147 (31.3)	168 (35.7)	44 (9.4)	26 (5.5)
Total	981 (100)	229 (23.3)	408 (41.6)	319 (32.5)	181 (18.5)	49 (5.0)	24 (2.5)
		175 (17.8)	216 (22.0)	358 (36.5)	288 (29.4)	75 (7.7)	44 (4.5)

HPV, human papillomavirus

1
2
3
4 1
5
6
7 **2 Figure Legends**
8
9

10 **3 Figure 1.** Study flowchart
11
12

13 **4 REFERENCES**
14
15

- 16 • 1. World Health Organization. Electronic address swi. Human papillomavirus vaccines: WHO
17
18
19 position paper, May 2017-Recommendations. *Vaccine*. 2017;35(43):5753-5.
20
21
- 22 • 2. Hanley SJ, Yoshioka E, Ito Y, Konno R, Hayashi Y, Kishi R, et al. Acceptance of and
23
24
25 attitudes towards human papillomavirus vaccination in Japanese mothers of adolescent girls.
26
27
28 *Vaccine*. 2012;30(39):5740-7.
29
30
- 31 • 3. Sawada M, Ueda Y, Yagi A, Morimoto A, Nakae R, Kakubari R, et al. HPV vaccination in
32
33
34 Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their
35
36
37 opinions toward the vaccine. *Int J Clin Oncol*. 2018;23(1):121-5.
38
39
- 40 • 4. Ueda Y, Enomoto T, Sekine M, Egawa-Takata T, Morimoto A, Kimura T. Japan's failure to
41
42
43 vaccinate girls against human papillomavirus. *Am J Obstet Gynecol*. 2015;212(3):405-6.
44
45
- 46 • 5. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. *Lancet*.
47
48
49 2015;385(9987):2571.
50
51
- 52 • 6. Sekine M, Kudo R, Adachi S, Yamaguchi M, Ueda Y, Takata T, et al. Japanese Crisis of
53
54
55 HPV Vaccination. *International Journal of Pathology and Clinical Research*. 2016;2(2):1-3.
56
57
- 58 • 7. Yagi A, Ueda Y, Egawa-Takata T, Tanaka Y, Nakae R, Morimoto A, et al. Realistic fear of
59
60

- 1
2
3
4 1 cervical cancer risk in Japan depending on birth year. *Hum Vaccin Immunother.* 2017;13(7):1700-4.
5
6
7 2 • 8. Shono A, Kondo M. Factors that affect voluntary vaccination of children in Japan. *Vaccine.*
8
9
10 3 2015;33(11):1406-11.
11
12
13 4 • 9. Inokuma Y, Kneller R. Imprecision in adverse event reports following immunization against
14
15
16 5 HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and
17
18
19 6 government policy. *Eur J Clin Pharmacol.* 2023;79(2):269-78.
20
21
22 7 • 10. Ministry of Health, Labour and Welfare of Japan. Correspondence about the routine
23
24
25 8 vaccination of human papilloma virus infection (recommendation). 2013. (in Japanese) Available:
26
27
28 9 https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/pdf/kankoku_h25_6_01.pdf.
29
30
31 10 [Accessed 25 Mar 2023]
32
33
34 11 • 11. World Health Organization. Meeting of the Global Advisory Committee on Vaccine Safety,
35
36
37 12 7–8 June 2017. *Wkly Epidemiol Rec.* 2017;92(28):393-402.
38
39
40 13 • 12. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination
41
42
43 14 symptoms in Japanese young women: Results of the Nagoya study. *Papillomavirus Res.*
44
45
46 15 2018;5(17):96-103.
47
48
49 16 • 13. World Health Organization . WHO Ten Threats to Global Health in 2019. 2019. Available:
50
51
52 17 <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>. [Accessed 25 Mar
53
54
55 18 2023]
56
57
58 19 • 14. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed,
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 systematic review. Preventive medicine. 2007;45(2-3):107-14.

2 • 15. Oster NV, McPhillips-Tangum CA, Averhoff F, Howell K. Barriers to adolescent
3 immunization: a survey of family physicians and pediatricians. The Journal of the American Board
4 of Family Practice / American Board of Family Practice. 2005;18(1):13-9.

5 • 16. Taylor JA, Darden PM, Slora E, Hasemeier CM, Asmussen L, Wasserman R. The influence
6 of provider behavior, parental characteristics, and a public policy initiative on the immunization
7 status of children followed by private pediatricians: a study from Pediatric Research in Office
8 Settings. Pediatrics. 1997;99(2):209-15.

9 • 17. Tsuchiya Y, Shida N, Izumi S, Ogasawara M, Kakinuma W, Tsujiuchi T, et al. Factors
10 associated with mothers not vaccinating their children against mumps in Japan. Public Health.
11 2016;137:95-105.

12 • 18. Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider
13 communication and HPV vaccination: The impact of recommendation quality. Vaccine.
14 2016;34(9):1187-92.

15 • 19. Gilkey MB, McRee AL. Provider communication about HPV vaccination: A systematic
16 review. Hum Vaccin Immunother. 2016;12(6):1454-68.

17 • 20. Collange F, Fressard L, Pulcini C, Sebbah R, Peretti-Watel P, Verger P. General
18 practitioners' attitudes and behaviors toward HPV vaccination: A French national survey. Vaccine.
19 2016;34(6):762-8.

- 1
2
3
4 1 • 21. Wong MCS, Lee A, Ngai KKK, Chor JCY, Chan PKS. Knowledge, Attitude, Practice and
5
6
7 2 Barriers on Vaccination against Human Papillomavirus Infection: A Cross-Sectional Study among
8
9
10 3 Primary Care Physicians in Hong Kong. PLoS ONE. 2013;8(8):e71827.
11
12
13 4 • 22. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine
14
15
16 5 hesitancy and healthcare providers. Vaccine. 2016;34(52):6700-6.
17
18
19 6 • 23. Sakanishi Y, Hara M, Fukumori N, Kusaba T, Tanaka K, Sugioka T, et al. Primary care
20
21
22 7 physician practices, recommendations, and barriers to the provision of routine and voluntary
23
24
25 8 vaccinations in Japan. An Official Journal of the Japan Primary Care Association. 2014;37(3):254-9.
26
27
28 9 • 24. Sakanishi Y, Yamamoto Y, Hara M, Fukumori N, Goto Y, Kusaba T, et al. Public subsidies
29
30
31 10 and the recommendation of child vaccines among primary care physicians: a nationwide cross-
32
33
34 11 sectional study in Japan. BMJ Open. 2018;8(7):e020923.
35
36
37 12 • 25. Jones J, Hunter D. Consensus methods for medical and health services research. Bmj.
38
39
40 13 1995;311(7001):376-80.
41
42
43 14 • 26. Watkins C, Moore L, Harvey I, Carthy P, Robinson E, Brawn R. Characteristics of general
44
45
46 15 practitioners who frequently see drug industry representatives: national cross sectional study. BMJ.
47
48
49 16 2003;326(7400):1178-9.
50
51
52 17 • 27. Klee D, Covey C, Zhong L. Social media beliefs and usage among family medicine
53
54
55 18 residents and practicing family physicians. Fam Med. 2015;47(3):222-6.
56
57
58 19 • 28. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Med. 2002;21(16):2409-19.

2 • 29. Lin C, Mullen J, Smith D, Kotarba M, Kaplan SJ, Tu P. Healthcare Providers' Vaccine

3 Perceptions, Hesitancy, and Recommendation to Patients: A Systematic Review. *Vaccines (Basel)*.

4 2021;9(7).

5 • 30. Abi Jaoude J, Khair D, Dagher H, Saad H, Cherfan P, Kaafarani MA, et al. Factors

6 associated with Human Papilloma Virus (HPV) vaccine recommendation by physicians in Lebanon,

7 a cross-sectional study. *Vaccine*. 2018;36(49):7562-7.

8 • 31. Rutten LJ, St Sauver JL, Beebe TJ, Wilson PM, Jacobson DJ, Fan C, et al. Clinician

9 knowledge, clinician barriers, and perceived parental barriers regarding human papillomavirus

10 vaccination: Association with initiation and completion rates. *Vaccine*. 2017;35(1):164-9.

11 • 32. Takeuchi J, Sakanishi Y, Okada T, Nakayama K, Chiba H, Suganaga R, et al. Factors

12 associated between behavior of administrating or recommending mumps vaccine and primary care

13 physicians' knowledge about vaccination: A nationwide cross-sectional study in Japan. *J Gen Fam*

14 *Med*. 2022;23(1):9-18.

15 • 33. Kubota M, Kondo K, Tomiyoshi Y, Fukushima W. Survey of pediatricians concerning the

16 human papillomavirus vaccine in Japan: Positive attitudes toward vaccination during the period of

17 proactive recommendation being withheld. *Hum Vaccin Immunother*. 2022;18(6):2131337.

18 • 34. Nagase YA-O, Ueda Y, Abe H, Yagi A, Sawada M, Nakagawa S, et al. Changing attitudes

19 in Japan toward HPV vaccination: a 5-year follow-up survey of obstetricians and gynecologists

- 1 regarding their current opinions about the HPV vaccine. 2020(2164-554X (Electronic)).
- 2
- 3
- 4 1
- 5
- 6
- 7 2
- 8
- 9
- 10 3
- 11
- 12
- 13 4
- 14
- 15
- 16 5
- 17
- 18
- 19 6
- 20
- 21
- 22 7
- 23
- 24
- 25 8
- 26
- 27
- 28 9
- 29
- 30
- 31 10
- 32
- 33
- 34 11
- 35
- 36
- 37 12
- 38
- 39
- 40 13
- 41
- 42
- 43 14
- 44
- 45
- 46 15
- 47
- 48
- 49 16
- 50
- 51
- 52 17
- 53
- 54
- 55 18
- 56
- 57
- 58 19
- 59
- 60
- 35. Kempe A, O'Leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, et al. HPV Vaccine Delivery Practices by Primary Care Physicians. *Pediatrics*. 2019;144(4).
 - 36. Rolls K, Hansen M, Jackson D, Elliott D. How Health Care Professionals Use Social Media to Create Virtual Communities: An Integrative Review. *J Med Internet Res*. 2016;18(6):e166.
 - 37. Ministry of Health, Labour and Welfare of Japan. Notices and Administrative Communication Regarding HPV Vaccine. 2021. (in Japanese) Available: <https://www.mhlw.go.jp/content/000875155.pdf> [Accessed 25 Mar 2023]
 - 38. Yagi A, Ueda Y, Nakagawa S, Ikeda S, Kakuda M, Hiramatsu K, et al. Can Catch-Up Vaccinations Fill the Void Left by Suspension of the Governmental Recommendation of HPV Vaccine in Japan? *Vaccines (Basel)*. 2022;10(9).
 - 39. Ministry of Health, Labour and Welfare of Japan. Notices and Administrative Communication Regarding HPV Vaccine. 2022. (in Japanese) Available: <https://www.mhlw.go.jp/content/000915791.pdf> [Accessed 25 Mar 2023]
 - 40. Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association . Vaccination Website “Vaccination for all” (in Japanese) Available: <https://www.vaccine4all.jp>. [Accessed 25 Mar 2023]
 - 41. Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association. The 5th vaccine seminar “Tiger’s Den” 2022 was held! (in Japanese). 2023. (in Japanese) Available:

1
2
3
4 1 <https://www.vaccine4all.jp/topics-detail.php?tid=63>. [Accesed 25 Mar 2023]
5
6


7 2 • 42. Lip A, Pateman M, Fullerton MM, Chen HM, Bailey L, Houle S, et al. Vaccine hesitancy
8
9
10 3 educational tools for healthcare providers and trainees: A scoping review. *Vaccine*. 2023;41(1):23-
11
12
13 4 35.
14
15

16 5 • 43. Tsui J, Vincent A, Anuforo B, Btoush R, Crabtree BF. Understanding primary care
17
18
19 6 physician perspectives on recommending HPV vaccination and addressing vaccine hesitancy. *Hum*
20
21
22 7 *Vaccin Immunother*. 2021;17(7):1961-7.
23
24

25 8 • 44. Ministry of Health, Labour and Welfare of Japan . Q & A regarding HPV vaccine. 2022. (in
26
27
28 9 Japanese) Available: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou/hpv_qa.html#Q2-2.
29
30
31 10 [Accesed 25 Mar 2023]
32
33

34 11 • 45. Ministry of Health, Labour and Welfare of Japan. Information provisions and
35
36
37 12 Administrative Communication Regarding HPV Vaccine. 2022. (in Japanese) Available:
38
39
40 13 <https://www.mhlw.go.jp/content/001021317.pdf> [Accesed 25 Mar 2023]
41
42

43 14 • 46. Okubo R, Yoshioka T, Ohfuji S, Matsuo T, Tabuchi T. COVID-19 Vaccine Hesitancy and
44
45
46 15 Its Associated Factors in Japan. *Vaccines (Basel)*. 2021;9(6).
47
48
49 16
50
51
52
53
54
55
56
57
58
59
60



Supplementary Table 1 Factors associated with administration of HPV vaccine for routine and voluntary vaccination

Factors	PCPs who administer HPV vaccine	PCPs who do not administer HPV vaccine	Crude odds ratio (95% CI)		Adjusted odds ratio* (95% CI)	
	n (%)	n (%)	Routine vaccination, n=981	<i>p</i> -value	Routine vaccination, n=977	<i>p</i> -value
	Routine vaccination, n=229 (23.3%)	Routine vaccination, n=752 (76.7%)				
	Voluntary vaccination, n=175 (17.8%)	Voluntary vaccination, n=806 (82.2%)	Voluntary vaccination, n=981		Voluntary vaccination, n=977	
Factors	n (%)	n (%)				
High scores on vaccination quiz (4–6 points)	172 (75.1)	339 (45.1)	3.68 (2.64–5.12)	<0.001	2.28 (1.58–3.28)	<0.001
	132 (75.4)	379 (47.0)	3.46 (2.39–5.01)	<0.001	2.71 (1.81–4.04)	<0.001
Sex: male	178 (77.7)	561 (74.6)	1.19 (0.84–1.69)	0.38	1.11 (0.75–1.65)	0.6
	131 (74.8)	608 (75.4)	0.97 (0.66–1.41)	0.87	0.89 (0.59–1.35)	0.58
Postgraduate year (y)						
3–5	14 (6.1)	78 (10.4)	Reference		Reference	
	12 (6.9)	80 (9.9)	Reference		Reference	
6–10	28 (12.2)	150 (20.0)	1.04 (0.52–2.09)	0.91	0.48 (0.20–1.18)	0.11
	21 (12.0)	157 (19.5)	0.89 (0.42–1.90)	0.77	0.48 (0.19–1.23)	0.13
11–20	95 (41.5)	263 (35.0)	2.01 (1.09–3.72)	0.026	0.83 (0.34–2.02)	0.68
	66 (37.7)	292 (36.2)	1.51 (0.78–2.92)	0.23	0.69 (0.27–1.75)	0.43
21–30	51 (22.3)	142 (18.9)	2.00 (1.04–3.84)	0.037	0.91 (0.37–2.27)	0.85
	41 (23.4)	152 (18.9)	1.80 (0.89–3.61)	0.099	0.97 (0.38–2.50)	0.96
31–40	34 (14.9)	100 (13.3)	1.89 (0.95–3.77)	0.069	0.80 (0.32–1.99)	0.63
	28 (16.0)	106 (13.2)	1.76 (0.84–3.67)	0.13	0.98 (0.38–2.53)	0.97
≥41	7 (3.1)	19 (2.5)	2.05 (0.73–5.79)	0.17	0.79 (0.23–2.67)	0.7
	7 (4.0)	19 (2.4)	2.46 (0.85–7.07)	0.096	1.35 (0.40–4.57)	0.63
Position of any specialist qualification	201 (87.8)	643 (85.6)	1.21 (0.77–1.88)	0.41	1.04 (0.57–1.89)	0.89
	154 (88.0)	690 (85.7)	1.22 (0.74–2.01)	0.43	1.12 (0.59–2.12)	0.73
Main practice category: primary care	183 (79.9)	514 (68.4)	1.84 (1.29–2.63)	0.001	1.18 (0.74–1.88)	0.5
	141 (80.6)	556 (69.0)	1.86 (1.25–2.79)	0.002	1.52 (0.93–2.49)	0.098
Practice setting						
University hospital or general hospital	28 (12.2)	253 (33.8)	Reference		Reference	
	36 (20.6)	245 (30.5)	Reference		Reference	
Other hospital	35 (15.3)	219 (29.2)	1.44 (0.85–2.45)	0.17	1.18 (0.68–2.06)	0.55
	29 (16.6)	225 (28.0)	0.89 (0.52–1.48)	0.62	0.68 (0.39–1.19)	0.18
Clinic	164 (71.6)	256 (34.2)	5.79 (3.74–8.96)	<0.001	2.64 (1.60–4.36)	<0.001
	109 (62.3)	311 (38.7)	2.39 (1.58–3.60)	<0.001	1.27 (0.77–2.08)	0.35
Others (i.e., University, research institution, government, and health organisation)	2 (0.87)	21 (2.8)	0.86 (0.19–3.86)	0.85	0.90 (0.22–3.73)	0.88
	1 (0.57)	22 (2.7)	0.31 (0.04–2.37)	0.26	0.37 (0.06–2.10)	0.26
Providing daily paediatric medical service (≥ 10% of total patients)	113 (49.3)	170 (22.6)	3.33 (2.45–4.55)	<0.001	1.78 (1.24–2.55)	0.002
	66 (37.7)	217 (26.9)	1.64 (1.17–2.32)	0.005	1.04 (0.70–1.55)	0.84
Mainly working in an urban area (≥50,000 people as an administrative unit of the local government)	164 (71.6)	555 (74.0)	0.89 (0.64–1.23)	0.48	1.07 (0.73–1.55)	0.74
	135 (77.1)	584 (72.6)	1.27 (0.86–1.87)	0.22	1.26 (0.83–1.91)	0.27
Experience as kindergarten or school physician	165 (72.1)	309 (41.1)	3.70 (2.68–5.11)	<0.001	2.12 (1.45–3.10)	<0.001
	106 (60.6)	368 (45.7)	1.83 (1.31–2.55)	<0.001	1.23 (0.82–1.84)	0.31
Experience raising children	176 (76.9)	545 (72.5)	1.26 (0.89–1.78)	0.19	0.86 (0.56–1.32)	0.48
	129 (73.7)	592 (73.5)	1.01 (0.70–1.47)	0.07	0.70 (0.45–1.08)	0.11
Information resource						
Government	189 (82.5)	558 (74.2)	1.64 (1.13–2.40)	0.01	1.25 (0.82–1.90)	0.29
	152 (86.9)	595 (73.8)	2.34 (1.47–3.73)	<0.001	1.90 (1.17–3.08)	0.009
Academia	226 (98.7)	687 (91.4)	7.13 (2.22–22.90)	0.001	1.76 (0.55–5.64)	0.34
	170 (97.1)	743 (92.2)	2.88 (1.14–7.28)	0.025	0.93 (0.35–2.43)	0.88
Commerce	71 (31.0)	212 (28.2)	1.14 (0.83–1.58)	0.41	0.85 (0.58–1.23)	0.38
	55 (31.4)	228 (28.3)	1.16 (0.82–1.66)	0.41	0.84 (0.57–1.25)	0.39
Social network service or mailing list by individuals or group of medical service providers	94 (41.1)	205 (27.3)	1.86 (1.36–2.53)	<0.001	1.26 (0.88–1.80)	0.21
	80 (45.7)	219 (27.2)	2.26 (1.61–3.16)	<0.001	1.82 (1.25–2.64)	0.002
None	0	19 (2.5)	0.08 (0.05–1.36)*	0.081	0.35 (0.02–8.24)	0.52
	0	19 (2.4)	0.12 (0.01–1.91)*	0.13	0.39 (0.02–8.00)	0.54

*Penalized maximum likelihood logistic regression. PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

Supplementary Table 2 Factors associated with recommendation of HPV vaccine for routine and voluntary vaccination

Factors	PCPs who recommend HPV vaccine	PCPs who do not recommend HPV vaccine	Crude odds ratio (95% CI)	<i>p</i> -value	Adjusted odds ratio (95% CI)	
	Routine vaccination, n=408 (41.6%)	Routine vaccination, n=573 (58.4%)	Routine vaccination, n=981		Routine vaccination, n=977	<i>p</i> -value
	Voluntary vaccination, n=216 (22.0%)	Voluntary vaccination, n=765 (78.0%)	Voluntary vaccination, n=981		Voluntary vaccination, n=977	
Factors	n (%)	n (%)				
High scores on vaccination quiz (4–6 points)	248 (60.8)	263 (45.9)	1.83 (1.41–2.36)	<0.001	2.17 (1.62–2.92)	<0.001
	131 (60.6)	380 (49.7)	1.56 (1.15–2.12)	0.005	1.88 (1.32–2.67)	<0.001
Sex: male	319 (78.2)	420 (73.3)	1.31 (0.97–1.76)	0.08	1.37 (0.99–1.90)	0.056
	174 (80.6)	565 (73.9)	1.47 (1.01–2.13)	0.045	1.67 (1.12–2.49)	0.012
Postgraduate year (y)						
3–5	44 (10.8)	48 (8.4)	Reference		Reference	
	24 (11.1)	68 (8.9)	Reference		Reference	
6–10	69 (16.9)	109 (19.0)	0.69 (0.42–1.15)	0.15	0.89 (0.47–1.68)	0.72
	30 (13.9)	148 (19.4)	0.57 (0.31–1.06)	0.074	0.81 (0.37–1.75)	0.59
11–20	153 (37.5)	205 (35.8)	0.81 (0.51–1.29)	0.38	1.03 (0.53–1.99)	0.94
	87 (40.3)	271 (35.4)	0.91 (0.54–1.54)	0.72	1.40 (0.63–3.08)	0.41
21–30	90 (22.1)	103 (18.0)	0.95 (0.58–1.57)	0.85	1.28 (0.64–2.53)	0.48
	52 (24.1)	141 (18.4)	1.04 (0.59–1.84)	0.88	1.73 (0.77–3.88)	0.19
31–40	45 (11.0)	89 (15.5)	0.55 (0.32–0.95)	0.032	0.73 (0.36–1.48)	0.38
	21 (9.7)	113 (14.8)	0.53 (0.27–1.02)	0.056	0.84 (0.36–1.98)	0.69
≥41	7 (1.7)	19 (3.3)	0.40 (0.15–1.05)	0.062	0.56 (0.19–1.62)	0.28
	2 (0.9)	24 (3.1)	0.24 (0.05–1.02)	0.062	0.38 (0.07–1.89)	0.24
Position of any specialist qualification	347 (85.1)	497 (86.9)	0.86 (0.60–1.24)	0.41	0.79 (0.49–1.29)	0.35
	184 (85.2)	660 (86.4)	0.91 (0.59–1.39)	0.65	0.74 (0.40–1.35)	0.32
Main practice category: primary care	281 (68.9)	416 (72.6)	0.84 (0.63–1.10)	0.21	0.79 (0.55–1.11)	0.18
	148 (68.5)	549 (71.7)	0.86 (0.62–1.19)	0.35	0.84 (0.55–1.27)	0.4
Practice setting						
University hospital or general hospital	143 (33.8)	143 (25.1)	Reference		Reference	
	81 (37.5)	200 (26.3)	Reference		Reference	
Other hospital	101 (24.8)	219 (29.2)	0.68 (0.49–0.96)	0.03	0.69 (0.48–1.00)	0.048
	53 (24.5)	201 (26.4)	0.65 (0.44–0.97)	0.03	0.69 (0.45–1.06)	0.091
Clinic	161 (39.5)	259 (45.4)	0.64 (0.47–0.87)	0.005	0.67 (0.46–0.98)	0.041
	77 (35.7)	343 (45.0)	0.55 (0.39–0.79)	0.001	0.67 (0.43–1.04)	0.075
Others (e.g., University, research institution, government, and health organisation)	8 (2.0)	15 (2.6)	0.55 (0.23–1.34)	0.19	0.51 (0.20–1.31)	0.16
	5 (2.3)	18 (2.4)	0.69 (0.25–1.91)	0.47	0.63 (0.21–1.84)	0.4
Providing daily paediatric medical service (≥10% of total patients)	95 (23.3)	188 (32.8)	0.62 (0.47–0.83)	0.001	0.50 (0.36–0.70)	<0.001
	43 (19.9)	240 (31.4)	0.54 (0.38–0.78)	0.001	0.52 (0.34–0.78)	0.002
Mainly working in an urban area (≥50,000 people as an administrative unit of the local government)	305 (74.9)	414 (72.4)	1.14 (0.85–1.52)	0.37	1.08 (0.78–1.47)	0.65
	171 (80.0)	547 (71.6)	1.59 (1.10–2.30)	0.014	1.42 (0.95–2.11)	0.084
Experience as kindergarten or school physician	190 (46.6)	284 (49.6)	0.89 (0.69–1.14)	0.36	1.09 (0.80–1.49)	0.57
	87 (40.3)	387 (50.6)	0.66 (0.48–0.90)	0.008	0.79 (0.55–1.14)	0.21
Experience raising children	296 (72.6)	425 (74.2)	0.92 (0.69–1.23)	0.57	0.79 (0.56–1.10)	0.16
	153 (70.8)	568 (74.3)	0.84 (0.60–1.18)	0.32	0.67 (0.45–1.00)	0.049
Information resource						
Government	294 (72.1)	453 (79.1)	0.68 (0.51–0.92)	0.011	0.69 (0.50–0.96)	0.026
	155 (71.8)	592 (77.4)	0.74 (0.53–1.04)	0.087	0.80 (0.55–1.16)	0.24
Academia	385 (94.4)	528 (92.2)	1.43 (0.85–2.40)	0.18	1.21 (0.63–2.35)	0.56
	202 (93.5)	711 (92.9)	1.10 (0.60–2.01)	0.77	0.94 (0.44–2.04)	0.88
Commerce	113 (27.7)	170 (29.7)	0.91 (0.69–1.20)	0.5	0.91 (0.67–1.25)	0.56
	60 (27.8)	223 (29.2)	0.93 (0.67–1.31)	0.69	0.91 (0.63–1.32)	0.62
Social network service or mailing list by individuals or group of medical service providers	136 (33.3)	163 (28.5)	1.26 (0.96–1.65)	0.1	1.33 (0.98–1.82)	0.071
	79 (36.6)	220 (28.8)	1.43 (1.04–1.96)	0.028	1.56 (1.09–2.24)	0.016
None	7 (1.7)	12 (2.1)	0.82 (0.32–2.09)	0.67	0.82 (0.25–2.68)	0.74
	4 (1.9)	15 (2.0)	0.94 (0.31–2.87)	0.92	0.84 (0.21–3.40)	0.81

PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

Checklist for Reporting Of Survey Studies (CROSS)

Section/topic	Item	Item description	Reported on page #
Title and abstract			
Title and abstract	1a	State the word “survey” along with a commonly used term in title or abstract to introduce the study’s design.	3
	1b	Provide an informative summary in the abstract, covering background, objectives, methods, findings/results, interpretation/discussion, and conclusions.	3-4
Introduction			
Background	2	Provide a background about the rationale of study, what has been previously done, and why this survey is needed.	6-8
Purpose/aim	3	Identify specific purposes, aims, goals, or objectives of the study.	8
Methods			
Study design	4	Specify the study design in the methods section with a commonly used term (e.g., cross-sectional or longitudinal).	8-9
	5a	Describe the questionnaire (e.g., number of sections, number of questions, number and names of instruments used).	9
	5b	Describe all questionnaire instruments that were used in the survey to measure particular concepts. Report target population, reported validity and reliability information, scoring/classification procedure, and reference links (if any).	9
Data collection methods	5c	Provide information on pretesting of the questionnaire, if performed (in the article or in an online supplement).	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Report the method of pretesting, number of times questionnaire was pre-tested, number and demographics of participants used for pretesting, and the level of similarity of demographics between pre-testing participants and sample population.	
	5d Questionnaire if possible, should be fully provided (in the article, or as appendices or as an online supplement).	-
	6a Describe the study population (i.e., background, locations, eligibility criteria for participant inclusion in survey, exclusion criteria).	8-9
Sample characteristics	6b Describe the sampling techniques used (e.g., single stage or multistage sampling, simple random sampling, stratified sampling, cluster sampling, convenience sampling). Specify the locations of sample participants whenever clustered sampling was applied.	9
	6c Provide information on sample size, along with details of sample size calculation.	-
	6d Describe how representative the sample is of the study population (or target population if possible), particularly for population-based surveys.	-
Survey administration	7a Provide information on modes of questionnaire administration, including the type and number of contacts, the location where the survey was conducted (e.g., outpatient room or by use of online tools, such as SurveyMonkey).	9
	7b Provide information of survey's time frame, such as periods of recruitment, exposure, and follow-up days.	8
	7c Provide information on the entry process: ->For non-web-based surveys, provide approaches to	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

		minimize human error in data entry.	
		→For web-based surveys, provide approaches to prevent “multiple participation” of participants.	
		Describe any preparation process before conducting the	-
Study preparation	8	survey (e.g., interviewers’ training process, advertising the survey).	
		Provide information on ethical approval for the survey if	23
Ethical considerations	9a	obtained, including informed consent, institutional review board [IRB] approval, Helsinki declaration, and good clinical practice [GCP] declaration (as appropriate).	
		Provide information about survey anonymity and	9
	9b	confidentiality and describe what mechanisms were used to protect unauthorized access.	
		Describe statistical methods and analytical approach.	13
	10	Report the statistical software that was used for data	
	a	analysis.	
	10	Report any modification of variables used in the analysis,	13
	b	along with reference (if available).	
		Report details about how missing data was handled. Include	13
Statistical analysis	10	rate of missing items, missing data mechanism (i.e., missing completely at random [MCAR], missing at random [MAR]	
	c	or missing not at random [MNAR]) and methods used to deal with missing data (e.g., multiple imputation).	
	10	State how non-response error was addressed.	-
	d		
	10	For longitudinal surveys, state how loss to follow-up was	-
	e	addressed.	
	10f	Indicate whether any methods such as weighting of items or	-
		propensity scores have been used to adjust for non-	

representativeness of the sample.

10 Describe any sensitivity analysis conducted. 13
g

Results

	11 Report numbers of individuals at each stage of the study.	14
	a Consider using a flow diagram, if possible.	
	11 Provide reasons for non-participation at each stage, if possible.	Figure 1:Study flowchart
Respondent characteristics	11 Report response rate, present the definition of response rate or the formula used to calculate response rate.	14
	Provide information to define how unique visitors are determined. Report number of unique visitors along with relevant proportions (e.g., view proportion, participation proportion, completion proportion).	-
Descriptive results	Provide characteristics of study participants, as well as information on potential confounders and assessed outcomes.	14-16, 25,26
	13 Give unadjusted estimates and, if applicable, confounder-adjusted estimates along with 95% confidence intervals and p-values.	14-16, Supplementar y Tabel 1-2
Main findings	13 For multivariable analysis, provide information on the model building process, model fit statistics, and model assumptions (as appropriate).	-
	Provide details about any sensitivity analysis performed. If there are considerable amount of missing data, report sensitivity analyses comparing the results of complete cases with that of the imputed dataset (if possible).	16

Discussion

		Discuss the limitations of the study, considering sources of	21-22
		potential biases and imprecisions, such as non-	
Limitations	14	representativeness of sample, study design, important	
		uncontrolled confounders.	
		Give a cautious overall interpretation of results, based on	21-22
Interpretations	15	potential biases and imprecisions and suggest areas for	
		future research.	
Generalizability	16	Discuss the external validity of the results.	22
Other sections			
Role of funding		State whether any funding organization has had any roles in	-
source	17	the survey's design, implementation, and analysis.	
Conflict of interest	18	Declare any potential conflict of interest.	24
Acknowledgements	19	Provide names of organizations/persons that are	23
		acknowledged along with their contribution to the research.	

BMJ Open

Association between administration or recommendation of the human papillomavirus vaccine and primary care physicians' knowledge about vaccination during proactive recommendation suspension: a nationwide cross-sectional study in Japan

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-074305.R2
Article Type:	Original research
Date Submitted by the Author:	03-Nov-2023
Complete List of Authors:	Sakanishi, Yuta; Sakanishi Internal Medicine and Pediatrics Clinic; Japan Primary Care Association, Committee for Infectious Diseases, Vaccine Team Takeuchi, Jiro; Nara Medical University, Institute for Clinical and Translational Science; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Suganaga, Rei; Tessyoukai Kameda Family Clinic Tateyama; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Nakayama, Kuniko; My family Clinic Gamagori; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Nishioka, Yosuke; Nishioka Memorial Central Clinic; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Chiba, Hiroshi; Family Medical Practice Hanoi; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Kishi, Tomomi; Japan Baptist Hospital; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Machino, Ako; Gondo Dermatological Clinic Mastumura, Mami; School of Public Health, Graduate School of Medicine, Kyoto University, Department of Preventive Services; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Okada, Tadao; Tessyoukai Kameda Family Clinic Tateyama; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association Suzuki, Tomio; Osaka Medical and Pharmaceutical University, Department of General Medicine; Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association
Primary Subject Heading:	General practice / Family practice
Secondary Subject Heading:	Public health, Epidemiology, Paediatrics
Keywords:	Primary Care < Primary Health Care, PREVENTIVE MEDICINE, Community child health < PAEDIATRICS

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60





I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1
2
3
4 1 TITLE PAGE
5
6

7 2 **Association between administration or recommendation of the human papillomavirus vaccine**
8
9
10 3 **and primary care physicians' knowledge about vaccination during proactive recommendation**
11
12
13 4 **suspension: a nationwide cross-sectional study in Japan**
14
15

16 5
17
18 6 Yuta Sakanishi*, MD, PhD, MPH¹), Jiro Takeuchi*, MD, PhD²), Rei Suganaga*, MD³), Kuniko
19
20
21 7 Nakayama*, MD, PhD, DTM&H⁴), Yosuke Nishioka*, MD⁵), Hiroshi Chiba*, MD, PhD, MPH⁶),
22
23
24 8 Tomomi Kishi*, MD⁷), Ako Machino, MD⁸), Mami Matsumura*, MD⁹), Tadao Okada*, MD, MPH³),
25
26
27 9 Tomio Suzuki*, MD, PhD.¹⁰
28
29

30 10
31
32
33 11 ¹) Sakanishi Internal Medicine and Pediatrics Clinic, Omuta, Japan
34

35
36 12 ²) Institute for Clinical and Translational Science, Nara Medical University, Kashihara, Japan
37

38
39 13 ³) Tessayoukai Kameda Family Clinic Tateyama, Tateyama, Japan
40

41
42 14 ⁴) My family Clinic Gamagori, Gamagori, Japan
43

44
45 15 ⁵) Nishioka Memorial Central Clinic, Shima, Japan
46

47
48 16 ⁶) Family Medical Practice Hanoi, Hanoi, Vietnam
49

50
51 17 ⁷) Japan Baptist Hospital, Kyoto, Japan
52

53 18 ⁸) Gondo Dermatological Clinic, Tosu, Japan
54

55 19 ⁹) Department of Preventive Services, School of Public Health, Graduate School of Medicine, Kyoto
56
57
58 20 University, Kyoto, Japan
59
60

1
2
3
4 1 ¹⁰⁾ Osaka Medical and Pharmaceutical University, Department of General Medicine, Takatsuki,
5
6
7 2 Japan

8
9
10 3 * Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association, Tokyo, Japan

11
12
13 4
14
15 5 Corresponding author:

16
17
18 6 Yuta Sakanishi, MD, PhD, MPH, Sakanishi Internal Medicine and Pediatrics Clinic, 2-8 Harayama-
19
20
21 7 machi, Omuta-shi, Fukuoka 836-0862, Japan (email:1976yuta@gmail.com)

22
23
24 8 Telephone: +81-944-52-2025, Fax: +81-944-52-2036

25
26
27 9
28
29
30 10 Short running title: HPV vaccination and primary care physicians

31
32
33 11
34
35
36 12 Keywords: cross-sectional study, HPV vaccine, physicians, primary care, vaccination

37
38
39 13
40
41
42 14 ORCID

43
44
45 15 Yuta Sakanishi <https://orcid.org/0000-0002-4059-6932>

46
47
48 16
49
50
51 17 Word count 4162 words

52
53 18

54
55
56 19

1
2
3
4 1
5
6
7 2 ABSTRACT
8
9

10 3 **Objective** The Japanese government suspended the proactive recommendation of the human
11
12
13 4 papillomavirus vaccine (HPVv) in 2013, and the vaccination rate of HPVv declined to <1% during
14
15
16 5 2014–2015. Previous studies have shown that the recommendation by a physician affects a
17
18
19 6 recipient's decision to receive a vaccine, and physicians' accurate knowledge about vaccination is
20
21
22 7 important to increase vaccine administration. This study aimed to evaluate the association between
23
24
25 8 physicians' knowledge of vaccination and the administration or recommendation of HPVv by
26
27
28 9 primary care physicians (PCPs) in the absence of proactive recommendations from the Japanese
29
30
31 10 government.

32
33 11 **Design** Cross-sectional study analysed data obtained through a web-based, self-administered
34
35
36 12 questionnaire survey.
37
38

39 13 **Setting** The questionnaire was distributed to Japan Primary Care Association (JPCA) members.
40
41

42 14 **Participants** JPCA members who were physicians and on the official JPCA mailing list (n=5,395)
43
44
45 15 were included.
46
47

48 16 **Primary and secondary outcome measures** The primary and secondary outcomes were the
49
50
51 17 administration and recommendation of HPVv, respectively, by PCPs. The association between PCPs'
52
53
54 18 knowledge regarding vaccination and each outcome was determined based on their background and
55
56
57
58
59
60

1
2
3
4 1 vaccination quiz scores and a logistic regression analysis to estimate the adjusted odds ratios
5
6
7 2 (AORs).
8
9

10 3 **Results** We received responses from 1,084 PCPs and included 981 of them in the analysis. PCPs
11
12
13 4 with a higher score on the vaccination quiz were significantly more likely to administer the HPVv for
14
15
16 5 routine and voluntary vaccination (AOR 2.28, 95% confidence interval [CI] 1.58–3.28; AOR 2.71,
17
18
19 6 95% CI 1.81–4.04, respectively) and recommend the HPVv for routine and voluntary vaccination
20
21
22 7 than PCPs with a lower score (AOR 2.17, 95% CI 1.62–2.92; AOR 1.88, 95% CI 1.32–2.67,
23
24
25 8 respectively).
26

27 9 **Conclusions** These results suggest that providing accurate knowledge regarding vaccination to PCPs
28
29
30 10 may improve their administration and recommendation of HPVv, even in the absence of active
31
32
33 11 government recommendations.
34
35

36 12

37

38

39 13 **Strengths and limitations of this study**

40

- 41
42 14 • This is the first study to evaluate the association between primary care physicians' (PCPs)
43
44
45 15 vaccination knowledge and HPV vaccine administration and recommendation without proactive
46
47
48 16 recommendation from the Japanese government.
49
- 50
51 17 • This nationwide study targeted the physician members of the Japan Primary Care Association,
52
53
54 18 which is the largest academic society for PCPs in Japan.
55
- 56
57 19 • A limitation of this study was its potential selection bias due to the voluntary participation of the
58
59
60

1
2
3
4 1 PCPs in the survey.
5
6

7 2 • Furthermore, the effects of vaccine hesitancy among parents and media on the PCPs were not
8
9
10 3 evaluated.
11
12

13 4
14
15

16 5 **Data availability statement**
17

18
19 6 Data are available from the corresponding author upon reasonable request.
20
21

22 7
23
24

25 8
26

27 9 **Keywords:** HPV vaccine; primary care physicians; administration; recommendation; vaccination
28
29

30 10
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 INTRODUCTION

2 The World Health Organization (WHO) recognises cervical cancer and other human
3 papillomavirus (HPV)-related diseases as important global public health concerns and recommends
4 the inclusion of HPV vaccines (HPVv) in national immunisation programmes.(1) In Japan, HPVv
5 was introduced in 2009 as a voluntary vaccine without recommendation or funding from the
6 government.(2, 3) In 2010, the Ministry of Health, Labour and Welfare (MHLW) initiated an urgent
7 promotional campaign for vaccination, and the Government of Japan provided subsidies to local
8 governments for HPVv.(2, 3) This campaign was successful, and the vaccination rate of HPVv
9 increased to 70–80% in the targeted group of young girls in 2012.(3-6) In April 2013, free-of-charge
10 HPV vaccination of 12- to 16-year-old girls was initiated as part of the routine vaccination
11 programme.(3, 7, 8) On the other hand, three doses of voluntary bivalent HPVv for ≥ 10 -year-old
12 females and quadrivalent HPVv for ≥ 9 -year-old females cost approximately ¥45,000 (US \$450, as of
13 April 2013). However, the media widely reported concerns regarding potential adverse effects of
14 HPV vaccination among young girls, including complex regional pain syndrome, giving rise to
15 social distrust and vaccine hesitancy related to HPVv.(3, 4, 7, 9) Consequently, the MHLW
16 suspended proactive recommendation of HPV vaccination in June 2013;(7, 10) the local
17 governments stopped sending individual notifications to the homes of girls eligible for HPVv
18 although it continued being a part of the routine vaccine programme.(10) The HPV vaccination rate
19 declined to less than 1% during 2014–2015.(5, 6)

1
2
3
4 1 The Global Advisory Committee on Vaccine Safety (GACVS) reviewed the safety data of HPVv
5
6
7 2 from 2008 to 2015 and found it to be extremely safe(11). In 2017, the GACVS expressed concerns
8
9
10 3 regarding the situation in Japan, stating that the mortality rate from cervical cancer was expected to
11
12
13 4 increase because HPVv was not proactively recommended.(11) In 2018, Suzuki et al. reported that
14
15
16 5 there was no association between HPVv and adverse post-vaccination symptoms in Nagoya,
17
18
19 6 Japan.(12) However, the MHLW did not resume the proactive recommendation of HPV vaccination
20
21
22 7 as of 2019. Vaccine hesitancy has also been reported in other countries, and the WHO identified it as
23
24
25 8 one of 10 threats to global health in 2019.(13)
26
27

28 9 Previous studies have shown that vaccine recommendation by a physician affects the recipient's
29
30
31 10 decision in receiving a vaccine.(14-19) Thus it is important for physicians to have accurate
32
33
34 11 knowledge regarding vaccination to increase vaccine administration or recommendation rates.(20-
35
36
37 12 22) In Japan, the HPVv is administered not only by paediatricians, obstetricians, and gynaecologists
38
39
40 13 (OBGYNs), but also by primary care physicians (PCPs).(23, 24) A 2012 nationwide survey on
41
42
43 14 practices and attitudes towards vaccination among PCPs in Japan(23, 24) showed that the proportion
44
45
46 15 of PCPs administering and actively recommending HPVv was 58.3% and 46.5%, respectively.(23) A
47
48
49 16 significant association between PCPs' awareness of public subsidies for HPVv and recommendation
50
51
52 17 of HPVv vaccination was reported.(24) As previously indicated, the government vaccination policy
53
54
55 18 for the HPVv changed following the survey(23, 24), and it was expected that these proportions
56
57
58 19 would also change. However, the current fraction of PCPs administering or recommending the HPVv
59
60

1
2
3
4 1 and the association between PCPs' knowledge about vaccination and their attitude towards HPVv in
5
6
7 2 Japan remain unknown. Therefore, this study aimed to evaluate the association between PCPs'
8
9
10 3 knowledge about vaccination and the administration or recommendation of HPVv without proactive
11
12
13 4 recommendation by the government.
14
15

16 5 17 18 19 6 **METHODS**

20 21 22 7 Study design, setting, and population

23
24
25 8 This cross-sectional study analysed data obtained from a web-based, self-administered questionnaire
26
27
28 9 conducted by the Preventive Medicine and Health Promotion Committee Vaccine Team of the Japan
29
30
31 10 Primary Care Association (JPCA), which is the largest academic association for PCPs in Japan. Most
32
33
34 11 JPCA physicians were internists working as PCPs at clinics or hospitals. The survey was conducted
35
36
37 12 from March to June 2019, and the inclusion criteria were JPCA members who were physicians and
38
39
40 13 on the official mailing list for JPCA members. PCPs who were junior residents within 2 years after
41
42
43 14 graduation from medical school were excluded, as this group cannot administer outpatient
44
45
46 15 vaccinations without the supervision of attending physicians. We excluded PCPs who lived outside
47
48
49 16 Japan, were retired, employed in a non-clinical setting, or had missing data.
50

51 52 17 53 54 55 18 Patient and public involvement

56
57
58 19 There was no patient or public involvement in this study.
59
60

1
2
3
4 15
6
7 2 Questionnaire

8
9
10 3 The questionnaire items were obtained from previous questionnaires administered by the Preventive
11
12
13 4 Medicine and Health Promotion Committee Vaccine Team of JPCA(23, 24) and were distributed
14
15
16 5 using the online mailing list for JPCA members. The questionnaire was conducted using an online
17
18
19 6 tool, SurveyMonkey. The questionnaire was self-conducted and anonymous. It collected data on the
20
21
22 7 participating physicians' attitudes regarding vaccines, including HPVv (administration or
23
24
25 8 recommendation), through a vaccination quiz; information resources on vaccinations; and baseline
26
27
28 9 characteristics, such as sex, career after graduation, main practice category, practice setting,
29
30
31 10 provision of daily paediatric medical service, population size of the main working area as an
32
33
34 11 administrative unit of the local government, experience as a kindergarten or school physician, and
35
36
37 12 experience raising children (details below).
38
39

40 13

41
42
43 14 Main outcome

44
45
46 15 The primary outcomes of this study were the administration of HPVv for routine and voluntary
47
48
49 16 vaccination, respectively. The PCPs were asked to respond with 'yes' or 'no' to the following
50
51
52 17 question: 'Do you administer routine/voluntary human papillomavirus vaccine?' Then, we
53
54
55 18 investigated the association between PCPs' knowledge of vaccination and vaccine administration for
56
57
58 19 each routine and voluntary vaccination, after adjusting for potential confounders (described below).
59
60

1
2
3
4 1 The secondary outcomes of this study were the recommendation of routine and voluntary HPV
5
6
7 2 vaccination by PCPs. The respondents were asked, ‘How do you recommend routine/voluntary
8
9
10 3 vaccination for HPV?’ The following response options were provided using a Likert-type scale:
11
12
13 4 ‘actively recommend’, ‘recommend occasionally’, ‘no opinion’, ‘do not actively recommend’, and
14
15
16 5 ‘do not recommend’. The response ‘actively recommend’ was considered ‘recommending
17
18
19 6 behaviour’, which is a more positive behaviour.⁽¹⁵⁾ Furthermore, the responses ‘recommend
20
21
22 7 occasionally’, ‘no opinion’, ‘do not actively recommend’, and ‘do not recommend’ were considered
23
24
25 8 ‘non-recommending behaviour’. Then, we investigated the association between PCPs’ knowledge of
26
27
28 9 vaccination and vaccine recommendation for routine and voluntary vaccination after adjusting for
29
30
31 10 possible confounders (described below).
32
33
34 11

37 12 Main factor

38
39
40 13 The main factor was PCPs’ knowledge of vaccination, which was assessed based on a vaccination
41
42
43 14 quiz. The quiz was created by the Preventive Medicine and Health Promotion Committee Vaccine
44
45
46 15 Team of the JPCA using the Delphi method.⁽²⁵⁾ The quiz comprised six general vaccine questions
47
48
49 16 encompassing Japanese vaccination affairs, including a question on HPVv. Scores of 0–6 were
50
51
52 17 assigned based on the number of correct answers to each of the six questions. To obtain a binary
53
54
55 18 variable, we designated scores above the average as high and those below the average as low. The
56
57
58 19 vaccination quiz score (high or low) was considered an independent variable.
59
60

1
2
3
4 1 Vaccination quiz
5
6

7 2 Q1. A 12-year-old boy has no history of mumps vaccination according to the Maternal and Child
8

9
10 3 Health Handbook. His mother states that he had developed mumps in his childhood. She mentions
11

12
13 4 that he had visited a clinic with bilateral parotid gland swelling, and the doctor had suspected mumps
14

15
16 5 based on clinical examination without blood tests. Is it then correct to recommend a mumps vaccine
17

18
19 6 to the boy? (Correct answer: correct)
20
21

22 7 Q2. A 3-month pregnant woman requests an influenza vaccine, and the only available influenza
23

24
25 8 vaccine in the hospital contains thimerosal. Is this vaccine acceptable or contraindicated for this
26

27
28 9 patient? (Correct answer: acceptable)
29
30

31 10 Q3. Is the 23-valent pneumococcal vaccine, an inactivated vaccine, less likely to cause swelling
32

33
34 11 when injected intramuscularly than when injected subcutaneously? (Correct answer: Correct)
35
36

37 12 Q4. Is there a limit to the number of vaccines (including live vaccines) that can be concurrently
38

39
40 13 administered? (Correct answer: there is no limit)
41
42

43 14 Q5. Is it correct that 'suspending proactive recommendation of HPV vaccination' means
44

45
46 15 'withholding local governments from sending individual pre-vaccination screening questionnaires
47

48
49 16 for HPV vaccine and notices to each household and actively calling for HPV vaccination through
50

51
52 17 various media rather than the suspension of routine vaccination'? (Correct answer: correct)
53
54
55
56
57
58
59
60

1
2
3
4 1 Q6. Is it correct that under the 'Adverse Event Following Immunization reporting system',
5
6
7 2 physicians are obligated to report to the Pharmaceuticals and Medical Devices Agency (PMDA)
8
9
10 3 when a vaccinated individual begins exhibiting certain symptoms? (Correct answer: correct)
11
12

13 4

16 5 Other factors

17
18
19 6 Other factors included the physician's sex, postgraduate years (3–5, 6–10, 11–20, 21–30, 31–40, and
20
21
22 7 ≥ 41 years), any specialist qualifications, including those related to primary care, main practice
23
24
25 8 category (primary care; family physician, general practitioner, hospitalist/general physician or others;
26
27
28 9 paediatricians, OBGYNs, industrial physician, researcher, administrative staff, and others), practice
29
30
31 10 setting (e.g., university hospital or general hospital, other hospital, clinic, others; university, research
32
33
34 11 institution, government, and health organisation), proportion of paediatric patients (number of
35
36
37 12 paediatric patients with respect to the total patient population) that was high ($\geq 10\%$) or low ($< 10\%$),
38
39
40 13 main working area as an administrative unit of the local government in an urban area ($\geq 50,000$
41
42
43 14 people), experience as a kindergarten or school physician, experience raising children as a parent,
44
45
46 15 and information resources about vaccinations (government, academic, commercial,(26) online
47
48
49 16 professional community such as website/Facebook group/Twitter/JPCA mailing list,(27) and none).
50
51

52 17

55 18 Statistical analysis

1
2
3
4 1 We performed univariate and multivariate logistic regression analysis to estimate the odds ratios,
5
6
7 2 adjusted odds ratios (AORs), and 95% confidence intervals (CIs), using binary variables for the main
8
9
10 3 outcome. We investigated the association between PCPs' knowledge of vaccination and HPVv
11
12
13 4 administration or recommendation.

14
15
16 5 Multiple logistic regression analysis was performed by adjusting for the following possible
17
18
19 6 confounding factors: physician's sex, postgraduate year, possession of any specialist qualifications,
20
21
22 7 including primary care, main practice category, practice setting, a high or low proportion of
23
24
25 8 paediatric patients, experience raising children as a parent, and information resources about
26
27
28 9 vaccinations.

29
30
31 10 We conducted a sensitivity analysis to inspect each variation only for HPVv knowledge (correct or
32
33
34 11 incorrect) rather than for the total quiz score. We used penalized maximum likelihood logistic
35
36
37 12 regression for the analyses when any confounding factors were completely separated.(28)

38
39
40 13 The analysis participants were selected after excluding participants with missing data for the main
41
42
43 14 outcome, main factor, and the above-mentioned possible confounders.

44
45
46 15 All statistical analyses used two-tailed tests of significance, with significance set at $p < 0.05$.

47
48
49 16 Analyses were performed using Stata/SE 14.2 (StataCorp LLC, College Station, TX, USA).

50 51 52 17 53 54 55 18 **RESULTS**

56 57 58 19 Study flow and demographics

1
2
3
4 1 Of the 10,470 physician members of the JPCA, 5,075 who did not subscribe to JPCA mails and
5
6
7 2 were, therefore, not on the mailing list were excluded. We received responses from 1,084 of 5,395
8
9
10 3 PCPs, with a response rate of 20.1%. The respondents were from all 47 prefectures of Japan. An
11
12
13 4 additional 103 participants were excluded because they lived outside Japan, performed nonclinical
14
15
16 5 work, or had missing data. The analysis included 981 participants (Figure 1). The median
17
18
19 6 (interquartile range) score for the vaccination quiz was 4 (range, 2–5) points. The minimum and
20
21
22 7 maximum scores were 0 and 6 points, respectively, and the mean (standard deviation) score was 3.47
23
24
25 8 (1.68) points. To obtain a binary variable, scores of ≥ 4 were designated as high, and scores of ≤ 3 as
26
27
28 9 low. Evaluation of the participant baseline characteristics revealed that 739 (75.3%) participants
29
30
31 10 were men, 358 (36.5%) had worked for 11–20 years after graduation, 420 (42.8%) worked in clinics,
32
33
34 11 719 (73.3%) worked in the urban areas, and 283 (28.9%) worked in a clinical setting where the
35
36
37 12 proportion of paediatric patients was $\geq 10\%$ (Table 1).
38
39
40 13

43 14 Factors associated with HPVv administration under routine vaccination

46 15 We found that 229 PCPs (23.3%) administered HPVv under routine vaccination (Table2). PCPs
47
48
49 16 with higher vaccination quiz scores were significantly more likely to administer HPVv as routine
50
51
52 17 vaccination than those with lower scores (AOR 2.28, 95% CI 1.58–3.28, $p < 0.001$) (Supplementary
53
54
55 18 Table 1-1). There was also a positive association between the administration of routine HPV
56
57
58 19 vaccination and PCPs who worked at clinics (AOR 2.64, 95% CI 1.60–4.36, $p < 0.001$), those who
59
60

1
2
3
4 1 had a higher proportion of paediatric patients (AOR 1.78, 95% CI 1.24–2.55, $p = 0.002$), and those
5
6
7 2 who had experience as a kindergarten or school physician (AOR 2.12, 95% CI 1.45–3.10, $p < 0.001$)
8
9
10 3 (Supplementary Table 1-1).
11
12

13 4 14 15 16 5 Factors associated with HPVv administration under voluntary vaccination 17

18
19 6 We found that 175 PCPs (17.8%) administered HPVv under voluntary vaccination. PCPs with
20
21
22 7 higher scores on the vaccination quiz were significantly more likely to administer HPVv as voluntary
23
24
25 8 vaccination than those with lower scores (AOR 2.71, 95% CI 1.81–4.04, $p < 0.001$) (Supplementary
26
27
28 9 Table 1-2). There was also a positive association between administration of voluntary HPVv and
29
30
31 10 PCPs who acquired information from governments (AOR 1.90, 95% CI 1.17–3.08, $p = 0.009$) and
32
33
34 11 those who participated in a social network service or mailing list from an individual or group of
35
36
37 12 medical service providers (AOR 1.82, 95% CI 1.25–2.64, $p = 0.002$) (Supplementary Table 1-2).
38
39

40 13 41 42 43 14 Factors associated with HPVv recommendation under routine vaccination 44

45
46 15 The PCPs selected the following options regarding the recommendation of HPVv under routine
47
48
49 16 vaccination: ‘actively recommend’, 408 PCPs (41.6%); ‘recommend occasionally’, 319 PCPs
50
51
52 17 (32.5%); ‘no opinion’, 181 PCPs (18.5%); ‘do not actively recommend’, 49 (5.0%); and ‘do not
53
54
55 18 recommend’, 24 (2.5%) (Table 2). PCPs with higher scores on the vaccination quiz were
56
57
58 19 significantly more likely to recommend HPVv under routine vaccination than those with lower
59
60

1
2
3
4 1 scores (AOR 2.17, 95% CI 1.62–2.92; $p < 0.001$) (Supplementary Table 2-1). However, there was a
5
6
7 2 negative association between recommending routine HPV vaccination and PCPs who worked at
8
9
10 3 other hospitals (AOR 0.69, 95% CI 0.48–1.00, $p = 0.048$) and clinics (AOR 0.67, 95% CI 0.46–0.98,
11
12
13 4 $p = 0.041$), those who had a higher proportion of paediatric patients (AOR 0.50, 95% CI 0.36–0.70, p
14
15
16 5 < 0.001), and those who acquired information from government sources (AOR 0.69, 95% CI 0.50–
17
18
19 6 0.96, $p = 0.026$) (Supplementary Table 2-1).
20
21
22 7

25 8 Factors associated with HPVv recommendation under voluntary vaccination

26
27
28 9 The PCPs selected the following options regarding the recommendation of HPVv under voluntary
29
30
31 10 vaccination: ‘actively recommend’, 216 PCPs (22.0%); ‘recommend occasionally’, 358 (36.5%); ‘no
32
33
34 11 opinion’, 288 (29.4%); ‘do not actively recommend’, 75 (7.7%); and ‘do not recommend’, 44 (4.5%)
35
36
37 12 (Table 2).
38
39

40 13 PCPs with higher vaccination quiz scores were significantly more likely to recommend HPVv
41
42
43 14 under voluntary vaccination than those with low scores (AOR 1.88, 95% CI 1.32–2.67, $p < 0.001$)
44
45
46 15 (Supplementary Table 2-2). There was also a positive association between the recommendation of
47
48
49 16 voluntary HPV vaccination and PCPs who were male (AOR 1.67, 95% CI 1.12–2.49, $p = 0.012$) and
50
51
52 17 those who participated in a social network service or mailing list for medical service from an
53
54
55 18 individual or group of providers (AOR 1.56, 95% CI 1.09–2.24, $p = 0.016$). However, there was a
56
57
58 19 negative association between the recommendation of voluntary HPV vaccination and PCPs who had
59
60

1
2
3
4 1 a higher proportion of paediatric patients (AOR 0.52, 95% CI, 0.34–0.78, $p = 0.002$) and those who
5
6
7 2 had experience raising children (AOR 0.67, 95% CI 0.45–1.00, $p = 0.049$) (Supplementary Table 2-
8
9
10 3 2).

11
12
13 4
14
15
16 5 The correlation coefficient between vaccine administration and recommendation for routine and
17
18
19 6 voluntary HPV vaccination was 0.17 and 0.23, respectively.
20
21
22
23 7

24 25 26 8 Sensitivity analysis

27
28
29 9 PCPs with correct responses to the HPV vaccination quiz were significantly more likely to
30
31
32 10 administer HPVv than those with incorrect responses regarding routine vaccination (AOR 2.06, 95%
33
34
35 11 CI 1.38–3.09, $p < 0.001$) and voluntary vaccination (AOR 2.16, 95% CI 1.39–3.34, $p = 0.001$).
36
37

38 12 PCPs with correct responses to the HPV vaccination quiz were also significantly more likely to
39
40
41 13 recommend HPV vaccination than those with incorrect responses regarding routine (AOR 1.51, 95%
42
43
44 14 CI 1.12–2.04, $p = 0.006$) and voluntary vaccination (AOR 1.53, 95% CI 1.07–2.19, $p = 0.02$).
45
46
47 15

48 49 50 16 **DISCUSSION**

51
52
53 17 Vaccine hesitancy is a global health concern(13), and hesitancy for HPV vaccination has been
54
55
56 18 reported in many countries, including Japan.(4-6) This is the first study to focus on the association
57
58
59 19 between PCPs' knowledge of vaccination and their practice or attitude towards HPVv in the absence
60

1
2
3
4 1 of proactive recommendations from the government of Japan. We found positive associations
5
6
7 2 between accurate vaccination knowledge among PCPs and the administration or recommendation of
8
9
10 3 HPVv under routine and voluntary vaccination. In addition, the sensitivity analysis showed that
11
12
13 4 physicians with accurate knowledge of HPV vaccination were likely to recommend HPVv.
14
15
16 5 A 2021 systematic review of 96 papers from 34 countries examined the perceptions, knowledge, and
17
18
19 6 recommendations of healthcare providers regarding vaccines. It showed that the healthcare
20
21
22 7 providers' recommendations were positively associated with their knowledge and experience, beliefs
23
24
25 8 about disease risk, and perceptions of vaccine safety, necessity, and efficacy.(29) The present results
26
27
28 9 are consistent with these findings.(29) In Lebanon, where HPVv is not included in the national
29
30
31 10 routine vaccination schedule as of 2017, physicians practicing in obstetrics and gynaecology,
32
33
34 11 paediatrics, family medicine, and infectious diseases with greater knowledge regarding HPV and
35
36
37 12 HPVv recommend HPVv more often than physicians with less knowledge (AOR 3.4).(30) Further, in
38
39
40 13 the United States, higher rates of completion of three HPVv doses (IRR 1.28) were observed among
41
42
43 14 the patients of primary care clinicians, including family medicine physicians, paediatricians, and
44
45
46 15 family and paediatric nurse-practitioners, with greater knowledge regarding HPV and HPVv (31).
47
48
49 16 Our results also support these findings. Another study investigating the association between PCPs'
50
51
52 17 knowledge of vaccination and the administration or recommendation of voluntary mumps
53
54
55 18 vaccination for adults showed the same positive associations.(32)
56
57
58
59
60

1
2
3
4 1 Compared to that in our previous study from 2012,(23) the proportion of PCPs recommending or
5
6
7 2 administering HPVv was lower in the present study: the proportion of HPVv administration
8
9
10 3 decreased from 58.3% for voluntary vaccination alone(23) to 23.3% for routine vaccination and
11
12
13 4 17.8% for voluntary vaccination (Table 2). The proportion of PCPs recommending HPVv decreased
14
15
16 5 from 46.5% for voluntary vaccination alone(23) to 41.6% for routine vaccination and 22.0% for
17
18
19 6 voluntary vaccination (Table 2).

20
21
22 7 A study conducted among paediatricians in Osaka, Japan, in 2020 and 2021 revealed that the
23
24
25 8 proportion of paediatricians who administered or actively recommended the HPVv for routine
26
27
28 9 vaccination was 44.5% and 32.5% in 2020 and 67.9% and 40% in 2021, respectively.(33) In
29
30
31 10 addition, a study conducted among OBGYNs in Osaka, Japan, showed that the proportion of
32
33
34 11 OBGYNs recommending the HPVv for teenagers was 70.1% in 2017(3) and 84.6% in 2019.(34) As
35
36
37 12 of 2018, the proportion of family physicians and paediatricians in the United States administering the
38
39
40 13 HPVv was 84.1% and 95.3%, respectively,(35) and the proportion of those who strongly
41
42
43 14 recommended the HPVv was 72–90% and 85–99% (11- to 12-year-old, 13- to 14-year-old, and ≥15-
44
45
46 15 year-old female patients), respectively.(35) Our study revealed that in Japan, PCPs may administer
47
48
49 16 routine HPVv less than paediatricians(33) and actively recommend routine HPVv more than
50
51
52 17 paediatricians(33) but less than OBGYNs.(3) In addition, our study shows that Japanese PCPs may
53
54
55 18 administer or recommend the HPVv less than family physicians in the United States.(35)
56
57
58
59
60

1
2
3
4 1 We also found positive associations between different information resources and administration or
5
6
7 2 recommendation of voluntary HPV vaccination. Information resources from social network services
8
9
10 3 or mailing lists from medical service providers seem to be positively associated with the
11
12
13 4 administration or recommendation of voluntary HPV vaccination. This might be because PCPs use
14
15
16 5 virtual communities as valuable knowledge portals for clinically relevant information(36) and could
17
18
19 6 be interested in how and why other physicians recommend and administer vaccination.(22, 32)
20
21
22 7 Government information resources were positively associated with the administration of voluntary
23
24
25 8 HPVv but were negatively associated with the recommendation of routine HPVv. As of 2019, the
26
27
28 9 MHLW had not resumed the proactive recommendation of routine HPV vaccination. Although the
29
30
31 10 suspension of proactive recommendation was not intended to discontinue routine vaccination, it may
32
33
34 11 have been misinterpreted as discontinuation of routine vaccination by some PCPs. Therefore, PCPs
35
36
37 12 referring to government sources for information regarding this policy may administer HPVv as part
38
39
40 13 of voluntary instead of routine vaccination and may not recommend routine HPV vaccination.
41
42
43 14 Alternatively, PCPs aware of the suspension may lose confidence to recommend the HPVv. A
44
45
46 15 previous study reported that the lack of government recommendations was a barrier for PCPs to
47
48
49 16 recommend vaccination.(23) In November 2021, the MHLW ended this suspension and resumed
50
51
52 17 proactively recommending HPV vaccination for girls born in or after the fiscal year (FY) 2006,
53
54
55 18 beginning in April 2022(37), and provided 'catch-up vaccinations' for 3 years, from April 2022 to
56
57
58 19 March 2025, for females born from FY1997 to FY2005, who became eligible for routine HPV
59
60

1
2
3
4 1 vaccination and may have missed the opportunity to receive the vaccination because of the
5
6
7 2 suspension.(38, 39) The results of our study suggest that providing accurate knowledge and
8
9
10 3 information about HPV vaccination to PCPs may help promote HPVv administration and
11
12
13 4 recommendation by PCPs and thereby increase the vaccination rate. The JPCA vaccine team
14
15
16 5 provides information about vaccination through websites(40) and regular onsite and online vaccine
17
18
19 6 seminars for physicians.(41) Further research can help determine the optimal methods to provide
20
21
22 7 accurate knowledge regarding vaccination to health care providers with vaccine hesitancy.(42)
23
24

25 8 Our study also shows that PCPs working at clinics, providing daily paediatric medical services
26
27
28 9 (more than 10% of total patients), and with experience as kindergarten or school physicians tend to
29
30
31 10 administer routine HPV vaccination (Supplementary Table 1). The target population for routine HPV
32
33
34 11 vaccination is 12- to 16-year-old girls, and PCPs experienced in treating this group may better
35
36
37 12 understand the need for routine vaccination; therefore, they may be more likely to administer the
38
39
40 13 vaccine. In contrast, PCPs working at clinics or other hospitals providing daily paediatric medical
41
42
43 14 services (more than 10% of total patients) were less likely to recommend routine HPV vaccination
44
45
46 15 (Supplementary Table 2). In addition, PCPs providing daily paediatric medical services (more than
47
48
49 16 10% of total patients) and with experience in raising children tended to be less likely to recommend
50
51
52 17 voluntary HPV vaccination (Supplementary Table 2). These results suggest that PCPs with more
53
54
55 18 opportunity to provide medical service to 12- to 16-year-old girls may have less confidence to
56
57
58
59
60

1
2
3
4 1 recommend the HPVv during the suspension of proactive recommendation by the MHLW or may be
5
6
7 2 more affected by the anxiousness or hesitancy of the parents.(19, 23, 43)
8
9

10 3 This study has some limitations. First, there was a potential selection bias due to the low response
11
12
13 4 rate. PCPs who more actively promoted vaccination may have been more likely to respond, and the
14
15
16 5 actual proportion of PCPs administering or recommending HPVv may be lower. Second, our study
17
18
19 6 did not consider voluntary HPV vaccination for men. In Japan, as of 2019, the target group for both
20
21
22 7 routine and voluntary HPV vaccination included only women. However, in 2020, administration of
23
24
25 8 voluntary quadrivalent HPVv was approved for men. Third, our study did not evaluate 9-valent
26
27
28 9 HPVv for voluntary vaccination, although in 2021, the 9-valent HPVv was approved for voluntary
29
30
31 10 vaccination(44) and will be approved for routine vaccination from April 2023 onwards.(45) Future
32
33
34 11 studies should include both men and women and consider the 9-valent HPVv. Fourth, we did not
35
36
37 12 evaluate the effects of vaccine hesitancy among parents or mainstream media and social media on
38
39
40 13 the PCPs.(43) The effect of vaccine hesitancy should be considered as one of the exposures in future
41
42
43 14 studies. Fifth, we did not evaluate the effects of unknown confounding factors, which is a general
44
45
46 15 limitation of observational studies. Finally, although the study participants were physician members
47
48
49 16 of the JPCA, the largest society for PCPs in Japan, the generalisability of the results to PCPs outside
50
51
52 17 of Japan is unclear. The policy for HPVv administration in Japan(38) changed after this study was
53
54
55 18 conducted, and further surveys are needed to assess the current situation of HPVv administration and
56
57
58 19 attitudes among PCPs.
59
60

1
2
3
4 1 Our results suggest that providing accurate knowledge regarding vaccination to PCPs may improve
5
6
7 2 their administration and recommendation of the HPV_v, even in the absence of active government
8
9
10 3 recommendations.

11
12
13 4

16 5 **CONCLUSIONS**

17
18
19 6 We revealed a positive association between PCPs' knowledge of vaccines and the administration or
20
21
22 7 recommendation of routine and voluntary HPV vaccination without a proactive recommendation
23
24
25 8 from the government. Several factors influence PCPs' perception of HPV vaccinations, ultimately
26
27
28 9 affecting public healthcare. The results of our study can be applied to other countries with similar
29
30
31 10 vaccination-related concerns, such as vaccine hesitancy and disagreements on vaccine policy
32
33
34 11 between the scientific community and governments.(9, 46)

35
36
37 12 Our results suggest that providing more knowledge about vaccination to PCPs may increase their
38
39
40 13 likelihood to administer or recommend the HPV_v, thereby improving vaccination rates.

41
42
43 14

46 15 **Data availability statement**

47
48
49 16 Data are available upon reasonable request.

50
51
52 17

55 18 **Ethics statements**

56
57
58 19 Patient consent for publication

1
2
3
4 1 We obtained written informed consent from all participants before conducting the survey.
5
6

7 2 Ethics approval
8
9

10 3 The study protocol was approved by the Institutional Review Board of Osaka Medical College (Rin-
11
12
13 4 763).
14
15

16 5
17
18

19 6 **Acknowledgments**

20
21
22 7 We thank Tesshu Kusaba, President of the Japan Primary Care Association, and head office staff for
23
24
25 8 helping us disseminate the questionnaire. We also thank all physicians who participated in this
26
27
28 9 survey. We thank Editage (www.editage.com) for English language editing.
29
30

31 10
32
33

34 11 **Contributors:** All authors declare they have contributed to this article. YS designed and
35
36
37 12 implemented the questionnaire survey, contributed to data analysis and interpretation, drafted the
38
39
40 13 manuscript, and critically revised it. JT designed and implemented the questionnaire survey,
41
42
43 14 contributed to data interpretation, and critically revised the manuscript. RS, KN, YN, HC, TK, and
44
45
46 15 AM designed and implemented the questionnaire survey, contributed to data interpretation, and
47
48
49 16 critically revised the manuscript. MM contributed to data interpretation and critically revised the
50
51
52 17 manuscript. TO and TS disseminated the questionnaire and critically revised the manuscript. All
53
54
55 18 authors have read and approved this manuscript version for submission.
56
57

58 19
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 **Funding:** This work was supported by JSPS KAKENHI (Grant Numbers JP19K19445).

2

3 **Competing interests:** None declared.

4

5 **Provenance and peer review:** Not commissioned; externally peer reviewed.

6

For peer review only

1
2
3
4 **TABLES**
5

6 **TABLE 1** Characteristics of the participants
7

	Participants, n=981
	n (%)
Sex: male	739 (75.3), Missing 0
Postgraduate year (y)	Missing 0
3–5	92 (9.4)
6–10	178 (18.1)
11–20	358 (36.5)
21–30	193 (19.7)
31–40	134 (13.7)
≥41	26 (2.7)
Main practice category: primary care	697 (71.1), Missing 0
Practice setting	Missing 3 (0.3)
University hospital or general hospital	281 (28.6)
Other hospital	254 (25.9)
Clinic	420 (42.8)
Others (e.g., University, research institution, government, and health organisation)	23 (2.3)
Providing daily paediatric medical service (≥ 10% of total patients)	283 (28.9), Missing 0
Mainly working in an urban area (≥50,000 people as an administrative unit of the local government)	719 (73.3), Missing 2 (0.2)
Experience as kindergarten or school physician	474 (48.3), Missing 0
Experience raising children	721 (73.5), Missing 0
Main practice category: primary care: Answered main practice category as family physician or general practitioner or hospitalist/general physician	

1
2
3 1
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 2
29
30
31 3
32
33
34 4
35
36
37 5
38
39
40
41
42
43
44
45
46

TABLE 2 Vaccination quiz scores and HPV vaccine administration or recommendation levels among primary care physicians

Vaccination quiz	Total, n (%)	Administration of HPV vaccine	Recommendation level for HPV vaccine, n (%)				
			Actively recommend	Recommend occasionally	No opinion	Do not actively recommend	Do not recommend
Routine HPV vaccination, n=981							
Voluntary HPV vaccination, n=981							
High scores (4–6 points)	511 (52.1)	172 (33.7)	248 (48.5)	179 (35.0)	59 (11.6)	19 (3.7)	6 (1.2)
Low scores (0–3 points)	470 (47.9)	132 (25.8)	131 (25.6)	211 (41.3)	120 (23.5)	31 (6.1)	18 (3.5)
		57 (12.1)	160 (34.0)	140 (29.8)	122 (26.0)	30 (6.4)	18 (3.8)
		43 (9.2)	85 (18.1)	147 (31.3)	168 (35.7)	44 (9.4)	26 (5.5)
Total	981 (100)	229 (23.3)	408 (41.6)	319 (32.5)	181 (18.5)	49 (5.0)	24 (2.5)
		175 (17.8)	216 (22.0)	358 (36.5)	288 (29.4)	75 (7.7)	44 (4.5)

HPV, human papillomavirus

1
2
3
4 1
5
6
7 **2 Figure Legends**
8
9

10 **3 Figure 1.** Study flowchart
11
12

13 **4 REFERENCES**
14
15

- 16 5 • 1. World Health Organization. Electronic address swi. Human papillomavirus vaccines: WHO
17
18
19 6 position paper, May 2017-Recommendations. *Vaccine*. 2017;35(43):5753-5.
20
21
22 7 • 2. Hanley SJ, Yoshioka E, Ito Y, Konno R, Hayashi Y, Kishi R, et al. Acceptance of and
23
24
25 8 attitudes towards human papillomavirus vaccination in Japanese mothers of adolescent girls.
26
27
28 9 *Vaccine*. 2012;30(39):5740-7.
29
30
31 10 • 3. Sawada M, Ueda Y, Yagi A, Morimoto A, Nakae R, Kakubari R, et al. HPV vaccination in
32
33
34 11 Japan: results of a 3-year follow-up survey of obstetricians and gynecologists regarding their
35
36
37 12 opinions toward the vaccine. *Int J Clin Oncol*. 2018;23(1):121-5.
38
39
40 13 • 4. Ueda Y, Enomoto T, Sekine M, Egawa-Takata T, Morimoto A, Kimura T. Japan's failure to
41
42
43 14 vaccinate girls against human papillomavirus. *Am J Obstet Gynecol*. 2015;212(3):405-6.
44
45
46 15 • 5. Hanley SJ, Yoshioka E, Ito Y, Kishi R. HPV vaccination crisis in Japan. *Lancet*.
47
48
49 16 2015;385(9987):2571.
50
51
52 17 • 6. Sekine M, Kudo R, Adachi S, Yamaguchi M, Ueda Y, Takata T, et al. Japanese Crisis of
53
54
55 18 HPV Vaccination. *International Journal of Pathology and Clinical Research*. 2016;2(2):1-3.
56
57
58 19 • 7. Yagi A, Ueda Y, Egawa-Takata T, Tanaka Y, Nakae R, Morimoto A, et al. Realistic fear of
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 cervical cancer risk in Japan depending on birth year. *Hum Vaccin Immunother.* 2017;13(7):1700-4.
- 2 • 8. Shono A, Kondo M. Factors that affect voluntary vaccination of children in Japan. *Vaccine.*
- 3 2015;33(11):1406-11.
- 4 • 9. Inokuma Y, Kneller R. Imprecision in adverse event reports following immunization against
- 5 HPV in Japan and COVID-19 in the USA, UK, and Japan-and the effects of vaccine hesitancy and
- 6 government policy. *Eur J Clin Pharmacol.* 2023;79(2):269-78.
- 7 • 10. Ministry of Health, Labour and Welfare of Japan. Correspondence about the routine
- 8 vaccination of human papilloma virus infection (recommendation). 2013. (in Japanese) Available:
- 9 https://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou28/pdf/kankoku_h25_6_01.pdf.
- 10 [Accessed 25 Mar 2023]
- 11 • 11. World Health Organization. Meeting of the Global Advisory Committee on Vaccine Safety,
- 12 7–8 June 2017. *Wkly Epidemiol Rec.* 2017;92(28):393-402.
- 13 • 12. Suzuki S, Hosono A. No association between HPV vaccine and reported post-vaccination
- 14 symptoms in Japanese young women: Results of the Nagoya study. *Papillomavirus Res.*
- 15 2018;5(17):96-103.
- 16 • 13. World Health Organization . WHO Ten Threats to Global Health in 2019. 2019. Available:
- 17 <https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019>. [Accessed 25 Mar
- 18 2023]
- 19 • 14. Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed,

- 1
2
3
4 1 systematic review. *Preventive medicine*. 2007;45(2-3):107-14.
5
6
7 2 • 15. Oster NV, McPhillips-Tangum CA, Averhoff F, Howell K. Barriers to adolescent
8
9
10 3 immunization: a survey of family physicians and pediatricians. *The Journal of the American Board*
11
12
13 4 *of Family Practice / American Board of Family Practice*. 2005;18(1):13-9.
14
15
16 5 • 16. Taylor JA, Darden PM, Slora E, Hasemeier CM, Asmussen L, Wasserman R. The influence
17
18
19 6 of provider behavior, parental characteristics, and a public policy initiative on the immunization
20
21
22 7 status of children followed by private pediatricians: a study from Pediatric Research in Office
23
24
25 8 Settings. *Pediatrics*. 1997;99(2):209-15.
26
27
28 9 • 17. Tsuchiya Y, Shida N, Izumi S, Ogasawara M, Kakinuma W, Tsujiuchi T, et al. Factors
29
30
31 10 associated with mothers not vaccinating their children against mumps in Japan. *Public Health*.
32
33
34 11 2016;137:95-105.
35
36
37 12 • 18. Gilkey MB, Calo WA, Moss JL, Shah PD, Marciniak MW, Brewer NT. Provider
38
39
40 13 communication and HPV vaccination: The impact of recommendation quality. *Vaccine*.
41
42
43 14 2016;34(9):1187-92.
44
45
46 15 • 19. Gilkey MB, McRee AL. Provider communication about HPV vaccination: A systematic
47
48
49 16 review. *Hum Vaccin Immunother*. 2016;12(6):1454-68.
50
51
52 17 • 20. Collange F, Fressard L, Pulcini C, Sebbah R, Peretti-Watel P, Verger P. General
53
54
55 18 practitioners' attitudes and behaviors toward HPV vaccination: A French national survey. *Vaccine*.
56
57
58 19 2016;34(6):762-8.
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 21. Wong MCS, Lee A, Ngai KKK, Chor JCY, Chan PKS. Knowledge, Attitude, Practice and Barriers on Vaccination against Human Papillomavirus Infection: A Cross-Sectional Study among Primary Care Physicians in Hong Kong. PLoS ONE. 2013;8(8):e71827.
- 22. Paterson P, Meurice F, Stanberry LR, Glismann S, Rosenthal SL, Larson HJ. Vaccine hesitancy and healthcare providers. Vaccine. 2016;34(52):6700-6.
- 23. Sakanishi Y, Hara M, Fukumori N, Kusaba T, Tanaka K, Sugioka T, et al. Primary care physician practices, recommendations, and barriers to the provision of routine and voluntary vaccinations in Japan. An Official Journal of the Japan Primary Care Association. 2014;37(3):254-9.
- 24. Sakanishi Y, Yamamoto Y, Hara M, Fukumori N, Goto Y, Kusaba T, et al. Public subsidies and the recommendation of child vaccines among primary care physicians: a nationwide cross-sectional study in Japan. BMJ Open. 2018;8(7):e020923.
- 25. Jones J, Hunter D. Consensus methods for medical and health services research. Bmj. 1995;311(7001):376-80.
- 26. Watkins C, Moore L, Harvey I, Carthy P, Robinson E, Brawn R. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional study. BMJ. 2003;326(7400):1178-9.
- 27. Klee D, Covey C, Zhong L. Social media beliefs and usage among family medicine residents and practicing family physicians. Fam Med. 2015;47(3):222-6.
- 28. Heinze G, Schemper M. A solution to the problem of separation in logistic regression. Stat

1
2
3
4 1 Med. 2002;21(16):2409-19.

5
6
7 2 • 29. Lin C, Mullen J, Smith D, Kotarba M, Kaplan SJ, Tu P. Healthcare Providers' Vaccine

8
9
10 3 Perceptions, Hesitancy, and Recommendation to Patients: A Systematic Review. *Vaccines (Basel)*.

11
12
13 4 2021;9(7).

14
15
16 5 • 30. Abi Jaoude J, Khair D, Dagher H, Saad H, Cherfan P, Kaafarani MA, et al. Factors

17
18
19 6 associated with Human Papilloma Virus (HPV) vaccine recommendation by physicians in Lebanon,

20
21
22 7 a cross-sectional study. *Vaccine*. 2018;36(49):7562-7.

23
24
25 8 • 31. Rutten LJ, St Sauver JL, Beebe TJ, Wilson PM, Jacobson DJ, Fan C, et al. Clinician

26
27
28 9 knowledge, clinician barriers, and perceived parental barriers regarding human papillomavirus

29
30
31 10 vaccination: Association with initiation and completion rates. *Vaccine*. 2017;35(1):164-9.

32
33
34 11 • 32. Takeuchi J, Sakanishi Y, Okada T, Nakayama K, Chiba H, Suganaga R, et al. Factors

35
36
37 12 associated between behavior of administering or recommending mumps vaccine and primary care

38
39
40 13 physicians' knowledge about vaccination: A nationwide cross-sectional study in Japan. *J Gen Fam*

41
42
43 14 *Med*. 2022;23(1):9-18.

44
45
46 15 • 33. Kubota M, Kondo K, Tomiyoshi Y, Fukushima W. Survey of pediatricians concerning the

47
48
49 16 human papillomavirus vaccine in Japan: Positive attitudes toward vaccination during the period of

50
51
52 17 proactive recommendation being withheld. *Hum Vaccin Immunother*. 2022;18(6):2131337.

53
54
55 18 • 34. Nagase YA-O, Ueda Y, Abe H, Yagi A, Sawada M, Nakagawa S, et al. Changing attitudes

56
57
58 19 in Japan toward HPV vaccination: a 5-year follow-up survey of obstetricians and gynecologists

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1 regarding their current opinions about the HPV vaccine. 2020(2164-554X (Electronic)).
- 2 • 35. Kempe A, O'Leary ST, Markowitz LE, Crane LA, Hurley LP, Brtnikova M, et al. HPV
3 Vaccine Delivery Practices by Primary Care Physicians. *Pediatrics*. 2019;144(4).
- 4 • 36. Rolls K, Hansen M, Jackson D, Elliott D. How Health Care Professionals Use Social Media
5 to Create Virtual Communities: An Integrative Review. *J Med Internet Res*. 2016;18(6):e166.
- 6 • 37. Ministry of Health, Labour and Welfare of Japan. Notices and Administrative
7 Communication Regarding HPV Vaccine. 2021. (in Japanese) Available:
8 <https://www.mhlw.go.jp/content/000875155.pdf> [Accessed 25 Mar 2023]
- 9 • 38. Yagi A, Ueda Y, Nakagawa S, Ikeda S, Kakuda M, Hiramatsu K, et al. Can Catch-Up
10 Vaccinations Fill the Void Left by Suspension of the Governmental Recommendation of HPV
11 Vaccine in Japan? *Vaccines (Basel)*. 2022;10(9).
- 12 • 39. Ministry of Health, Labour and Welfare of Japan. Notices and Administrative
13 Communication Regarding HPV Vaccine. 2022. (in Japanese) Available:
14 <https://www.mhlw.go.jp/content/000915791.pdf> [Accessed 25 Mar 2023]
- 15 • 40. Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association .
16 Vaccination Website “Vaccination for all” (in Japanese) Available: <https://www.vaccine4all.jp>.
17 [Accessed 25 Mar 2023]
- 18 • 41. Committee for Infectious Diseases, Vaccine Team, Japan Primary Care Association. The 5th
19 vaccine seminar “Tiger’s Den” 2022 was held! (in Japanese). 2023. (in Japanese) Available:

1
2
3
4 1 <https://www.vaccine4all.jp/topics-detail.php?tid=63>. [Accesed 25 Mar 2023]
5
6


7 2 • 42. Lip A, Pateman M, Fullerton MM, Chen HM, Bailey L, Houle S, et al. Vaccine hesitancy
8
9
10 3 educational tools for healthcare providers and trainees: A scoping review. *Vaccine*. 2023;41(1):23-
11
12
13 4 35.

14
15
16 5 • 43. Tsui J, Vincent A, Anuforo B, Btoush R, Crabtree BF. Understanding primary care
17
18
19 6 physician perspectives on recommending HPV vaccination and addressing vaccine hesitancy. *Hum*
20
21
22 7 *Vaccin Immunother*. 2021;17(7):1961-7.

23
24
25 8 • 44. Ministry of Health, Labour and Welfare of Japan . Q & A regarding HPV vaccine. 2022. (in
26
27
28 9 Japanese) Available: https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou/hpv_qa.html#Q2-2.
29
30
31 10 [Accesed 25 Mar 2023]
32
33

34 11 • 45. Ministry of Health, Labour and Welfare of Japan. Information provisions and
35
36
37 12 Administrative Communication Regarding HPV Vaccine. 2022. (in Japanese) Available:
38
39
40 13 <https://www.mhlw.go.jp/content/001021317.pdf> [Accesed 25 Mar 2023]
41
42

43 14 • 46. Okubo R, Yoshioka T, Ohfuji S, Matsuo T, Tabuchi T. COVID-19 Vaccine Hesitancy and
44
45
46 15 Its Associated Factors in Japan. *Vaccines (Basel)*. 2021;9(6).
47
48
49 16
50
51
52
53
54
55
56
57
58
59
60



Supplementary Table 1-1 Factors associated with administration of HPV vaccine for routine vaccination

Factors	PCPs who administer HPV vaccine, n=229 (23.3%) n (%)	PCPs who do not administer HPV vaccine, n=752 (76.7%) n (%)	Crude odds ratio (95% CI), n=981	p-value	Adjusted odds ratio* (95% CI), n=977	p-value
High scores on vaccination quiz (4–6 points)	172 (75.1)	339 (45.1)	3.68 (2.64–5.12)	<0.001	2.28 (1.58–3.28)	<0.001
Sex: male	178 (77.7)	561 (74.6)	1.19 (0.84–1.69)	0.38	1.11 (0.75–1.65)	0.6
Postgraduate year (y)						
3-5	14 (6.1)	78 (10.4)	Reference		Reference	
6-10	28 (12.2)	150 (20.0)	1.04 (0.52–2.09)	0.91	0.48 (0.20–1.18)	0.11
11-20	95 (41.5)	263 (35.0)	2.01 (1.09–3.72)	0.026	0.83 (0.34–2.02)	0.68
21–30	51 (22.3)	142 (18.9)	2.00 (1.04–3.84)	0.037	0.91 (0.37–2.27)	0.85
31–40	34 (14.9)	100 (13.3)	1.89 (0.95–3.77)	0.069	0.80 (0.32–1.99)	0.63
≥41	7 (3.1)	19 (2.5)	2.05 (0.73–5.79)	0.17	0.79 (0.23–2.67)	0.7
Position of any specialist qualification	201 (87.8)	643 (85.6)	1.21 (0.77–1.88)	0.41	1.04 (0.57–1.89)	0.89
Main practice category: primary care	183 (79.9)	514 (68.4)	1.84 (1.29–2.63)	0.001	1.18 (0.74–1.88)	0.5
Practice setting						
University hospital or general hospital	28 (12.2)	253 (33.8)	Reference		Reference	
Other hospital	35 (15.3)	219 (29.2)	1.44 (0.85–2.45)	0.17	1.18 (0.68–2.06)	0.55
Clinic	164 (71.6)	256 (34.2)	5.79 (3.74–8.96)	<0.001	2.64 (1.60–4.36)	<0.001
Others (i.e., University, research institution, government, and health organisation)	2 (0.87)	21 (2.8)	0.86 (0.19–3.86)	0.85	0.90 (0.22–3.73)	0.88
Providing daily paediatric medical service (≥ 10% of total patients)	113 (49.3)	170 (22.6)	3.33 (2.45–4.55)	<0.001	1.78 (1.24–2.55)	0.002
Mainly working in an urban area (≥ 50,000 people as an administrative unit of the local government)	164 (71.6)	555 (74.0)	0.89 (0.64–1.23)	0.48	1.07 (0.73–1.55)	0.74
Experience as kindergarten or school physician	165 (72.1)	309 (41.1)	3.70 (2.68–5.11)	<0.001	2.12 (1.45–3.10)	<0.001
Experience raising children	176 (76.9)	545 (72.5)	1.26 (0.89–1.78)	0.19	0.86 (0.56–1.32)	0.48
Information resource						
Government	189 (82.5)	558 (74.2)	1.64 (1.13–2.40)	0.01	1.25 (0.82–1.90)	0.29
Academia	226 (98.7)	687 (91.4)	7.13 (2.22–22.90)	0.001	1.76 (0.55–5.64)	0.34
Commerce	71 (31.0)	212 (28.2)	1.14 (0.83–1.58)	0.41	0.85 (0.58–1.23)	0.38
Social network service or mailing list by individuals or group of medical service providers	94 (41.1)	205 (27.3)	1.86 (1.36–2.53)	<0.001	1.26 (0.88–1.80)	0.21
None	0	19 (2.5)	0.08 (0.05–1.36)*	0.081	0.35 (0.02–8.24)	0.52

*Penalized maximum likelihood logistic regression. PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

Supplementary Table 1-2 Factors associated with administration of HPV vaccine for voluntary vaccination

Factors	PCPs who administer HPV vaccine, n=175 (17.8%) n (%)	PCPs who do not administer HPV vaccine, n=806 (82.2%) n (%)	Crude odds ratio (95% CI), n=981	p-value	Adjusted odds ratio* (95% CI), n=977	p-value
High scores on vaccination quiz (4–6 points)	132 (75.4)	379 (47.0)	3.46 (2.39–5.01)	<0.001	2.71 (1.81–4.04)	<0.001
Sex: male	131 (74.8)	608 (75.4)	0.97 (0.66–1.41)	0.87	0.89 (0.59–1.35)	0.58
Postgraduate year (y)						
3-5	12 (6.9)	80 (9.9)	Reference		Reference	
6-10	21 (12.0)	157 (19.5)	0.89 (0.42–1.90)	0.77	0.48 (0.19–1.23)	0.13
11-20	66 (37.7)	292 (36.2)	1.51 (0.78–2.92)	0.23	0.69 (0.27–1.75)	0.43
21–30	41 (23.4)	152 (18.9)	1.80 (0.89–3.61)	0.099	0.97 (0.38–2.50)	0.96
31–40	28 (16.0)	106 (13.2)	1.76 (0.84–3.67)	0.13	0.98 (0.38–2.53)	0.97
≥41	7 (4.0)	19 (2.4)	2.46 (0.85–7.07)	0.096	1.35 (0.40–4.57)	0.63
Position of any specialist qualification	154 (88.0)	690 (85.7)	1.22 (0.74–2.01)	0.43	1.12 (0.59–2.12)	0.73
Main practice category: primary care	141 (80.6)	556 (69.0)	1.86 (1.25–2.79)	0.002	1.52 (0.93–2.49)	0.098
Practice setting						
University hospital or general hospital	36 (20.6)	245 (30.5)	Reference		Reference	
Other hospital	29 (16.6)	225 (28.0)	0.89 (0.52–1.48)	0.62	0.68 (0.39–1.19)	0.18
Clinic	109 (62.3)	311 (38.7)	2.39 (1.58–3.60)	<0.001	1.27 (0.77–2.08)	0.35
Others (i.e., University, research institution, government, and health organisation)	1 (0.57)	22 (2.7)	0.31 (0.04–2.37)	0.26	0.37 (0.06–2.10)	0.26
Providing daily paediatric medical service (≥ 10% of total patients)	66 (37.7)	217 (26.9)	1.64 (1.17–2.32)	0.005	1.04 (0.70–1.55)	0.84
Mainly working in an urban area (≥ 50,000 people as an administrative unit of the local government)	135 (77.1)	584 (72.6)	1.27 (0.86–1.87)	0.22	1.26 (0.83–1.91)	0.27
Experience as kindergarten or school physician	106 (60.6)	368 (45.7)	1.83 (1.31–2.55)	<0.001	1.23 (0.82–1.84)	0.31
Experience raising children	129 (73.7)	592 (73.5)	1.01 (0.70–1.47)	0.07	0.70 (0.45–1.08)	0.11
Information resource						
Government	152 (86.9)	595 (73.8)	2.34 (1.47–3.73)	<0.001	1.90 (1.17–3.08)	0.009
Academia	170 (97.1)	743 (92.2)	2.88 (1.14–7.28)	0.025	0.93 (0.35–2.43)	0.88
Commerce	55 (31.4)	228 (28.3)	1.16 (0.82–1.66)	0.41	0.84 (0.57–1.25)	0.39
Social network service or mailing list by individuals or group of medical service providers	80 (45.7)	219 (27.2)	2.26 (1.61–3.16)	<0.001	1.82 (1.25–2.64)	0.002
None	0	19 (2.4)	0.12 (0.01–1.91)*	0.13	0.39 (0.02–8.00)	0.54

*Penalized maximum likelihood logistic regression. PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

Supplementary Table 2-1 Factors associated with recommendation of HPV vaccine for routine vaccination

Factors	PCPs who recommend HPV vaccine, n=408 (41.6%) n (%)	PCPs who do not recommend HPV vaccine, n=573 (58.4%) n (%)	Crude odds ratio (95% CI), n=981	p-value	Adjusted odds ratio (95% CI), n=977	p-value
High scores on vaccination quiz (4–6 points)	248 (60.8)	263 (45.9)	1.83 (1.41–2.36)	<0.001	2.17 (1.62–2.92)	<0.001
Sex: male	319 (78.2)	420 (73.3)	1.31 (0.97–1.76)	0.08	1.37 (0.99–1.90)	0.056
Postgraduate year (y)						
3–5	44 (10.8)	48 (8.4)	Reference		Reference	
6–10	69 (16.9)	109 (19.0)	0.69 (0.42–1.15)	0.15	0.89 (0.47–1.68)	0.72
11–20	153 (37.5)	205 (35.8)	0.81 (0.51–1.29)	0.38	1.03 (0.53–1.99)	0.94
21–30	90 (22.1)	103 (18.0)	0.95 (0.58–1.57)	0.85	1.28 (0.64–2.53)	0.48
31–40	45 (11.0)	89 (15.5)	0.55 (0.32–0.95)	0.032	0.73 (0.36–1.48)	0.38
≥41	7 (1.7)	19 (3.3)	0.40 (0.15–1.05)	0.062	0.56 (0.19–1.62)	0.28
Position of any specialist qualification	347 (85.1)	497 (86.9)	0.86 (0.60–1.24)	0.41	0.79 (0.49–1.29)	0.35
Main practice category: primary care	281 (68.9)	416 (72.6)	0.84 (0.63–1.10)	0.21	0.79 (0.55–1.11)	0.18
Practice setting						
University hospital or general hospital	143 (33.8)	143 (25.1)	Reference		Reference	
Other hospital	101 (24.8)	219 (29.2)	0.68 (0.49–0.96)	0.03	0.69 (0.48–1.00)	0.048
Clinic	161 (39.5)	259 (45.4)	0.64 (0.47–0.87)	0.005	0.67 (0.46–0.98)	0.041
Others (e.g., University, research institution, government, and health organisation)	8 (2.0)	15 (2.6)	0.55 (0.23–1.34)	0.19	0.51 (0.20–1.31)	0.16
Providing daily paediatric medical service (≥10% of total patients)	95 (23.3)	188 (32.8)	0.62 (0.47–0.83)	0.001	0.50 (0.36–0.70)	<0.001
Mainly working in an urban area (≥50,000 people as an administrative unit of the local government)	305 (74.9)	414 (72.4)	1.14 (0.85–1.52)	0.37	1.08 (0.78–1.47)	0.65
Experience as kindergarten or school physician	190 (46.6)	284 (49.6)	0.89 (0.69–1.14)	0.36	1.09 (0.80–1.49)	0.57
Experience raising children	296 (72.6)	425 (74.2)	0.92 (0.69–1.23)	0.57	0.79 (0.56–1.10)	0.16
Information resource						
Government	294 (72.1)	453 (79.1)	0.68 (0.51–0.92)	0.011	0.69 (0.50–0.96)	0.026
Academia	385 (94.4)	528 (92.2)	1.43 (0.85–2.40)	0.18	1.21 (0.63–2.35)	0.56
Commerce	113 (27.7)	170 (29.7)	0.91 (0.69–1.20)	0.5	0.91 (0.67–1.25)	0.56
Social network service or mailing list by individuals or group of medical service providers	136 (33.3)	163 (28.5)	1.26 (0.96–1.65)	0.1	1.33 (0.98–1.82)	0.071
None	7 (1.7)	12 (2.1)	0.82 (0.32–2.09)	0.67	0.82 (0.25–2.68)	0.74

PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

Supplementary Table 2-2 Factors associated with recommendation of HPV vaccine for voluntary vaccination

Factors	PCPs who recommend HPV vaccine, n=216 (22.0%) n (%)	PCPs who do not recommend HPV vaccine, n=765 (78.0%) n (%)	Crude odds ratio (95% CI), n=981	p-value	Adjusted odds ratio (95% CI), n=977	p-value
High scores on vaccination quiz (4–6 points)	131 (60.6)	380 (49.7)	1.56 (1.15–2.12)	0.005	1.88 (1.32–2.67)	<0.001
Sex: male	174 (80.6)	565 (73.9)	1.47 (1.01–2.13)	0.045	1.67 (1.12–2.49)	0.012
Postgraduate year (y)						
3–5	24 (11.1)	68 (8.9)	Reference		Reference	
6–10	30 (13.9)	148 (19.4)	0.57 (0.31–1.06)	0.074	0.81 (0.37–1.75)	0.59
11–20	87 (40.3)	271 (35.4)	0.91 (0.54–1.54)	0.72	1.40 (0.63–3.08)	0.41
21–30	52 (24.1)	141 (18.4)	1.04 (0.59–1.84)	0.88	1.73 (0.77–3.88)	0.19
31–40	21 (9.7)	113 (14.8)	0.53 (0.27–1.02)	0.056	0.84 (0.36–1.98)	0.69
≥41	2 (0.9)	24 (3.1)	0.24 (0.05–1.02)	0.062	0.38 (0.07–1.89)	0.24
Position of any specialist qualification	184 (85.2)	660 (86.4)	0.91 (0.59–1.39)	0.65	0.74 (0.40–1.35)	0.32
Main practice category: primary care	148 (68.5)	549 (71.7)	0.86 (0.62–1.19)	0.35	0.84 (0.55–1.27)	0.4
Practice setting						
University hospital or general hospital	81 (37.5)	200 (26.3)	Reference		Reference	
Other hospital	53 (24.5)	201 (26.4)	0.65 (0.44–0.97)	0.03	0.69 (0.45–1.06)	0.091
Clinic	77 (35.7)	343 (45.0)	0.55 (0.39–0.79)	0.001	0.67 (0.43–1.04)	0.075
Others (e.g., University, research institution, government, and health organisation)	5 (2.3)	18 (2.4)	0.69 (0.25–1.91)	0.47	0.63 (0.21–1.84)	0.4
Providing daily paediatric medical service (≥10% of total patients)	43 (19.9)	240 (31.4)	0.54 (0.38–0.78)	0.001	0.52 (0.34–0.78)	0.002
Mainly working in an urban area (≥50,000 people as an administrative unit of the local government)	171 (80.0)	547 (71.6)	1.59 (1.10–2.30)	0.014	1.42 (0.95–2.11)	0.084
Experience as kindergarten or school physician	87 (40.3)	387 (50.6)	0.66 (0.48–0.90)	0.008	0.79 (0.55–1.14)	0.21
Experience raising children	153 (70.8)	568 (74.3)	0.84 (0.60–1.18)	0.32	0.67 (0.45–1.00)	0.049
Information resource						
Government	155 (71.8)	592 (77.4)	0.74 (0.53–1.04)	0.087	0.80 (0.55–1.16)	0.24
Academia	202 (93.5)	711 (92.9)	1.10 (0.60–2.01)	0.77	0.94 (0.44–2.04)	0.88
Commerce	60 (27.8)	223 (29.2)	0.93 (0.67–1.31)	0.69	0.91 (0.63–1.32)	0.62
Social network service or mailing list by individuals or group of medical service providers	79 (36.6)	220 (28.8)	1.43 (1.04–1.96)	0.028	1.56 (1.09–2.24)	0.016
None	4 (1.9)	15 (2.0)	0.94 (0.31–2.87)	0.92	0.84 (0.21–3.40)	0.81

PCPs, primary care physicians; HPV, human papillomavirus; CI, confidence interval

Checklist for Reporting Of Survey Studies (CROSS)

Section/topic	Item	Item description	Reported on page #
Title and abstract			
Title and abstract	1a	State the word “survey” along with a commonly used term in title or abstract to introduce the study’s design.	3
	1b	Provide an informative summary in the abstract, covering background, objectives, methods, findings/results, interpretation/discussion, and conclusions.	3-4
Introduction			
Background	2	Provide a background about the rationale of study, what has been previously done, and why this survey is needed.	6-8
Purpose/aim	3	Identify specific purposes, aims, goals, or objectives of the study.	8
Methods			
Study design	4	Specify the study design in the methods section with a commonly used term (e.g., cross-sectional or longitudinal).	8-9
	5a	Describe the questionnaire (e.g., number of sections, number of questions, number and names of instruments used).	9
Data collection methods	5b	Describe all questionnaire instruments that were used in the survey to measure particular concepts. Report target population, reported validity and reliability information, scoring/classification procedure, and reference links (if any).	9
	5c	Provide information on pretesting of the questionnaire, if performed (in the article or in an online supplement).	-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Report the method of pretesting, number of times questionnaire was pre-tested, number and demographics of participants used for pretesting, and the level of similarity of demographics between pre-testing participants and sample population.	
	5d Questionnaire if possible, should be fully provided (in the article, or as appendices or as an online supplement).	-
	6a Describe the study population (i.e., background, locations, eligibility criteria for participant inclusion in survey, exclusion criteria).	8-9
Sample characteristics	6b Describe the sampling techniques used (e.g., single stage or multistage sampling, simple random sampling, stratified sampling, cluster sampling, convenience sampling). Specify the locations of sample participants whenever clustered sampling was applied.	9
	6c Provide information on sample size, along with details of sample size calculation.	-
	6d Describe how representative the sample is of the study population (or target population if possible), particularly for population-based surveys.	-
Survey administration	7a Provide information on modes of questionnaire administration, including the type and number of contacts, the location where the survey was conducted (e.g., outpatient room or by use of online tools, such as SurveyMonkey).	9
	7b Provide information of survey's time frame, such as periods of recruitment, exposure, and follow-up days.	8
	7c Provide information on the entry process: ->For non-web-based surveys, provide approaches to	-

		minimize human error in data entry.	
		→For web-based surveys, provide approaches to prevent “multiple participation” of participants.	
		Describe any preparation process before conducting the	-
Study preparation	8	survey (e.g., interviewers’ training process, advertising the survey).	
		Provide information on ethical approval for the survey if	23
Ethical considerations	9a	obtained, including informed consent, institutional review board [IRB] approval, Helsinki declaration, and good clinical practice [GCP] declaration (as appropriate).	
		Provide information about survey anonymity and	9
	9b	confidentiality and describe what mechanisms were used to protect unauthorized access.	
		Describe statistical methods and analytical approach.	13
	10a	Report the statistical software that was used for data analysis.	
	10	Report any modification of variables used in the analysis,	13
	b	along with reference (if available).	
Statistical analysis	10c	Report details about how missing data was handled. Include rate of missing items, missing data mechanism (i.e., missing completely at random [MCAR], missing at random [MAR] or missing not at random [MNAR]) and methods used to deal with missing data (e.g., multiple imputation).	13
	10d	State how non-response error was addressed.	-
	10e	For longitudinal surveys, state how loss to follow-up was addressed.	-
	10f	Indicate whether any methods such as weighting of items or propensity scores have been used to adjust for non-	-

	representativeness of the sample.	
	10 Describe any sensitivity analysis conducted.	13
	g	
<hr/>		
Results		
<hr/>		
	11 Report numbers of individuals at each stage of the study.	14
	a Consider using a flow diagram, if possible.	
	11 Provide reasons for non-participation at each stage, if possible.	Figure 1:Study flowchart
Respondent characteristics	b	
	11 Report response rate, present the definition of response rate or the formula used to calculate response rate.	14
	c	
	Provide information to define how unique visitors are determined. Report number of unique visitors along with relevant proportions (e.g., view proportion, participation proportion, completion proportion).	-
	d	
Descriptive results	Provide characteristics of study participants, as well as information on potential confounders and assessed outcomes.	14-16, 25,26
	12	
	13 Give unadjusted estimates and, if applicable, confounder-adjusted estimates along with 95% confidence intervals and p-values.	14-16, Supplementar y Tabel 1-2
	a	
	13 For multivariable analysis, provide information on the model building process, model fit statistics, and model assumptions (as appropriate).	-
Main findings	b	
	Provide details about any sensitivity analysis performed. If there are considerable amount of missing data, report sensitivity analyses comparing the results of complete cases with that of the imputed dataset (if possible).	16
	13 c	
<hr/>		
Discussion		
<hr/>		

		Discuss the limitations of the study, considering sources of potential biases and imprecisions, such as non-representativeness of sample, study design, important uncontrolled confounders.	21-22
Limitations	14		
		Give a cautious overall interpretation of results, based on potential biases and imprecisions and suggest areas for future research.	21-22
Interpretations	15		
Generalizability	16	Discuss the external validity of the results.	22
Other sections			
Role of funding source	17	State whether any funding organization has had any roles in the survey's design, implementation, and analysis.	-
Conflict of interest	18	Declare any potential conflict of interest.	24
Acknowledgements	19	Provide names of organizations/persons that are acknowledged along with their contribution to the research.	23